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SUMMARY
Sodium dodecyl sulphate polyacrylamide disc gel 
electrophoresis has been used to evaluate the induction of 
hepatic microsomal cytochrome P-450 in the rat by isosafrole 
and related compounds. Many of the benzodioxole compounds 
examined formed metabolite-cytochrome P-450 complexes in vitro 
but few were capable of forming an isolable metabolite 
complex in vivo. The formation of a stable metabolite complex 
in vivo is apparently associated with induction of cytochrome 
P-450 and induction of a polypeptide of molecular weight 
53,000. The induction of cytochrome P-450 by benzodioxole 
compounds displays a high degree of structural specificity, 
requiring a dioxole ring and a lipophilic side chain for 
optimal induction.
Isosafrole interacts with phenobarbitone to produce 
additive induction, but with methylcholanthrene it produces 
a synergistic induction of cytochrome P-450.
Treatment of genetically "responsive" C57BL/10 
and "nonresponsive"DBA/2 mice produced metabolite-cytochrome 
P-450 complexes and increases in monooxygenase activities in 
both strains. Following treatment with isosafrole the 
induction of a microsomal polypeptide of mol. wt. 54,000 was 
demonstrated in both strains on gel electrophoresis.
Addition of isosafrole to isolated rat hepatocytes 
resulted in the initial formation of a Type I spectrum, and . 
subsequent formation of peaks at 42 7 and 458 nm.
The mechanism of induction by benzodioxole compounds 
is discussed in the light of this and evidence for the 
instability of the metabolite-cytochrome P-450 complex formed 
initially in vivo.
Variation in the rate of diplacement, of metabolite 
complexes formed in vivo with alkenyl-substituted benzodioxole 
compounds suggests a role for lipophilic stabilization of the 
metabolite-complex in the oxidized state.
Benzofuran showed differing inducing characteristics 
compared to benzodioxole compounds, and caused induction 
of epoxide hydratase and glutathione S-transferases. Benzofuran 
administration also caused decreases in cytochrome P-450 levels 
and aminopyrine N-demethylase activities.
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CHAPTER 1 
INTRODUCTION
1. INTRODUCTION
1.1. Cytochrome P-450
1.1.1. Historical Aspects: the rise' of cytochrome P-450
The importance of oxygen in metabolism and
energy generation by aerobic organisms has been recognized
for many years, with the most familiar role of oxygen as
the terminal electron acceptor in the respiratory .chain.
An alternative role for oxygen became evident following
demonstrations of enzymic incorporation of molecular
18oxygen into substrates using 0 2 (Mason et aZ.,1955?
Hayaishi et at, , 1955). This led to a classification of 
the types of enzymes catalyzing reactions of molecular 
oxygen into three categories (Mason, 1957): oxygen trans­
ferases, electron transfer oxidases and mixed function 
oxidases. The presence of an enzyme system in rabbit 
liver microsomal fractions which could hydroxylate numerous 
aromatic compounds and required NADPH and molecular 
oxygen was reported by Brodie et at, (1955). This enzyme 
system has been termed a mixed function oxidase by Mason
(1957). However, Hayaishi (1962) suggested the designation 
monooxygenase, a term which more accurately describes the 
action of the enzyme, involving the insertion of a single 
oxygen atom into the substrate molecule.
The discovery by Klingenberg (1958) and Garfinkel
(1958) of a microsomal pigment to which carbon monoxide 
bound avidly,, led to the characterization of a unique 
haemoprotein by Omura and Sato (1962, 1964 a,b) which they 
termed cytochrome P-450. The name is derived from the 
observation that the carbon monoxide complex of the reduced 
cytochrome displays an absorption maximum in the Soret 
region at 450 nm. The first evidence for the participation 
of cytochrome P-450 in monooxygenase reactions was reported 
by Estabrook et at,(1963). Using Warburg’s arrangement for 
the photochemical action spectrum, these authors demon­
strated that light of 450 nm was optimal for the reversal
of the carbon monoxide inhibition of steroid C-21
hydroxyl at ion.. By the late 1960s it was realized that 
cytochrome P-450 was of major importance in the metabolism 
of many foreign chemicals including drugs, carcinogens, 
insecticides and in the metabolism of endogenous compounds 
including steroids and fatty acids.
Much of the early knowledge about the properties
of cytochrome P-450 came from studies on purified 
preparations of the NADH-dependent soluble•cytochrome 
P-450cam isolated from Pseudomonas putida (Katagiri et at 
1968? Peterson, 1971). Initial attempts to solubilize 
mammalian cytochrome P-450 using different types of 
detergent resulted in conversion to inactive cytochrome 
P-420 (Omura and Sato, 1964 a). This was overcome by
glycerol (Ichikawa and Yamano, 1967). Solubilization of
the membrane bound enzyme led to the resolution of three 
components: cytochrome P-450, NADPH: cytochrome P-450 
reductase and phospholipid, which when combined would 
catalyze the hydroxylation of lauric acid (Lu and Coon, 
1968).
1.1.2. Occurrence
Cytochrome P-450 occurs widely throughout nature 
and has been found in a large number of mammals, various 
avian, amphibian, fish and insect species, in plants, yeasts 
and in bacteria. In mammals cytochrome P-450 has been 
reported in liver, kidney, lung, intestinal mucosa, testis, 
placenta, corpus tuteum^ brain, adrenal gland, spleen, 
heart, aorta wall, lymphocytes, platelets and skin. In most 
tissues cytochrome P-450 is found in the endoplasmic 
reticulum but it is also found in mitochondria of steroido­
genic tissues such as the adrenal gland (Harding et at,9 
1964; Harding and Nelson, 1966) and the corpus tuteum(Yohro. 
and Horie, 1967). The distribution of cytochrome P-450 has 
been the subject of a review by Wickramasinghe (1975).
1.1.3. Structure of cytochrome P-450
The classification of cytochromes is made 
into three types: a, b or c,-according to their absorption 
maxima. Cytochrome P-450 is classified as a b-type 
cytochrome> and in common with other b-type cytochromes, 
contains an iron protoporphyrin IX prosthetic group. 
Cytochrome P-450 differs from other b-type cytochromes in 
that it can react with oxygen, cyanide and carbon monoxide, 
and also in that it has an intense red-shifted absorption 
peak at 450 nm when the reduced haemoprotein is complexed 
with carbon monoxide. Treatment of cytochrome P-450 with 
various agents brings about conversion to cytochrome P-^420, 
which has the spectrum of a typical b-type cytochrome, with 
a Soret band at 420 nm. The nature of these agents, e.g. 
detergents or lipase, indicates that the haem of cytochrome 
P-450 is bound in a highly lipophilic environment (Omura 
and Sato, 1964 a; Imai and Sato, 1967 b). However, 
proteases and denaturants such as urea which primarily 
alter the native conformation of the haemoprotein, also 
cause the conversion of cytochrome P-450 to cytochrome 
P-420 (Mason et aZ.,, 1965). Thus protein structure and 
lipid environment appear to be important for the maintenance 
of the unusual spectral properties of cytochrome P-450.
The iron atom of cytochrome P-450 haem has 
four planar ligand interactions with the nitrogen atoms 
of the protoporphyrin ring system,and has two axial ligand, 
positions available for further binding. Electron spin 
(paramagnetic) resonance spectroscopy (ES(P)R) has been 
widely used in conjunction with optical spectroscopy to 
study cytochrome P-450 and in particular the nature of the 
fifth and sixth ligands. EPR is used to detect unpaired 
electrons and is particularly useful for the study of 
transition metal complexes such as haemoproteins.
Cytochrome P-450 has been shown to exist in both high- spin 
(5 unpaired electrons) and low spin states (Jefcoate and 
Gaylor, 1969; Hill et aZ.,,19.70) and in the normal oxidized
state exists in the low spin form (Tsai et aZ.,,1970).
Following the observation of a loss of low spin 
character after treatment of.hepatic microsomes with 
p-chloromercuribenzoate,Mason et at, (1965) suggested that 
a sulphur atom was liganded to the haem of cytochrome 
P-450. Subsequent studies using model systems with thiol 
agents and haemoglobin or metmyoglobin showed similar 
low spin EPR spectra (Jefcoate and Gaylor, 1969; Hill et at, 
1970; Blumberg and Peisach, 1971; Peisach et at,9 1973;
Collman et a7.1975; Tang et at,3 1976) to those obtained 
with cytochrome P-450 from mammalian (Jefcoate and Gaylor, 
1969; Peisach et at,9 1973; Stern et at,s 1973) and bacterial 
(Tsai et at,9 1970) sources. Stern and Peisach (1974) 
demonstrated the formation of an absorption maximum at 
450 nm following the addition of carbon monoxide to a 
model system of reduced haem, thiol and a strong base.
From this study they concluded that a thiolate anion:’is 
required to produce the characteristic spectrum of cytochrome 
P-450.
Although cytochrome P-450 has been shown to have 
a heterogeneous ligand field in the vicinity of haem ' 
(Peisach et aZ.^1973), the nature of the sixth ligand is 
still undecided. Various proposals have been made which 
include the imidazole nitrogen of a histidine residue 
(Jefcoate and Gaylor, 1969; Tang et at,s 1976; Chevion et 
at,9 1977), a hydroxyl group (Nebert et at,s 1976; Kumaki 
and Nebert, 1978) and water (Peterson and Griffin, 1973; 
Griffin and Peterson, 1975).
Microsomes from control and phenobarbitone- 
pretreated rats contain cytochrome P-450 which produces a 
predominantly low spin EPR signal. However, following 
treatment with 3-methylcholanthrene, an increase in the 
high spin character is observed, with g-values near 8 , 3.7 
and 1.7 (Peisach et at,3 1973). The absorption maximum
of oxidized microsomes from rats treated with methylcholan- 
threne was shifted to 394 nm.(high spin) whereas the 
absorbance maximum of oxidized control and phenobarbitone- 
pretreated-microsomes was at 418 nm (low spin) (Estabrook 
et at,3 1972 a). This high spin character has been 
attributed to the presence of methylcholanthrene bound to 
cytochrome P-450 which remains there because of its high 
degree of lipophilicity. The loss of high spin character 
during purification has been attributed to the removal of 
bound methylcholanthrene (Stern et at,9 1973? Hashimoto 
and Imai, 1976).
1.1.4. Cytochrome P-450 dependent spectral changes
Characteristic spectral changes can be observed 
when various substances are added to microsomal suspensions. 
These•spectral changes can be monitored by difference 
spectroscopy.
The first report of a cytochrome P-450 dependent 
spectral change was made by Narasimhulu et at, (1965), using 
17-hydroxyprogesterone in microsomes from adrenal cortex. 
Similar spectra were later described by Remmer et at, (1966) 
Imai and Sato (1966) and Schenkman et ai, (1967) following 
the addition of various compounds to microsomal suspensions 
from liver.
These spectral changes can be divided into three 
categories: Type I, Type II and Reverse Type I (Type RI) 
(Schenkman et at.>1961, 1972). Type I spectral changes 
are characterized by an absorption maximum at 385-390 nm 
and a minimum at 415-4-25 nm; Type II are characterized by 
an absorption maximum at 425-435 nm and a minimum at 390- 
400 nm. The Type RI spectrum is essentially a mirror image 
of a Type I spectral change and is typified by a minimum 
at 385-390 nm and a maximum at 415-425 nm.
Schenkman et at. (1967) suggested that these
spectral changes were due to interaction between oxidized
cytochrome P-450 and the added compound. These authors
devised a method of measuring an apparent affinity constant
for a given compound analogous to the Michaelis constant
(K^) for enzyme substrate complexes. A double reciprocal
plot (Lineweaver and Burk, 1934) of spectral change versus
substrate concentration produced an intercept on the 1 x 1
axis which the authors termed the spectral dissociation
constant or K . This constant is defined as the s
concentration of reactant that results in 50% of the 
maximal spectral change, and is by definition independent 
of protein concentration. The magnitude of the spectral 
change is dependent not only on the substrate concentration, 
but also on:.the concentration of cytochrome P-450 in the 
microsomal suspension (Estabrook et at.3 1972 b). The 
maximal absorbance change (A'Amax) is analogous to the 
maximal velocity (vmax) °f enzyme reactions.
The Type I spectral change is elicited by a 
wide range of endogenous and exogenous substrates of 
cytochrome P-450. These include steroids, fatty acids, 
barbiturates and polycyclic aromatic hydrocarbons. In 
general, compounds which elicit the Type I spectral change 
are lipophilic. Schenkman and Sato (1968) suggested that 
Type I compounds interact with the apoprotein portion of 
cytochrome P-450 rather than with haem. The role of 
phospholipids in the Type I interaction is uncertain. 
Treatment of microsomes with phospholipase C (Chaplin and 
Mannering, 1970; Eling and Di Augustine, 1971) or extraction 
with isooctane. (Leibman and Estabrook, 1971) which removed, 
about 70% of the phospholipids present, decreased or 
eliminated Type I binding spectra. In contrast, Vore et at. 
(19 74) reported that extraction of microsomes with butan-1- 
ol and acetone removed about 80% of the phospholipids 
present yet increased the binding of some Type I substrates.
Various other authors (Narasimhulu, 1975; Levin et at.
1974) have reported that lipid is not essential for Type 
I binding. A correlation between Kg values and lipid 
solubility for some Type I ligands has been demonstrated 
by Kitigawa et at. (1972) and Al-Gailany (1975; Al-
Gailany et at. 9 1975).
The events involved at the molecular level
during binding of Type I compounds cannot be fully
appreciated without resort to EPR studies.. The interaction
of a Type I compound with cytochrome P-450 is associated
with conversion of the haemoprotein iron from low to
high spin (Whysner et at.9 1970; Jefcoate and Gaylor,
1970; Waterman et at.9 1973; Tsai et at.9 1970). This
increase in high spin character is thought to be due to
thdisplacement of the 6 ligand of cytochrome P-450 haem, 
which in turn decreases the ligand field strength of the.. 
haem, and results in a hypsochromic shift.
Type II spectral changes are brought about by
the interaction of amines with cytochrome P-450 (Schenkman
et at.9 1967; Jefcoate et at.9 1969; Schenkman,1970).
Other compounds containing nitrogen atoms with a lone pair
of electrons such as pyridine and imidazole also elicit the
Type II spectrum (Temple, 1971). This type of spectral
change is thought to be caused by ferrihaemochrome
formation, involving electron transfer between the nitrogen
atom of the added compound and the sixth ligand position
of the haem iron (Schenkman et- at.^ 1961) , and in. which the
2 3nitrogen atom is primarily an sp or sp hybrid, with a 
spatially, accessible lone electron pair (Kulkarni et at.9 
1974; Mailman et at.9 1974). Aniline has been reported to 
compete with carbon monoxide for reduced cytochrome P-450 
indicating interaction at the haem iron (Schenkman et at.9 
1967). In addition, aniline produces two Soret peaks, a t :
425 and 455 (Imai and Sato, 1967 b) similar to those
produced by ethyl isocyanide which has been shown to compete
with carbon monoxide (Omura and Sato, 1964 a). The formation
ofv-the Type II spectrum is associated with the production 
of a low spin iron species which produces a red-shifted 
absorbance peak. This is thought to be caused by an 
increase in ligand field strength.
Few compounds which give rise to a Type II 
spectrum are metabolized by cytochrome P-450. However, 
aniline, a compound which acts as a substrate for cytochrome 
P-450 and produces a Type II spectrum, has been shown to 
have a Type I component (Schenkman, 1970). This Type I 
component is thought to be related to aniline metabolism.
The Type RI (Reverse (inverse) Type I. or 
modified Type II) has often been likened to the Type II 
interaction (Whysner et at.a 1970). However, whereas Type 
II compounds can displace carbon monoxide, Type RI compounds 
cannot, nor do they alter aniline binding to the oxidized 
haemoprotein (Schenkman et at.9 1973). A diverse range of 
compounds produce the Type RI spectral change including 
phenacetin, acetanilide, short chain monohydric alcohols, 
warfarin and several allyl-containing barbiturates. It has 
been suggested that the Type RI spectrum is a reversal of 
the Type I spectral change caused by displacement of bound 
endogenous substrates (Diehl et at. 9 1970; Schenkman et at.a 
1969,1972,1973). Diehl et at. (1970) showed that butanol, 
when added to microsomes containing sufficient cyclohexane 
to saturate the Type I binding site, produced a difference 
spectrum which was the exact mirror image of the cyclo- 
hexarie (Type I) binding spectrum.. Schenkman et at. (1973) 
found that on solvent extraction of microsomes, the Type RI 
spectrum induced by phenacetin was reduced. Similarly, 
extraction of microsomes from 3-methylcholanthrene-treatedt. 
rats resulted in the elimination of the Type RI spectrum 
of hexobarbitone (Vore et at.9 1974). Powis et at. (1977) 
found that addition of bovine serum albumin to microsomal 
suspensions resulted in a Type RI binding spectrum, which the 
authors concluded was due to displacement of endogenous 
substrates from cytochrome P-450.
In contrast to the results of Schenkman et at. 
(1973), Vore et at. (1974) found increased Type RI binding 
for phenacetin and ethanol using butanol-acetone extracted 
microsomes. Al-Gailany (1975) also proposed that Type RI 
binding is due to binding at a specific site of cytochrome 
P-450 rather than:.simply displacing endogenous substrates.
This hypothesis was based on data using fluorescent probes, 
which suggested that Type I, Type II and Type RI sites were 
in differing environments with respect to their lipophilicity.
It has been suggested that since many compounds 
which give a Type RI interaction contain oxygen, the 
oxygen atoms act much like nitrogen atoms as nucleophiles 
and displace the sixth ligand of cytochrome P-450 (Mailman 
et at.s 1974). The hypsochromic shift from Type H  spectral 
maxima is due to the lower nucleophilicity of the groups 
involved in the Type RI interaction. Yoshida and Kumaoka 
(1975) also concluded from binding spectral studies that 
Type RI binding is due to a haem ligand interaction 
between high spin cytochrome P-450 and the Type RI compound. 
Kumaki et at. (1978) reached a similar conclusion from 
binding spectral and EPR studies.
The exact nature of the Type RI spectrum has
yet to be fully understood, although it seems likely that
the mechanism of interaction between cytochrome P-450 and
Type RI compounds may involve one or more of the above
mechanisms, depending on the nature of the compound and the
cytochrome P-450 species present. Multiple interactions
between compounds and various sites of cytochrome P-450
%
are possible (Yoshida and Kumaoka, 1975). It seems that 
the Type RI interaction involves the conversion of a high 
spin cytochrome to a low spin-cytochrome species, and the 
sixth ligand position of the iron becomes occupied by a weak 
ligand. Whether this weak ligand is the oxygen atom of the . 
Type RI compound or the intrinsic sixth ligand of the protein 
is a matter for speculation.
1.1.5. Mechanism
Estabrook et al. (1972 a) proposed a scheme for the
mechanism of cytochrome P-450::action.
Initially a substrate reacts with the low spin 
form of ferric cytochrome P-450 to form a high spin ferric 
cytochrome P-450-substrate complex. Associated with this is 
the observation of the Type I spectral change and an increase 
in the high spin EPR signal. This increase in high spin 
character shifts the redox potential of the cytochrome to 
less negative values (Sligar, 1976; Sligar et al.9 1979) .and 
results in an increased flow of electrons to.cytochrome P-450 
(Ristau et al.9 1979; Sligar et al.9 1979). The ferric 
cytochrome P-450-substrate complex undergoes one electron 
reduction by accepting an electron from NADPH via the flavo- 
protein enzyme NADPH: cytochrome P-450 reductase. The ferrous 
cytochrome P-450-substrate complex reacts with oxygen producing 
an oxygenated reduced cytochrome P-450-substrate ternary 
complex. The observation of an absorbance maximum at 440 nm 
has been attributed to this ternary complex (Estabrook et al.9 
1971; Werringloer and Estabrook, 1975; Guengerich et al. ., 1976) .
The oxycytochrome P-450 complex then undergoes a 
further one electron reduction. This electron may be donated 
by NADPH: cytochrome P-450 reductase. However, several 
studies have indicated that this reduction can also be mediated 
by NADH: cytochrome b^ reductase and cytochrome b 5 (Hildebrandt 
and Estabrook, 1971; Estabrook et al.9 1971; Cohen and 
Estabrook, 1971 a,b,c; Sasame et al.9 1973), providing an 
explanation for the synergistic effect of NADH on microsomal 
monooxygenation. Studies by Lu et a I. (1974) indicated that 
the involvement of cytochrome b^ in the NADPH-dependent reaction 
varies with both the. substrate and the species of cytochrome 
P-450 present.. Imai and Sato (1977) have shown that,
although cytochrome b^ is not obligatory for this reduction 
step, if NADH, cytochrome b^ and NADH: cytochrome b,- 
reductase are included in a reconstituted system of cytochrome 
P-450, NADPH: cytochrome P-450 reductase, sodium cholate 
and NADPH with benzphetamine or dimethylaniline as substrate, 
the second electron is supplied almost exclusively by NADH 
via cytochrome b^.
After transfer within the ternary complex of 
one oxygen atom and uptake of two protons, the -complex 
dissociates to give oxidized cytochrome P-450, water and 
hydroxylated substrate. The nature of the active oxygen 
intermediate involved in the substrate' hydroxylation 
reaction remains unknown. Hamilton (1964) suggested that 
monooxygenases ca’taTyse their reactions by means of an 
oxygen atom transfer or oxenoid mechanism, because of their 
similarity to nitrene and carbene reactions. Support for 
this mechanism has been provided by the observation of the 
'NIH shift* (Guroff et al.9 1967) or the displacement of an 
existing ring substituent to an adjacent position by the 
incoming hydroxyl group. Hrycay and O'Brien (1971 a,b) 
provided evidence that cytochrome P-450 could function as 
a peroxidase with organic hydroperoxides. Following the 
report by Kadlubar et al. (1973) that organic peroxides 
could support the oxidative N-dealkylation of a variety of 
amine substrates in rat liver microsomes, Rahimtula and 
O'Brien (1974, 1975) showed that cumene hydroperoxide and 
other hydroperoxides could sustain the hydroxylation and
O-dealkylation of a variety of substrates in rabbit liver 
microsomes in the absence of NADPH and molecular oxygen.
Other "active.oxygen" containing compounds such as sodium 
periodate and sodium chlorite have been, shown to support the 
hydroxylation of various steroids and fatty acids in the 
absence of NADPH and molecular oxygen (Hrycay et aZ.,1975 
a, b, 1976). Iodosobenzene can also serve as an effective
oxygen donor to cytochrome P-450 in the deethylation of
7-ethoxycoumarin (Lichtenberger et al.9 1976). During
the course of reactions supported by cumene hydroperoxide,
one mole of cumene hydroperoxide is consumed for every mole
of substrate hydroxylated, and the major reaction product
is phenyl-2-propanol (cumenol)XRahimtula and O ’Brien, 1974).
The "NIH shift" also occurs during hydroperoxide-dependent
aromatic hydroxylations (Rahimtula et aZ.,, 1978). The
appearance of a free radical signal as determined by EPR
and distinctive optical spectral changes led to the proposal
that a ferryl ion complex (in resonance-with a ferric oxene 
4 + — 3 +
complex Fe  0 ^  Fe - 0) was the active oxygen species
involved in cytochrome P-450 mediated reactions (Rahimtula 
et al. 9 1974).
1.1.6. Induction and purification of multiple forms
of cytochrome P-450
In this section the inducing effects of various 
compounds will be considered. These agents act in vivo 
to increase the rate of production and/or decrease the rate 
of degradation of an enzyme, and are to be distinguished 
from agents which enhance the activity of cytochrome P-450 
in vitro. The activation of monooxygenase reactions in 
vitro: has recently been reviewed (Cinti, 1978). Agents 
which will bring about activ ation of cytochrome P-450 
dependent reactions include ethyl isocyanide, metyrapone,
2,2 1-bypyridine, 1,10-phenanthroline, 7,8 -benzoflavone, 
acetone, various divalent cations and polyamines.
The initial observation of an inducing effect 
of a foreign compound on the metabolism of another foreign 
compound was' made by the Millers and their associates 
(Miller et al.9 1952; Conney et al.9 1956) who described 
a reduction in' hepatoma formation by, and an increase in the
metabolism of aminoazo dyes following treatment of rats 
with methylcholanthrene. Further work has shown that an 
increase in various monooxygenase activities concomitant 
with an induction of cytochrome P-450 occurs following 
exposure to, or administration of a wide variety of 
compounds (Conney, 1967; Remmer, 1972). These include 
barbiturates, polycyclic hydrocarbons, steroids, insecticides, 
pesticides, ethanol and environmental contaminants. There is 
increasing evidence to * suggest that multiple forms of 
cytochrome P-450 exist and that different inducing agents 
increase, the levels of different forms of cytochrome 
P-450.
The classical inducing agents are phenobarbitone 
and 3-methylcholanthrene. Phenobarbitone causes an 
increase in cytochrome P-450 levels. Pretreatment with 
methylcholanthrene causes a change in the absorbance maximum 
of the reduced carbon monoxide difference spectrum from 
450 nm to 466-448 nm (Alvares et al.9 1967). This altered 
form, termed cytochrome P-448, or cytochrome P^-450 also 
has an altered ethyl isocyanide difference spectrum (Sladek 
and Mannering, 1966) . Further evidence for different forms 
of cytochrome P-450 is provided by major differences in the 
catalytic properties of the induced haemoprotein since 
phenobarbitone increases the metabolism of a wide range of 
substrates but methylcholanthrene is more specific in its 
action (Conney, 1967). Several model substrates of microsomal 
monooxygenases are metabolized to give different products 
in microsomal suspensions from animals pretreated with 
inducing agents. These include biphenyl (Creaven and Parke, 
1966; Burke and Bridges, 1975), testosterone (Kuntzman et al. 
1968; Conney et al.9 1973), benzo (a) pyrene Rasmus sen _andr 
Wang, 1974),chlorobenzene (Selander et al.9 1975) and ' 
warfarin((Pbhl et al.9±911).
Sodium dodecyl sulphate (SDS) poylacrylamide gel . 
electrophoresis has been used to separate microsomal ' 
proteins. Microsomes from phenobarbitone- and methyl-
cholanthrene-pretreated rats (Alvares and Siekevitz, 1973; 
Welton and Aust, 1974), mouse .(Haugen et al.a 1976) and rabbit 
(Haugen et al.9 1975) livers showed preferential induction 
of proteins in the 45,000-60,000 molecular weight region.
In general, the proteins induced by polycyclic aromatic 
hydrocarbons have a higher molecular weight than those 
induced by phenobarbitone. Recent studies have shown that 
nitrogen-containing carcinogens (Cameron et a1.9 1976) and 
isosafrole (Dickins et al. 9 1978) induce proteins with . 
different molecular weights from those induced by methyl­
cholanthrene or. phenobarbitone.
Although it could easily be demonstrated that 
different forms of cytochrome P-450 exist in animals 
treated with different inducing agents, the question of the 
existence of a population of different forms in control 
animals or animals pretreated with inducing agents was 
more difficult to resolve. One of the earliest studies 
indicating the presence of multiple forms of cytochrome 
P-450-was carried out by Conney et a l .(1968), who described 
differences in the carbon monoxide:oxygen ratio required 
for 50% inhibition of the hydroxylation of testosterone 
in the .63-, 7a- and 16a- positions. Comai and Gaylor (1973) 
reported the presence of three forms of cytochrome P-450 in 
control microsomes, using cyanide and octy.lamine as ligands. 
These three forms were preferentially induced by 3-methyl- 
cholanthrene, phenobarbitone or dietary ethanol. Werringloer 
and Estabrook (1975) described four classes of cytochrome 
P-450 in control rat liver, on the basis of their reactivity 
with carbon monoxide, benzphetamine, ethyl:'isocyanide and 
metyrapone. Treatment with inducing agents produced 
selective increases in different pools. Examination of 
the developmental changes in induction in the rat, mouse and 
rabbit with'3-naphthoflavone, 3-methylcholanthrene and 
2,3,7,8 -tetrachlorodibenzo-p-dioxin (TCDD) using SDS gel 
electrophoresis, difference spectroscopy and substrate 
specificity has shown that two forms of cytochrome P-450
(cytochrome P-448 and Pq-450) are induced (Guenther and 
Nebert, 1978; Atlas et al.9 1977).
Much of the evidence for multiplicity of cytochrome P-450 
has been obtained from studies on purified preparations.
Early work with reconstituted systems indicated that 
substrate specificity resides in the cytochrome P-450 
fraction (Lu et al.9 1971,1973; Nebert et al.9 1973), as 
NADPH: cytochrome P-450 and phospholipid fractions could be 
used interchangeably. As development of purification 
techniques progressed, it became possible to isolate more 
than one cytochrome P-450 fraction from a single microsomal 
preparation. Ryan et al. (1975 a) reported the purification 
of two cytochromes in microsomes from phenobarbitone- and 
methylcholanthrene-pretreated rats. Antibodies raised against 
highly purified cytochrome P-450 from phenobarbitone- 
treated rats and cytochrome I,P-448" from methylcholanthrene- 
treated rats indicated the presence of at least six different 
proteins in the purified fractions (Thomas et al.9 1976 a,b) . 
Purification of cytochrome P-450 from rabbit liver microsomes 
indicated the presence of at least six forms following 
treatment with inducing agents (Haugeniet al.9 1975).
SDS-polyacrylamide gel electrophoresis has 
provided one of the most compelling arguments for the 
existence of multiple, forms of cytochrome P-450.
Differences in the electrophoretic mobilities of purified 
cytochrome P-450 preparations from the same group!of 
animals have been described for several species, either in 
control animals or those treated with inducing agents 
(Haugen et al. .,1975; Ryan et al.9 1975 b; References in 
Table 1.1.). As an extension of this technique, peptide 
mapping has been carried out by limited proteolysis of
Table 1.1. Isolation of multiple forms of cytochrome P-450 from
various species
Species Inducer
Rat . Control
Control
Control
Control
Control
Rat Phenobarbitone
Phenobarbitone 
Phenobarbitone
Rat Methylcholanthrene
Rat Polychlorinated
biphenyls
Rabbit Control
Control
Phenobarbitone
3-naphthoflavone
TCDD
Mouse
(B6D2F/J) Phenobarbitone
Forms isolated Reference
Fractions 'C' & 'X' West et al. (1979)
P-450I & P-450^
Fractions A,B,C
Four fractions
Cytochromes P-450 
and P-451
Fraction 'C' 
Fractions A,B,D 
P-450 , P-450,
P-450 , P-450 a c
P-450 ,■'P-450. , a b
P-450
P-450 LM , LM3a'
LM3b' m 7 
P-450 A and B
P-450 LM2, LM r
LM. '4
P-450 LM.
P-450 , P-450, ,
P-4503 bc
A^ fA21C^ t^2
(C57BL/6)Methylcholanthrene P^-450, P-448
Gibson and Schenkman 
(1978)
Guengerich (1977 a) 
Warner et al. (1978) 
Angosin et al. (1979)
West et al. (1979) 
Guengerich (1978 b)
Ryan et al. (1979 a)
Ryan et al. (1979 a)
Ryan et al. (1979 a)
Coon et al. (1977)
Philpot and Aring (1976) 
Haugen et al. (1975)
Haugen and Coon (1976)
Johnson and Muller- 
Eberhard (1977 a,b,c)
Huang et al. (1976) 
Negishi and Nebert (1979)
purified proteins, followed by electrophoresis of the 
polypeptide fractions, and differences between different 
.cytochrome P-450 preparations have been demonstrated 
(Guengerich, 19 78 a; Johnson et at., 1979; Ryan et al.9 
1979 a).
Differences in amino acid composition have also 
been found with different forms of purified cytochrome P-450. 
Rabbit cytochrome P-450 LM^ has been found to have approx­
imately 60 amino acid residues more than LM2 (Haugen and 
Coon, 19 76) with notable differences in the number of 
residues of alanine, valine, lysine and tryptophan.
Guengerich (1978 a) described differences in amino acid 
composition of three homogenous forms of cytochrome P-450 
from rat liver. Three forms of cytochrome P-450 purified 
from rat liver following treatment with inducing agents have 
been shown to have different amino acid compositions (Botelho 
et al.9 1979).
The molecular biology of the induction of 
cytochrome P-450 has recently been reviewed by Bresnick 
(1978). The mechanism of induction of cytochrome P-450 
is thought to involve de novo protein synthesis, since 
administration of inhibitors of protein synthesis prevents 
increases in monooxygenase, activities. Although the inhibitors 
cycioheximide, actinomycin D and a-amanitin all differ in 
their effects on cellular metabolism since they inhibit the 
peptidyl transferase reaction in protein synthesis, DNA 
dependent RNA synthesis and RNA polymerase II respectively, 
they all prevent induction of cytochrome P-450 (Cutroneo 
and Bresnick, 1973; Gelboin and Blackburn, 1963; Jacob et al,9 
1974). One of the initial effects of an inducer appears to 
he de novo synthesis of RNA, since a-amanitin given up to 
8 h after phenobarbitone prevents induction, whereas after 
this time induction is not prevented (Jacob et al.9 1974).
Reduced degradation or stabilization of various components 
involved in the enzyme synthetic process may be brought 
about by cytochrome P-450 inducers (Seifert and Vacha, 19 70; 
Louis-Ferdinand and Fuller, 1970, 1972; Black et a l .3 1971; 
‘Pousada and Lechner, 1972). The primary event involved in 
the induction of cytochrome P-450 has yet to be identified, 
although it has been suggested that inducers may bind to a 
receptor protein, which then exerts the inducing effect.
The mechanism of induction by polycyclic aromatic hydrocarbons 
may be mediated by such a receptor (Poland and Kende, 1976). 
Singlet oxygen has been proposed as a possible mediator of 
the induction process (Paine, 19 78) with inducing agents 
binding to cytochrome P-450, but acting as poor acceptors of 
active oxygen. This would result in uncoupling of electron 
flow and a release of singlet oxygen which would cause an 
increase in lipid peroxidation. The concentration of lipid 
peroxides could control the induction of cytochrome P-450- 
(Paine/ .1978).
Steroid hormones including corticosteroids, 
androgens and certain synthetic steroids have been shown to 
induce hepatic microsomal enzyme activities (Selye, 19 70).
One of the most potent steroid inducers is the catatoxic 
steroid pregnenolone 16a-carbonitrile (PCN), which causes an 
induction of monooxygenase activities different from either 
phenobarbitone-or methylcholanthrene in the rat (Lu et 
19 72). Electrophoretic evidence suggests that PCN may induce 
a novel haemoprotein (Birnbaum et a 19 76).
A large number of polyhalogenated compounds will 
act as inducing agents. DDT (1,1,1-trichloro-2,2-bis [p- 
chlorophenylethane ] ), dieldrin and aldrin produce induction 
patterns similar to that of phenobarbitone (Hart and Touts, 
1965). Commercial mixtures of polychlorinated biphenyls 
(PCB) appear to have an inducing effect similar to a mixture 
of phenobarbitone and methylcholanthrene (Alvares and 
Kappas, 1977; Ryan et al,^ 1977). The separation of PCB 
isomers to give two types of inducer has been reported 
(Goldstein et al.9 1977). Commercial mixtures of polybromin- 
ated biphenyls (PBB) give similar results (Dent et at.3 19 76,
1977, 1978)'. However, electrophoretic studies have shown that
the induction pattern of PBBs differs from the additive 
induction of methylcholanthrene and phenobarbitone. The 
major component of Firemaster, 2,2',4,4',5,5'-hexabromo- 
•biphenyl has been reported to be a phenobarbitone type 
inducing agent (Moore et cl1*s 1978a). TCDD induces cytochrome 
P-448 in rats and mice, and the pattern of enzyme activities 
which are induced resembles that following methylcholanthrene 
pretreatment (Poland and Glover, 1975; Haugenret al.3 1976). 
However, TGDD is reputedly 30,000 times more potent than 
methylcholanthrene as an inducer (Poland' and Glover, 19 74).
The inducing properties of flavones were first 
described by Wattenberg et al, (1968). Many of these 
compounds are inducers of the methylcholanthrene type, and 
are relatively non-carcinogenic. The most potent inducer 
5,6 -benzoflavone (B-naphthoflavone, BNF) induces cytochrome 
P-450 to a similar degree as methylcholanthrene, and 
presumably acts via a similar induction mechanism (Boobis et 
al.3 1977).
Ethanol has been reported to induce some cytochrome 
P-450 catalysed reactions (Joly et a l 1973). A form of 
cytochrome P-450 preferentially induced by ethanol with 
specific spectral, catalytic and electrophoretic properties 
has been reported (Joly et al,, 1977; Ohnishi and Lieber,
1977) .
In summary, a large number of different compounds 
are capable of inducing cytochrome P-450. It is evident that 
cytochrome P-450 exists in multiple forms, and one or more 
of these forms may be increased on exposure to an inducing 
agent. The different forms of cytochrome P-450 may be 
distinguished by their spectral, catalytic, immunological 
and electrophoretic properties.
1.1.7. Inhibition of cytochrome P-450
Cytochrome P-450 mediated monooxygenation is a 
complex series of reactions, and interference with any one 
of these may represent a possible mechanism of inhibition.
The possible sites of inhibition have been summarized by 
Netter (1973). The most widely studied types of inhibitor 
are those which compete for the substrate binding site or 
the site of oxygen activation (haem iron).
The classical inhibitor of cytochrome,P-450 is 
carbon monoxide which binds to the reduced haemoprotein in 
a reversible interaction. The reduced haemoprotein-carbon 
monoxide complex is photodissociable, with an optimum 
wavelength at about 450 nm (Diehl et at. .,1969;Cooper :et al.jl911)*
SKF 525-A (3-diethylaminoethyldiphenylvalerate) 
is a widely used inhibitor of monooxygenation. This compound 
gives a Type I binding spectrum and so competes with cytochrome 
P-450 substrates for the binding site. In addition, SKF 525-A 
forms metabolites which bind to the haem iron of cytochrome 
P-450, and thus compete with oxygen for the reduced haemo­
protein (Hildebrandt, 1973). On metabolism in vitro an 
absorbance maximum at 452 nm is formed (Schenkman et 1972).
A similar absorbance maximum is formed in vivo at 455 nm and 
has been attributed to a metabolite-cytochrome P-450 complex. 
(Buening and Franklin, 1976). Both competitive and non­
competitive inhibition kinetics have been described for SKF 
525-A (Anders and Mannering, 1966; Ikeda et al,, 1968). 
Competition probably occurs between SKF 525-A and substrate 
for the active site of cytochrome P-450, whereas non­
competitive inhibition is thought to be due to formation 
of an inactive metabolite-cytochrome P-450 complex.
On metabolism in vitro benzphetamine gives 
oxidized metabolites which bind to cytochrome P-450 to give 
a spectrally manifested complex (Werringloer and Estabrook,
1973). A large number of phenylalkylamines yield similar
inhibitor complexes with cytochrome P-450 on metabolism in 
vitro (Franklin, 1974 a,b,c,d); N-oxidation has been shown 
to be a prerequisite for complex formation (Jonsson and 
Lindeke, 1976; Lindeke et at,3 1978) with phenylathy1amines. 
Although the oxidation state of nitrogen involved has not 
been unequivocally established, it has been suggested that 
either as a nitroso compound (Lindeke et aZ.,, 1978; Jonsson 
and Lindeke, 1976; Mansuy et aZ.^1977) or a nitroxide radical 
(Jonsson and Lindeke, 1976; Lindeke et al.3 1978) could be 
possibilities. Studies on model porphyrin-nitroso-alkane 
complexes indicated the formation of a highly stable ligand 
interaction (Mansuy et at,31977; Mansuy, 1978). Although 
the amphetamines can form a metabolite-cytochrome P-450 
complex in vitro these complexes are not formed in vivo 
(Franklin, 1971, 1974 d). The preferential metabolism of 
oxidized intermediates by glutathione S-transferases, rather ' 
than further metabolism to give a nitroso compound or nitroxide 
radical which is capable of forming a complex, is thought to 
account for this lack of complex formation in vivo (Hirata 
et at,3 1977, 1979).
The metabolite-complexes formed by SKF 525-A and the 
amphetamines are stable in the reduced state, but are unstable 
on oxidation with ferricyanide (Buening and Franklin, 1976). 
Another class of nitrogen containing compounds, the 1,1- 
disubstituted hydrazines have recently been reported to form 
metabolite complexes with cytochrome P-450 which are more 
stable in the oxidized form (Hines and Prough, in the press).
Metyrapone (2-methyl-l,2-bis [pyrid-3-yl] propan-
1 -one) is a potent inhibitor of monooxygenation and binds 
to cytochrome P-450 to give a Type II binding spectrum in the 
oxidized state. In the reduced state metyrapone binds to 
cytochrome P-450 to give an absorbance maximum at 446 nm 
(Hildebrandt et at.3 1969). The major mode of metyrapone 
inhibition is non-competitive, although recent studies have 
shown that metyrapone will undergo oxidative metabolism 
(De Graeve et al,3 1979).
Metyrapone has been shown to bind preferentially 
to cytochrome P-450 induced by phenobarbitone (Ullrich et 
al.j 19 73). However, 1, 8 -benzoflavone. (a-naphthoflavone, 
ANF) has been shown to have a very high affinity for 
cytochrome "P-448" induced by polycyclic aromatic hydro­
carbons, and is a potent inhibitor of reactions catalysed by 
this form of haemoprotein (Gelboin et aZ-,.,1970). - Metyrapone 
and ANF have been used in conjunction to produce.differential 
patterns of inhibition and so to provide an indication of the 
type of cytochrome P-450 present (Ullrich et al. , 19 75 b; 
Burke et al.3 19 77). A third inhibitor tetrahydrofuran 
which have been reported to be specific for cytochrome P-450 
induced by ethanol (Ullrich et al.3 1975 b) has also been 
used in this kind of study.
Ellipticine, a polyaromatic pyridine compound, 
binds by its pyridinic nitrogen atom to cytochrome P-450 to 
produce absorbance maxima at 428 nm in the oxidized state 
and 455 nm in the reduced state (Lesca-..et aZ.jl978), and is 
an extremely good inhibitor of monooxygenation.
Aryl- and alkyl-substituted imidazoles have been 
widely used as inhibitors of bacterial (Lipscomb and Gunsalus,
1973) and insect (Wilkinson et al,3 1974 a,b) cytochrome P-450 
dependent monooxygenation and are also extremely potent 
inhibitors of mammalian monooxygenases. These compounds
give Type I binding spectra, and It values of 0.5yM have 
been reported for some hepatic microsomal reactions (Leibman 
and Ortiz, 1973). Benzimidazole elicits a Type II spectrum 
when added to hepatic microsomal preparations (Mailman et al.3
1974). The binding of an homologous series of 2-alkylbenzi- 
midazoles to cytochrome P-450 and subsequent inhibition has 
been extensively studied (Dickins, 19 78; Dickins et aZ.31975; 
Dickins and Bridges, 1976).
Various sulphydryl reagents inhibit cytochrome 
P-450 dependent monooxygenation. Mersalyl (Franklin and 
Estabrook, 19 71), p-chloromercuribenzoate (Orrenius, 1965; 
Kampffmeyer and Kiese, 1963, 1964; Illing and Netter, 1975) 
and N-ethylmaleimide (Kampffmeyer and Kiese, 1963, 1964) 
are examples of such reagents. It has been suggested 
that p-chloromercuribenzoate inhibits at various stages 
in the cytochrome P-450 reaction cycle, including NADPH: 
cytochrome P-450 reductase and the formation of a ternary 
oxygen-cytochrome P-450-substrate complex (Illing and 
Netter, 19 75), although conversion of cytochrome P-450 
to cytochrome P-420 is also a major inhibitory factor 
(Mason et at.3±965).
Benzodioxole (methylenedioxyphenyl) compounds 
constitute another type of inhibitor of cytochrome P-450. 
Inhibition by these compounds will be discussed in detail 
in a later section.
1.1.8. Denaturation and destruction of cytochrome P-450
A wide variety of substances have been reported 
to bring about the conversion of cytochrome P-450 to its 
inactive form cytochrome P-420. These agents include cholate 
(Klingenberg, 1958), deoxycholate, phospholipase A and 
steapsin (Omura and Sato, 1964 a,b), trypsin, urea and 
sulphydryl reagents such as p-chloromercuribenzoate (Mason 
et at.3 1965), and high concentrations of neutral salts such 
as potassium thiocyanate, sodium iodide and guanidine 
(Imai and Sato, 1967 a). Agents which bring abotit this 
conversion generally act by blocking or oxidizing the thiolate 
haem ligand, ot by disrupting the membrane environment of 
cytochrome P-450.. ,
Degradation of the haem moiety is a possible . 
mechanism for destruction of cytochrome P-450. NADPH- 
dependent lipid peroxidation has been shown to
lead to the destruction of cytochrome P-450 haem (Levin et al.3 
1973 a,b; Jacobson et al.3 1973), and lipid peroxidation 
has been implicated in the loss of cytochrome P-450 caused 
by carbon tetrachloride (For review see De Matteis, 1978).
Allyl substituted barbiturates (Levin et al,3 1973 a),
2-allyl-2-isopropylacetamide (AIA) (De Matteis, 1970) and 
flu roxene (2 ,2 ,2 -trifluoroethylvinylether)Xlvanetich et al.3 
19 76) cause loss of cytochrome P-450 on metabolism. Carbon 
disulphide. (Bond and De Matteis, 1969) causes a loss of 
cytochrome P-450 which is thought to be mediated by a reaction 
with the apoprotein rather than haem.
Heavy metals such as cobalt (Tephly and Hibbeln,
19 71) nickel, and platinum (Maines and Kappas, 19 77), and 
cadmium (Hadley et al.3 1974) cause a loss of cytochrome 
•P-450 following administration to animals. The mechanism of 
this loss of cytochrome P-450 may be due to conversion of 
cytochrome P-450 to cytochrome P-420 by reaction with sulphy­
dryl groups and also induction of haem oxygenase (for review 
see De Matteis, 1978).
1.2. 1,3-BENZODIQXOLE (METHYLENEPIQXYPHENYL) COMPOUNDS
1.2.1. Occurrence
Benzodioxole compounds are found widely distributed 
throughout the plant kingdom, since they constitute a group 
of secondary metabolites. They are frequently found in 
foodstuffs and in the essential oils of spices. Certain 
benzodioxole compounds including safrole are found in star 
anise oil, camphor oil, sesame oil, nutmeg, mace, cinammon, 
ginger, black pepper, parsley., mint, carrot and dill 
(Benjarowicz and Kirsch, 1963; Weil, 1965; Furia and Bellanca, 
1971; Fishbein and Falk, 1969). Benzodioxole compounds have 
also been found in cigarette smoke (Schmeltz et at,3 1966).
The discovery of the synergistic effect of sesame oil, which 
contains sesamin and sesamolin, on the insecticide action 
of pyrethrum (Eagleson, 1942) stimulated research in both 
naturally occurring and synthetic benzodioxole compounds;
The most widely used synthetic benzodioxole compound is 
piperonyl butoxide.
1.2.2. Metabolism
Benzodioxole compounds are metablized by three 
principal routes: oxidation of the methylene bridge to yield 
ultimately carbon dioxide; extensive metabolism of the side 
chain; rapid oxidation of simple side chains to yield piper- - 
onylic acid and its conjugates.
The metabolism of piperonyl butoxide has been 
extensively studied in both.insects and mammals. In rats 
and mice, oxidative cleavage of the methylene bridge to yield 
carbon dioxide is the principal route of metabolism, and 
small amounts of 6 -propylpiperonylglycine appear in the 
urine (Kamienski and Casida, 1970) . A total of 28 metabolites 
have been identified in urine and bile (Fishbein et at, 3
1969), many of which retain the methylene carbon atom, 
indicating extensive modification of the side chain. In house­
flies, metabolism of the methylene carbon atom is much slower 
than in mice (Casida et al,3 1966), and although piperonyl 
butoxide is extensively metabolized, many of the metabolites 
retain the methylene bridge intact (Esaac and Casida, 1969).
The methylene bridges of safrole, isosafrole, 
myristicin and dihydrosafrole are extensively metabolized to 
carbon dioxide in the mouse (Casida et al,3 1966). Following 
oral or intraperitoneal administration of safrole, isosafrole 
or myristicin to rats, Oswald et al, (1969) demonstrated
nitrogen-containing metabolites in the urine. Dihydrosafrole 
did not form any nitrogen-containing metabolites, suggesting 
a requirement, for the allyl or propenyl group. The metabolites 
are thought to be condensation products of the 1 1-keto-deriv- 
ative with dimethylamine, piperidine or pyrrolidine, although 
1 1-ketosafrole has not been directly identified as a metabolite 
of safrole (Borchert et al,} 1973 b;', Stillwell, et al, 3 1974). . 
An extensive study of the metabolism of safrole in the rat and 
guinea pig (Stillwell et al,3 1974) showed that safrole is 
metabolized by demethylenation to form a catechol, hydroxy- 
lation to form 1 1hydroxysafrole (Borchert et al,3 1973 a) and 
epoxidation to give safrole-2 ',31-oxide which is further 
metabolized to 2 1 ,3'-dihydroxypropylbenzodioxole. Since allyl 
catechol and 1 1-hydroxysafrole contain a double bond, these can 
be further metabolized to give epoxides and diols. The meta­
bolites containing available hydroxyl groups were excreted 
mainly as glucuronic acid conjugates. In rat liver cell 
cultures safrole and isosafrole are extensively metabolized by. 
demethylenation.. and hydroxylation of the side. chain to give 
epoxides and diols (Delaforge et al,3 1977; Janiaud et al,9
1976).
Human volunteers metabolized low doses of safrole 
to give allyl catechol as the major metabolite, with no 
‘1 1-hydroxysafrole in the urine (Benedetti et al,/ 1977).
In insects safrole, myristicin and dihydrosafrole 
are eliminated directly by volatilization and also by
demethylenation although this is less significant than in 
mammals (Casida .^ et al,3 1966). In houseflies the major 
route of metabolism for safrole and isosafrole is 
oxidation to give piperonylic acid, which is conjugated 
with amino acids, while dihydrosafrole is metabolized to 
give sesamol (Esaac and Casida,''r 1968) .
In the mouse piperonyl alcohol, piperonal and 
piperonylic acid all appear rapidly in the urine as 
piperonyl glycine or as :■ free piperonylic acid, and 
little or no scission of the methylene bridge occurs 
(Kamienski amd Casida, 1970). In the housefly a variety of 
amino acid conjugates of piperonylic acid are found, 
including piperonyl alanine, -serine,-glutamate,-glutamine 
and -glycine (Esaac and Casida, 1968, 1969).
1.2.3. Toxicity and carcinogenicity of benzodioxole
compounds'
Most benzodioxole compounds have a relatively 
low toxicity. The parent compound, 1,3-benzodioxole has a 
high acute toxicity in the rat with an oral LD^Q of 0.5g/kg, 
whereas safrole, isosafrole and dihydrosafrole have oral LD^Q 
values in the range of 1.0-2.5 g/kg in the rat (Jenner et al,3 
1964). In contrast, piperonyl butoxide which has a long 
oxygen-containing side chain has values in the range
0.6 -11.5 g/kg for the rat and mouse (Sarles et al.3 1949).
In general very few toxic effects have been 
described for benzodioxole compounds as a group. Safrole, 
isosafrole and dihydrosafrole are known to cause severe 
liver lesions (Taylor al,3 1964). These authors concluded 
from a study of the structural requirements for production 
of hepatotoxicity that although many allyl compounds are 
hepatotoxic, the production of lesions was independent of the; 
nature of the 3-carbon side chain, but that a 3-carbon side 
chain and methylenedioxy-- group were necessary. Piperonyl 
butoxide is thought to cause some dermatological problems 
in man (For review of the toxicology of piperonyl butoxide
see Haley, 1978), and the benzodioxole compounds in sesame 
oil (sesamin, sesamolin) cause contact dermatitis (Neering 
e-t aZ. j 1975). Many of the toxic effects of benzodioxole 
compounds are due to their ability to inhibit cytochrome 
P-450 mediated metabolism. Piperonyl butoxide has been 
shown to increase the acute toxicity of Freons 112 and 
113, griseofulvin and benzolta) pyrene in infant mice 
(Epstein et al,9 1967 a,b).
. Data from acute and sub-acute studies indicated 
that safrole caused liver damage (Jacobs, 1958; Leidy, 1958), 
and on investigation of chronic exposure, safrole was found 
to be a weak hepatocarcinogen (Homburger et al,3 1961, 1962; 
Long et al,3 1961, 1963). Safrole, isosafrole and dihydro­
safrole have all been found to produce tumours in the rat 
(IARC, 1976), with isosafrole producing liver tumours and 
dihydrosafrole producing oesophageal tumours..
It has been proposed that the metabolite of safrole 
1 1-hydroxysafrole is the proximate carcinogen (Borchert et al, 
19 73 a) and further studies have indicated that an electro- 
phile produced from safrole such as safrole-1 1-sulphate, 
l'-hydroxysaf role-2*-,~3'-oxide, 1 '-oxosafrole or safrole-2 ' ,3'- 
oxide may be the ultimate carcinogen (Wislocki et al,9 1976,
1977).
1.2.4. Inhibition of monooxygenation and insecticide
synergism
The initial observation of the synergistic 
interaction of benzodioxole compounds with insecticides was 
made by Eagleson (1942) who found that sesame oil potenti­
ated the action of pyrethrum in houseflies. The active 
components of sesame oil were found to be sesamin and 
sesamolin. Several synthetic products derived from safrole
are used commercially as insecticide synergists, including 
piperonyl butoxide, tropital and propyl isome, the most 
widely used being piperonyl butoxide. The benzodioxole 
compounds can be used to potentiate the action of a wide 
range of insecticides including carbamates, chlorinated 
hydrocarbons, organophosphates and rotenoids. The action 
of benzodioxole compounds in reducing the rate of metabolism
of insecticides was first demonstrated in insects (Winter-
ingham et al,3 1955; Sun and Johnson, 1960) and
subsequently in mice (Robbins et al,3 1959; Fine and
Molloy, 1964) . Benzodioxole compounds: have, been found to. 
inhibit microsomal oxygenation of a wide variety of 
substrates both in insects and mammals. The effects of 
benzodioxole compounds on enzyme activities have been 
reviewed both with regard to their synergistic action 
(Casida,1970) and general biological’ actions (Hodgson and 
Philpot, 1974; Haley, 1978). Casida et al, (1966) first 
suggested that benzodioxole compounds were alternative 
substrates for monooxygenation. The kinetics of the inhibition 
of monooxygenation atrfirst appeared confusing, with inhibition 
by benzodioxole compounds being described as competitive, 
non-competitive ,:.partly competitive, . partly progressive and 
curvilinear (Natsatsugawa and Dahm, 1965; Lewis at aZ.> 19.65; 
Anders, 1968; Hansen and Hodgson, 1971). Type I binding 
spectra for benzodioxole compounds were demonstrated in 
microsomes from mammalian (Matthews et al,3 1970) and insect 
(Philpot and Hodgson, 19 70) origin.
Perry and Bucknor (19 70) and Matthews and Casida
(1970) using houseflies, and Matthews et al, (1970), using 
mice, demonstrated a decrease in cytochrome .P-450 levels after 
treatment in vivo with piperonyl butoxide. Subsequent 
investigations by Philpot and Hodgson (1971 a) and Franklin
(1971) revealed the formation of an unusual difference 
spectrum following the incubation of piperonyl butoxide in vitro 
with liver microsomes and NADPH. Under these conditions,
two absorption maxima at 42 7 and 455 nm were produced, similar 
to the spectrum formed on addition of ethyl isocyanide to 
reduced cytochrome P-450. Metabolism was found to be 
essential for the generation of the spectrum, and Franklin
(1971) suggested that it was due to the formation of a 
complex of an oxidative metabolite with cytochrome P-450.
The ligand nature of this complex is supported by the 
observation that carbon monoxide binding and Typel'II 
binding are decreased following metabolism of piperonyl 
butoxide in vitro (Philpot and Hodgson, 1971 a), and light 
of approximately 450-460 nm wavelength has been found to 
be optimal for dissociation;of the complex (Ullrich and 
Schnabel, 1973 a).
The discovery of the metabolite complex with 
cytochrome P-450 facilitated the interpretation of the 
inhibitory properties of benzodioxole compounds which have 
been explained thus (Philpot and Hodgson, 1971 a? Franklin,-• 
1971): initially, competitive inhibition occurs between 
substrate and benzodioxole compound for metabolism, followed 
by non-competitive inhibition on formation of a complex 
between reduced cytochrome P-450 and a benzodioxole 
metabolite.
The formation of similar metabolite-cytochrome 
P-450 complexes in vivo has also been reported. Philpot 
and Hodgson (1971 b) described absorption peaks at 427 and 
455 nm in microsomes from mice treated with piperonyl 
butoxider and Parke and Rahman (1971) and Elcombe et al.
(1975 a) reported an absorption maximum at 455 nm following 
treatment of rats with safrole or isosafrole. These 
complexes are isolated in the oxidized state and can be 
visualized by the addition of reducing agents such as sodium 
dithionite, NADPH or NADH.
Although the complex formed in vivo with safrole is stable 
throughout the microsomal procedure and is resistant to 
dialysis for several hours, it-can be displaced under 
certain conditions (Elcombe et al,3 1975 a). Certain 
compounds which bind to cytochrome P-450 to produce a Type 
I spectrum are capable of displacing the benzodioxole- 
metabolite from cytochrome P-450, resulting in a time 
dependent increase in the magnitude of the binding spectrum. 
Displacement only occurred when the complex was present in 
the oxidized state, and subsequent measurement of carbon 
monoxide binding indicated an increase over that obtained 
in undisplaced microsomes. An increase in monooxygenase 
activity following displacement has also been demonstrated 
(Elcombe et al.3 1977), and the increase in magnitude of the 
Type I spectrum is accompanied by release of isosafrole 
related material from microsomes (Elcombe et al,3 1976).
1.2.5. The benzodioxole metabolite cytochrome P-450
complex
The formation of the metabolite-cytochrome P-450 
complex in vitro has been shown to require both NADPH and 
molecular oxygen (Franklin, 1971). However, cumene hydro­
peroxide which will support cytochrome P-450 mediated, 
reactions in the absence of NADPH and oxygen, will also 
support the formation of metabolite-cytochrome P-450 complexes 
with safrole (Elcombe et al,3 1975 b) or piperonyl butoxide, 
(Kulkarni and Hodgson, 1978).
Various theories have been postulated about the 
nature of the metabolite involved in the production of the 
two absorption.peaks on metabolism of benzodioxole compounds. 
The methylenedioxy group appears to be an absolute requirement 
for the formation of the complex, and various workers have 
suggested that benzodioxole compounds ligand to cytochrome
P-450 following modification of this group. Replacement of 
both hydrogen atoms of the methylene group with oxygen 
or methyl groups abolished synergistic activity (Weiden and 
Moorefield, 1965) , and replacement with deuterium reduced 
activity.
Hennessy (1965) proposed that abstraction of a 
hydride ion from the methylene group could lead to the 
formation of an electrophilic benzodioxolium ion:
Q
This ion could then react with the iron atom of cytochrome P-450 
to inhibit metabolism.
Hansch (1968), using a structure activity 
relationship to equate synergistic activity with homolytic, 
steric and hydrophobic constants, suggested that abstraction 
of a hydrogen atom occurs to form a free radical which would 
act as a n .inhibitor of insecticide metabolism:
C-H
Ullrich and Schnabel (1973 a) proposed that 
benzodioxole compounds could lose § proton during metabolism 
to form a carbanion which would form a ligand complex with 
cytochrome P-450.
This metabolite is analogous to the carbanion metabolite of 
.fluorene - which forms a complex with cytochrome P-450.
The carbanion nature of the fluorene metabolite was- 
established by its characterstic absorption at 375 nm and
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its reactivity with H and CO2 (Ullrich and Schnabel, 19 73 b). 
It was suggested that the fluorenyl carbanion liganded to the 
haem of cytochrome P-450 and that a similar metabolite which 
could bind to cytochrome P-450 was formed by benzodioxole 
compounds.
In the presence of NADPH in a microsomal system, 
various halogenated hydrocarbons have been shown to elicit 
maxima at 455 nm (Uehleke et al.s 1973). Halothane (1,1,1- 
trifluoro-2 -chloro-2 -bromoethane) forms an absorbance 
maximum at 4 70 nm under metabolizing conditions and low 
oxygen tension, and to explain this observation Mansuy et al. . 
(1974) proposed that a trifluoromethyl carbene species was the 
metabolite which gave rise to the spectrum. Wolf et al.
(19 77) investigated the formation of metabolite-cytochrome 
P-450 complexes with a number of halogenated methanes in 
the presence of NADPH in microsomes. These authors demonstrated 
the production of. carbon monoxide following metabolism of 
the halogenated compounds and suggested that the active 
metabolite involved in both processes was a carbene formed, 
by abstraction of two halogen atoms from the molecule. 
Crystalline complexes of iron-tetraphenylporphyrin with a 
variety of halogenated carbenes have been characterized 
(Mansuy et al.3 1978). Three possible mechanisms for the 
generation of a carbene attached to cytochrome P-450 . 
have-been proposed by Ullrich et al,- (1975 a): 
i) by diazo compounds
2 +
R-CH = N 2 -- ►  R-CH-Fe + N 2
ii) by reduction of geminal dihalogen compounds 
R-CHX2 — ►  R-CH-Fe2+ + 2X~
iii) by hydroxylation and elimination of water
Mechanisms i and ii have been demonstrated with 1,1,1-tri- 
fluorodiazoethane and halothane (Mansuy et at., 19 74) and 
polyhalogenated methanes (Wolf, et al.3 1977). Ullrich et al. 
(19 75 a) proposed that the action of cytochrome P-450 on 
benzodioxole compounds represented an example of the third 
type of mechanism:
Consideration of the various possible mechanisms 
indicate that some are more probable than others. The 
formation of a carbanion is 'unlikely, since the methylene 
hydrogen atoms of benzodioxole compounds are not acidic.
The fluorenyl carbanion is unstable and discharged by oxygen 
and carbon dioxide (Ullrich and Schnabel, 19 73 a,b), whereas 
benzodioxole complexes are not (Elcombe, 1976). Dithio- 
threitol, a free radical scavenger, does not inhibit the 
formatidn of the benzodioxole metabolite complex, so a free 
radical mechanism is unlikely (Elcombe, 1976). The formation 
of a carbene represents the most attractive hypothesis, not 
only on mechanistic consideration of its formation, but also 
because of the electronic similarity of a benzodioxole carbene 
to the cyanide ion and alkylisocyanides (Werringloer and 
Estabrook, 1978). Recently, the isolation of an iron II 
(tetraphenylporphyrin) (1 ,3-benzodioxol-2-carbene) complex 
has been reported (Mansuy et al.3 1979), and spectral 
similarities of this complex to the metabolite-cytochrome 
P-450 complex lend support to the possible carbene nature of 
the latter.
1.2.6. Induction of monooxygenase activity by benzodioxole
compounds
Treatment of animals with benzodioxole compounds 
results in initial, inhibition of cytochrome P-450 dependent
reactions. However, after longer periods the inhibitory 
phase is followed by induction (Jaffe et al. 9 1969; Skrinjaric-
£poljar et a l 19 71) . The inductive phase has also been 
observed by pther authors (Wagstaff and Short, 1971; Lake et al.s 
19 73; Yu and Terriere, 1974).
The properties of the induced cytochrome have 
not been well documented. Lotlikar and Wasserman (19 72) 
reported the induction of 3- and 5-hydroxylation.of 2-acetamido- 
fluorene to a greater extent than N-hydroxylation by isosafrole 
and safrole. This is similar to the pattern, observed with 
methylcholanthrene. Elcombe et al. (19 75 a) described a shift
in the carbon monoxide absorbance maximum to 448 n m 'on treatment 
of rats with safrole. However, Parke and Rahman (19 70) observed 
induction of both 2 - and 4-hydroxylation of biphenyl by : 
isosafrole and safrole, and similar induction of cytochrome 
"P-450" and "P-448" mediated activities has been reported 
(Wagstaff and Short, 1971; Lake et a l 1973; Vainio and 
Parkki, 1976). The determination of the nature of the 
induction by benzodioxole compounds has been complicated 
both by the presence of the inhibitory complex and by 
displacement which occurs on incubation of microsomes with some 
substrates in the oxidized state. Recent studies by Dickins 
(1978) have shown that aminopyrine N-demethylase, biphenyl 2- 
and 4-hydroxylase, ethoxycoumarin 0-deethylase and ethoxy- 
resorufin 0 -deethylase are all increased by treatment of rats 
with isosafrole, and increases in activity are also observed 
after displacement of the metabolite complex by preincubation 
with substrate.
SDS disc gel electrophoresis of rat liver microsomes 
has shown that pretreatment with either safrole or isosafrole 
induces a haemoprotein band with a molecular weight inter­
mediate between those of the major proteins induced by methyl­
cholanthrene and phenobarbitone (Dickins et al.s 1978; Dickins,
1978).
The present study attempts to examine electrophoresis as an 
evaluative technique for induction of cytochrome P-450, and 
the structural requirements for the particular induction 
exemplified by safrole and isosafrole.
CHAPTER 2
METHODS
2. METHODS
2.1. CHEMICALS
Isosafrole was purchased from Merck GmbH 
(Darmstadt,West Germany) and safrole was obtained from 
Hopkin and Williams Ltd. (Essex, England). Piperonal, sesamol,
1 .3-benzodioxole, piperonyl alcohol, 2 ,3-benzofuran, eugenol, 
methylisoeugenol, trans-stilbene oxide and dihydrosafrole were 
supplied by Aldrich Chemical Co. Ltd. (Poole, Dorset). Apiol 
was purchased from Pfaltz and Bauer (Stamford, Connecticut,
USA) and myristicin was obtained from Saber Laboratories Inc. 
(Morton Grove, Illinois, USA). Piperonyl butoxide was kindly 
donated by Mr. G. Poll (Wellcome Research Laboratories, 
Berkhamsted, England), and 1 1-hydroxysafrole was generously 
provided by Dr. M. Delaforge (Dept, of Biochemistry, University 
of Surrey).
NADH, NADPH, glucose-6 -phosphate (disodium salt), 
glucose-6 -phosphate dehydrogenase, collagenase, hyaluronidase,
2 -oxoglutarate (monosodium salt), glutamate dehydrogenase,
2.3-dihydroxynaphthalene, Coomassie Brilliant Blue G, 3-
R
methylcholanthrene, bovine serum albumin and Tris (Trizma 
base) were all obtained from the Sigma Chemical Co. Ltd.
(Poole, Dorset).
Acrylamide and N,N'-methylenebisacrylamide (both 
specially purified for electrophoresis), sodium dodecyl 
sulphate (specially purified for biochemical research), 
1 -iodoheptane, 1 -iodopentane, propan -2 -one, pentan-2 -one, 
heptan-2-one and gelatin were all purchased from British 
Drug Houses Ltd. (Poole, Dorset).
Ethoxyresorufin (50 yM in methanol) and resorufin 
(10 yM in ethanol) were purchased from Pierce and Warriner 
(UK) Ltd. (Chester, Cheshire), and ethylmorphine was 
obtained from May and Baker Ltd. (Dagenham, Essex). Diethyl- 
aminoethyl-2,2-diphenylvalerate (SKF 525-A) was obtained 
from Smith, Kline and French (Welwyn Garden City, Herts.).
Pregnenolone 16a-carbonitrile (PCN) was obtained from
Dr. H. Jonen (Institute of Pharmacology, Mainz, West Germany).
Combiteck standard proteins were obtained from
the Boehringer Corporation.(Lewes, Sussex).
3Benzo(a)pyrene-4,5-oxide and G £ h]-benzo(a)pyrene- 
4,5-oxide (366mCi/mmol) were the generous gifts of Dr. G.M. 
Cohen (Dept, of Biochemistry, University of Surrey).
2 . 2 . SYNTHESIS OF BENZODIOXOLE COMPOUNDS.
Naphthodioxole .
The method of Bonthorne and Cornforth (1969) was 
used to methylenate dihydroxynaphthalene to give naphtho­
dioxole:
+cH2d2 °\Q/ + 2HCI
2 ,3-Dihydroxynaphthalene (16.0 g) was dissolved in dimethyl 
sulphoxide (50 ml), and methylene dichloride (10 ml) was 
added. The mixture was heated on an oil bath u.nder reflux
The reaction was started by the addition of solid sodium
The reaction mixture was allowed to cool and was extracted 
with diethyl ether (3 x 50 ml portions). The ether was 
removed by distillation under reduced pressure and the solid 
was dried under vacuum. Purity was assessed by thin layer 
chromatography using a hexane: ether (2 :1 , v/v) solvent systems- 
The melting point (97-99°) was in good agreement with that 
quoted by Bonthorne and Cornforth (1969).
3 1-Ketoalk-11-enylbenzodioxoles
These compounds were prepared by mixed aldol 
condensation reaction between piperonal and 2 -ketoalkanes, 
using the method of Sedenberg and Wachs (1948)
To a mixture of ethanol (37 g) , 5M sodium hydroxide (5g) 
was added piperonal (30g) and the appropriate 2-ketoalkane 
(0.2 mol), with stirring. The mixture was stirred at room 
t e m p e r a t u r e  for thirty minutes and allowed to stand overnight.
to 1 2 0 ° and was kept under nitrogen throughout the reflux
hydroxide (8.3 g) and the mixture was refluxed for 40 min
The yellow crystals formed were removed by filtration, 
recrystallized from methanol three times, and dried under 
vacuum. The melting points were in good agreement with
1948 ) . Purity was assessed by thin layer chromatography 
using hexane/ether (2:1, v/v) as solvent system.. Each
compound migrated as a single spot with the following R_F
values:
oct-1 1-enylbenzodioxole) were synthesized using a two stage 
process involving a Grignard reaction to give l'-hydroxy- 
alkylbenzodioxoles followed by dehydration to give alk-1 1- 
enylbenzodioxoles. The first stage of the synthesis is.2 
adapted from Mameli and Alagna (1905).
prepared by placing 2 .2 g of magnesium turnings in a 1 0 0 ml 
two necked flask fitted with a dropping funnel, condenser 
and drying tube. Diethyl ether (20 ml, sodium dried) was 
placed in the flask/ 1 -iodopentane or 1 -iodoheptane (0 . 1  mole) 
in ether ( 2 0 ml) was slowly added via the dropping funnel 
and the reaction vessel was warmed until the reaction 
proceeded. When the generation of the Grignard reagent was 
complete, piperonal (15 g, 0.1 mole) dissolved in ether 
(40 ml) was added slowly with stirring, and the mixture was
those published (Gheorghiu, 19331; Hedenberg and Wachs,
M.P. (Lit.value) R_r
Alk-11-enylbenzodioxoles
These compounds (hex-11-enylbenzodioxole and
The appropriate alkyl magnesium iodide" was
boiled for 30 min. The reaction mixture was cooled on ice 
and 1M sulphuric acid (100 ml) was added to hydrolyse the 
metal complex. The ether layer was removed and washed with 
sodium bicarbonate solution (100 ml, 5% w/v), extracted 
three times with saturated sodium metabisulphite solution 
( 1 0 0  ml portions) and finally washed with sodium bicarbonate 
solution (100 ml, 5% w/v). The ether layer was dried with 
anhydrous magnesium sulphate and the ether was then removed 
by vacuum distillation.
The crude mixture of I'-hydroxyalkylbenzodioxole 
was refluxed in toluene (75 ml) containing 4-toluene 
sulphonic acid in a Dean and Stark water separator for 1 h . 
The toluene was extracted with aqueous sodium hydroxide 
(0.05N, 50 ml) to remove 4-toluene sulphonic acid, dried 
with anhydrous magnesium sulphate and the toluene was 
removed by distillation. The remaining oil was chromato­
graphed on a silica gel column (Kieselgel 60, 70-230 mesh,
2.8 x 45 cm) using hexane/ether (9:1) as the solvent system. 
The first 100ml of eluate was discarded, and then fractions 
(10 ml) were collected. Aliquots (lOyl) were spotted on a 
thin layer chromatography plate, and the reaction with 
chromotropic acid spray reagent (Gunner and Hand, 1968) 
and fluorescence quenching were noted. Fractions which gave 
positive reactions to the spray reagent were chromatographed 
using hexane/ether (9:1) as solvent (hexenylbenzodioxole:
R 0.90? octenylbenzodioxole: R 0.90). Fractions whichF F
contained one compound were pooled and the solvent was removed 
by rotary evaporation„ Samples of the first major peak 
eluted from the column were analysed by mass spectrometry 
and nuclear magnetic resonance spectroscopy. Mass spectrum 
for hexenylbenzodioxolezm./e 204 (M+) , 161 (M^C^H^) , 131 (M 
-CH2 O, C^H^) , 103. (M^CH^O, C 5 H -^|) , with metastable ions at 
m/e 127.06 (204+161) , 106.59 (161+131) and 80.59 (131+103).
Mass spectrum for octenylbenzodioxole: m/e 232 (M+) ,
161 (M+-C H.^) , 148 (M+- C6 HiZ) , 131 (M+-CH2 0, CgH^) ,
103 (M+-CH2 0, C7 H15) with metastable ions at m/e 111.72 (232 
161) and 106. 59. .(161 -»■ 131) . The n.m.r. spectrum for 
both hexenylbenzodioxole and octenylbenzodioxole in CDCl^ 
are shown in Figs 2.1. amd 2.2., and are compatible with 
structures of trans-hex-1 1-enyl-1 ,3-benzodioxole and trans- 
oct -1 '-enyl-1 ,3-benzodioxole.
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2.3. ANIMALS
Male Wistar Albino rats (150-180g) were obtained 
from the University of Surrey. Mice used in this study were 
of two strains: C57BL/10 obtained from Bantin and Kingman 
Ltd. (Hull); and DBA/2 obtained from OLAC 1976 Ltd. (Bicester, 
Oxon.). Male mice of 25-30g bodyweight were used.
The rats were housed in cages with sawdust bedding 
(Lee and Co., Chertsey, Surrey) and were allowed food (Spratts 
Animal Diet No. 1.) and water ad libitum. Mice were housed 
in wire bottomed cages over sawdust and were allowed food 
and water ad libitum. A twelve hour light/dark cycle was 
in operation (0700-1900 light) at a temperature of 22° and 
50% humidity.
2.3.1. Pretreatment of animals
Controls
Control animals received either isotonic saline 
(0 .9% w/v), corn oil (2.5 ml/kg bodyweight for rats) or 
sunflower oil ( 1 0 ml/kg bodyweight for mice) by intraperitoneal 
(i.p.) injection on each of three consecutive days. Animals 
were killed 24h after the last injection.
Phenobarbitone
Phenobarbitone (sodium salt) was administered as 
a solution in 0.9% (w/v) saline. Rats and mice received 80 
mg/kg by i.p. injection once daily for three consecutive 
days, and were killed 24h after the last injection.
3-Methylcholanthrene
3-Methylcholanthrene was administered to rats; as 
a solution in corn oil and to mice as a solution in sunflower 
oil. Both species received 20 mg/kg by i.p. injection daily 
for 3 days, and were killed 24h after the last injection.
Pregnenolone 16a-carbonitrile (PCN)
PCN was administered orally to rats as a suspension 
in water (with 1 drop of Tween 80 in 10 ml water) at a 
dose level of 20 mg/kg twice daily for 3 days. Mice received
PC.-N by i.p. injection of a suspension in sunflower oil at 
a dose level of 50 mg/kg for 3 days. The animals were killed 
24h after the last injection.
Substituted Benzodioxole and related compounds
Isosafrole and the other compounds studied were 
administered by i.p. injection in corn oil at a dose level 
of 150 mg/kg for 3 days. Each animal received 2.5 ml corn 
oil/kg. Mice received isosafrole at the same dose level in 
sunflower oil (10 ml/kg). However, piperonyl butoxide was 
administered to mice at a level of 500 mg/kg in sunflower' 
oil daily for three days.
SKF 525-A
SKF 525-A was dissolved in 0.9% (w/v) saline and 
administered to rats by i.p. injection at 1 0 0  mg/kg daily 
for three days. The animals were killed 24h after the last 
injection.
Phenobarbitone-isosafrole, methylcholanthrene-isosafrole, oil- 
isosafrole,
Rats received either phenobarbitone, methylchol- 
anthrene or corn oil for three consecutive days as described 
above. On the fourth day, the animals received isosafrole 
(150 mg/kg) by i.p. injection, and were killed 24h after 
the administration of isosafrole.
2.4.1. Preparation of microsomes
Rats and mice were killed by cervical dislocation, 
the livers were rapidly excised and placed in the ice cold 
1.15% (w/v) KCl. (Gall bladders were removed from the livers 
of mice). The livers were washed, blotted dry and weighed. 
Subsequent operations were carried out at 0-4°. The livers 
were scissor minced and homogenized in three volumes (w/v) 
of ice cold 1.15% (w/v) KCl using a motor driven,Potter- 
Elvehjem glass-Teflon homogenizer (3 return strokes). The 
homogenate was then centrifuged in 5Q ml polycarbonate 
tubes at 20,000 g (13,000 rev/min) for 20 min using an 8 xSV ■
50 aluminium angle head rotor in an M.S.E. "High Speed 18"
refrigerated centrifuge. The supernatant was decanted and
recentrifuged at 105,000 g (40,000 rev/min) for 1 h usinga v
an 8 x 25 ml aluminium angle head rotor in an M.S.E. "Super­
speed 50" refrigerated centrifuge, or at 116,000 g (40,000av
rev/min) for 50 min using an 8 x 35 ml aluminium angle head
rotor in an M.S.E. "Superspeed 65". The supernatant obtained
was discarded, and the pellet was resuspended in ice cold
1.15% (w/v) KCl using a Potter-Elvehjem glass-Teflon
homogenizer. The resultant suspension was recentrifuged at
either 105,000 g for 1 h or 116,000 g for 50 min. The3av 3av
washed microsomal pellet was finally resuspended in 20 mM 
Tris-HCl (pH 7.4) containing 250 mM sucrose and 5.4 mM EDTA, 
to a concentration equivalent to Ig wet weight of liver per 
ml. The microsomal suspension was stored in 2ml aliquots 
in polycarbonate sample cups at -40°.
2.4.2. Preparation of isolated rat hepatocytes
Hepatocytes were isolated according to the method
of Fry et at. (1976) using livers from phenobarbitone-pretreated 
rats (50-60 g).
Rats were killed by cervical dislocation, and the
liver lobes were excised into Dulbecco's phosphate buffered 
saline (Mg - and Ca -free) , PBS'A*. The liver lobes 
were dried between filter papers, and were cut with a heavy 
duty blade to give slices of 0.5-1.0 mm thickness. The 
slices were then placed in a 250 ml conical flask (3g tissue 
per flask) containing 10 ml PBS'A*, and the flask was shaken 
for 10 min \in a shaking water bath at 37° (approx. 100 oscill- 
ations/min). The supernatant was discarded, and,this washing 
was repeated twice. This was followed by two 10 min incu­
bations with PBS 1A 1 containing 0.5 mM ethyleneglycol-bis- 
(3-aminoethylether) N,N'-tetraacetic acid (EGTA). After
++treatment with EGTA each flask:.received 10 ml of Hank's Mg - 
free balanced salt solution containing 5 mM C a C l c o l l a g e n -  
ase (0.05% w/v) and hyaluronidase (0.01% w/v). The flasks 
were then incubated for 60 min at 37° in the shaking water 
bath. The resulting suspension was filtered through a layer 
of bolting cloth :(125 y pore size) , and the resulting 
suspension was centrifuged at 50g&v for 1 min. The pellet 
was twice washed with PBS*A* {minus phenol red). The cells 
were finally suspended in PBS'A* (minus phenol fed) 
containing 0 .1 % (w/v)glucose and kept on ice until required. 
Viability was assessed by the ability of the cells to 
exclude trypan blue, and was generally 75-80%.
2.4.3. Protein Assay
Protein was determined by a modified method of 
Lowry et at. (1951) using bovine serum albumin as standard.
Reagents
50 mM NaOH
1 % (w/v) hydrated copper sulphate
2 % (w/v) sodium potassium tartrate
50 mM NaOH containing 2% (w/v) sodium carbonate
Folin-Ciocalteau phenol reagent diluted with water
(1 :2 ,v/v)
Bovine serum albumin in 50 mM NaOH (250yg/ml)
Method
Microsomal samples were diluted with 50 mM NaOH 
to give appropriate protein concentrations. The protein 
standard was diluted with 50 mM NaOH to give concentrations o f , 
50,100,250,200 and 250 yg/ml. Copper sulphate, sodium 
potassium tartrate and sodium carbonate were mixed in the 
ratio 1:1:100 by volume immediately before use. The protein 
standards, samples and blanks (0.5 ml) were mixed with the 
sodium carbonate reagent (5.0 ml) and allowed to stand for.
10 min at room temperature. Diluted Folin-Ciocalteau phenol 
reagent was added, and the solutions were mixed immediately. 
After at least 30 min at room temperature, the absorbance 
at 715 nm was recorded using a Pye Unicam SP 500 spectro­
photometer.
2.5. SPECTROPHOTOMETRY
Spectral measurements were made using a Pye 
Unicam SP 1800, a Perkin Elmer 356 dual beam dual wavelength 
spectrophotometer, a Varian Carey 219 split beam spectro­
photometer, or an Aminco DW2 UV-Vis spectrophotometer.
All;.four: instruments: were equipped with thermostatted cuvette 
holders. Measurements were made in either the split beam 
mode (using two cuvettes, sample wavelength X 1=> reference 
wavelength X or the dual beam mode (using a single cuvette 
X X 2 ) •
2.5.1. Cytochrome P-450 determination
The method of Omura and Sato (1964a) was used to 
measure cytochrome P-450. Microsomes (5: ml of a suspension 
of 1 mg protein/ml) in 66 mM Tris HC1 (pH 7.4) were divided 
equally between two cuvettes. A baseline of equal light 
absorbance between 400 and 500 nm was established, and the 
contents of both cuvettes was reduced by the addition of 
solid sodium dithionite (1-2 mg). Carbon monoxide was 
bubbled throught the contents of the sample cuvette for 20 s 
and the difference spectrum was recorded. The absorbance 
change at the absorbance maximum (approx. 450 nm) was
measured relative to that at 490 nm, and the concentration
<
of cytochrome P-450 was calculated using an extinction 
coefficient of 91mM-?‘cm
2.5.2. . Determination of benzodioxole metabolite-cytochrome
P-450 complexes.
Following administration of substituted benzodi­
oxole and related compounds, the presence of a metabolite- 
cytochrome P-450 complex isolated in the microsomal fraction 
was determined by measuring the dithionite reduced Minus 
oxidized spectrum between 400 and 500 nm. A microsomal 
suspension '(5 ml of 1 mg protein/ml in 66 mM Tris-HCl, pH 7.4) 
was divided equally,between two cuvettes and a baseline of 
equal light absorbance between 400 and 500 nm was established.
The contents of the sample cuvette were reduced by the 
addition of sodium dithionite, and the reduced minus 
oxidized spectrum was recorded. The presence of a peak at 
455 nm was interpreted as being indicative of a metabolite- 
cytochrome P-450 complex and was expressed in terms of 
absorbance at 455 nm minus absorbance at 490 nm per mg of 
microsomal protein. The absorbance difference at 427 nm :: 
relative to 490 nm was also measured. Although in some 
cases this is almost totally due to cytochrome b^, in others 
it is thought to be due partly to cytochrome b^ and partly 
to a metabolite-cytochrome complex.
2.5.3. Measurement of cytochrome b^
Cytochrome b^ was measured by reduction with NADH 
in microsomes.
Reagents
66 mM Tris-HCl buffer (pH 7.4)
11.5 mM NADPH in 66 mM Tris-Hcl (pH 7.4)
Method
Microsomal suspension diluted with 66 mM Tris-HCl 
(pH 7.4) to give a final concentration of 1 mg protein/ml 
was divided equally between two cuvettes and a baseline of 
equal light absorbance was established between 400 and 4 40 
nm. NADH (0.45 mM) was added to the sample cuvette and the 
spectrum recorded. The concentration of cytochrome b^ was 
determined by measuring the difference in absorbance 
between 424 and 409 nm, using an extinction coefficient of 
185 mM ^.cm
2.5.4. .Ligand induced binding'spectra
Binding spectra were elicited as described by 
Schenkman et aZ-.(1967) . Microsomes (5ml of a suspension 
containing lmg protein/ml in. 66 mM-Tris HC1, pH 7.4) were 
divided equally between two cuvettes and placed in a
thermostatted cuvette holder at 37°. A baseline of equal 
light absorbance between 350 and 500 nm was established.
The ligand was added to the sample cuvette in yl quantities 
of a solution in buffer or N,N-dimethylformamide, using a 
Terumo microlitre syringe (Shandon Southern Co. Ltd., 
Camberley, Surrey). An equal volume of solvent was added 
to the reference cuvette, and the contents of both cuvettes 
were mixed by gentle inversion. The difference spectrum 
between 350 and 500 nm was recorded.
2.5.5. NADPH; Regeneration and oxidation
During enzyme assays and spectral determinations 
where NADPH was required over long periods, an NADPH 
generating system was used. This consisted of 4.0 mM glucose-
6-phospha.te, and 2 units/ml of glucose-6-phosphate dehydro­
genase (E.C.1.1.1.49). In the presence of 200-400 yM NADPH 
this system was used to maintain constant NADPH concentrations 
for long time periods.
In certain cases it was necessary to oxidize 'iNADPH 
rapidly. This was brought about by the addition of 2.5 mM 
sodium- 2-oxoglutarate, 5.0 mM NH^Cl and 20 units/ml of 
glutamate dehydrogenase (E.C.1.4.1.2) to the microsomal 
suspension.
2.6. ASSAYS OF MONOOXYGENASE ACTIVITIES IN VITRO
2.6.1. Ethylmorphine and aminopyrine N-demethylation
Ethylmorphine and aminopyrine are metabolized in 
vitro .to give N-demethylated products, and formaldehyde 
which can be measured using Nash reagent (Nash,1953).
Reagents
2M ethylmorphine or aminopyrine in dimethylformamide 
700 mM Zinc Sulphate
320 mM Barium hydroxide (saturated solution)
2M Ammonium acetate containing 0.2% (v/v) acetylacetone
2.3 mM Formaldehyde 
66 mM Tris-HCl (pH 7.4)
31.12 mM NADPH in 66 mM Tris-HCl (pH 7.4)
40 mM Glucose-6-phosphate (sodium salt) containing 
20 units/ml glucose-6-phosphate dehydrogenase 
in 66 mM Tris-HCl (pH 7.4)
Method
Microsomal suspension (T mg protein/ml), 66 mM 
Tris-HCl (pH 7.4) ,. glucose-6-phosphate (4.0 mM), glucose-6- 
phosphate dehydrogenase (2 units/ml) and substrate (2.0 mM) 
were placed in 10 ml Sovfrel test tubes, giving a final incu­
bation of 2.5 ml. The tubes were preincubated for 5 min at 
37°. in a shaking water bath. This reaction was initiated with
NADPH (250 yM) and the incubation continued for 10 min. Zinc
sulphate solution (0.5 ml) and barium hydroxide solution (0.5 
ml) were mixed together in clean test tubes and the reaction 
was terminated by adding aliquots (1.0 ml) of the incubation, 
mixture to the zinc sulphate and barium hydroxide mixture.
The tubes were mixed and centrifuged at 1,500 g&v for 10 min. 
Aliquots (1.0 ml) of a freshly prepared mixture of acetyl­
acetone and ammonium acetate solution were pipetted into clean 
test tubes, and to these were added aliquots (1.0 ml) of the 
centrifuged incubation mixtures. These tubes were then 
incubated at 37° for 30 min, allowed to cool at room tempera- 
ture.and the absorbance at 405 nm was determined. Formaldehyde 
standards and appropriate blanks were run in parallel.
2.6.2. Biphenyl 2- and 4-hydroxylation
Biphenyl is metabolized to give two major products: 
2- and 4-hydroxybiphenyl. These products can be measured 
fluorimetrically in the same incubation mixture because of 
different fluorescent properties of 2- and 4-hydroxybiphenyl. 
The method used is a modification of that of Creaven et al. 
(1965).
Reagents
1.0 M Biphenyl in 'dime thy If or inamide 
4 N HCl
100 mM Sodium Hydroxide
n-Heptane containing 1% (v/v) 3-methyl-1-butanol 
250 mM Succinic acid
353 yM 4-hydroxybiphenyl in 5% (v/v) ethanol
70.5 yM 2-hydroxybiphenyl in 5% (v/v) ethanol 
66 mM Tris-HCl (pH 7.4)
25 mM NADPH in 66 mM Tris-HCl (pH 7.4)
40 mM Glucose-6-phosphate containing 20 units/ml
glucose-6^phosphate dehydrogenase in 66 mM Tris- 
HC1 (pH.7.4)
Method
Microsomal suspension (1 mg protein/ml), 66 mM 
Tris-HCl buffer (pH 7.4), glucose-6-phosphate (4.0 mM), glucose
6- phosphate dehydrogenase (2 units/ml) and biphenyl (2.0 mM) 
were added to give a final incubation volume of 2.0 ml in a . 
Soveril test tube. The tubes were preincubated for 5 min at 
37°. The reaction was initiated with NADPH (250 yM) and the 
incubation was continued for 10 min. The reaction was termin­
ated by placing the tubes on ice and adding 4 M HCl (0.5 ml). 
The 2- and 4-hydroxybiphenyl standards (14.1 yM and 70.6 yM 
respectively) and biphenyl (2,0 mM) were added to the appropri­
ate standard and blank tubes after the reaction was stopped.
The tube contents were mixed, and to each tube was added 
n-heptane containing 1% (v/v) 3-methyl-1-butanol (7.0 ml).
The tubes were capped and mixed on a tumble mixer for 10 min. 
The caps were removed and the tubes were centrifuged at 2,000
g for 5 min at 4°. Portions (2.0 ml) of the upper (heptane) av
layer were pipetted into clean Sovirel tubes and 100 mM NaOH 
(5.0 ml) was added to each tube. The tubes were capped and 
extracted as before, and then centrifuged at 2,000gav for 
15 min at 4°. The upper (heptane) layer and the suspension 
at the interface were removed using a Pasteur pipette attached 
to a water pump. Aliquots (2.0 ml) of the aqueous layer
were placed directly in the. fluorimeter cuvette, and 250 mM 
succinate (0.5 ml) was added with mixing. The fluorescence 
of 4-hydroxybiphenyl was measured using an excitation wave­
length of 275 nm and an emission wavelength of 338 nm, and 
the fluorescence of 2-hydroxybiphenyl using an excitation 
wavelength of 295 nm and an emission, wavelength of 415 nm.
2.6.3. 7-Ethoxyresorufin-0-deethylation
7-Ethoxyresorufin is metabolized by hepatic micro­
somes. to a single fluorescent product: resorufin. The • 
reaction can be measured continuously by monitoring the 
increasing fluorescence of resorufin. The method used is a 
modification of that described by Burke and Mayer (1975).
Reagents
50 yM 7-Ethoxyresorufin in methanol 
10 yM Resorufin in ethanol 
66 mM Tris-HCl (pH 7.4)
31.12 mM NADPH in 66 mM Tris-HCl (pH 7.4)
Method
Microsomal suspension (200 yg protein/ml)# 7-ethoxy 
resorufin (0.2 yM) and 66 mM Tris-HCl (pH 7.4) in a final 
volume of 2.5 ml were mixed together in a fluorescence cuvette 
The cuvette contents were allowed to equilibrate to 37° for 
5 min in a thermostatted cell holder. The reaction was 
initiated by ...the addition of NADPH (250 yM) and the time- 
dependent increase in fluorescence at 586 nm was monitored 
using an excitation wavelength of 510 nm. At the end of the 
reaction resorufin (40 nM) was added to calibrate the 
measurement of the reaction process.
2.7. ASSAYS OF OTHER MICROSOMAL AND SOLUBLE ENZYMES
IN' WTRO
2.7.1. Epoxide hydratase (E.C. 4.2.1.63)
Epoxide hydratase activity was measured by the 
hydration of G £^H ] -benzo(a)pyrene-4,5-oxide to [^H ] -
benzo(a)pyrene-4,5-dihydrodiol, using the method of Schmassmann 
et al. (1976).
Reagents
3 mM P h ] -Benzo(a)pyrene-4,5-oxide (0.96 m Ci/m mol) 
in acetonitrile
500 mM Tris-HCl (pH 9.0)
Method
Microsomal suspension (0.2 mg protein/ml), 100 mM 
Tris-HCl (pH 9.0) and distilled water were mixed in Sovirel 
test tubes to give a final volume of 0.5 ml. After a 2 min 
preincubation at 37°, the reaction was initiated by the addition 
of [ h ] -benzo(a)pyrene-4,5-oxide C150 yM, 72 . nCi). The 
incubation was continued for 10 min, and the reaction was. 
stopped by the addition of petroleum ether (b.p. 40-60°)
(3.5 ml), followed by mixing and cooling on ice. DMSO (0.5 
ml) was added and the tubes were capped and mixed for 3 min 
on a rotary mixer. After centrifugation at 400 g for 1 min, 
the petroleum ether was removed by aspiration, and the process 
was repeated twice•using extraction times of 5 and 10 min.
The product, benzo(a)pyrene-4,5-dihydrodiol was then extracted 
into ethyl acetate (1 ml) by mixing for 10 min. The phases 
were separated by centrifugation at 400 g for 3 min and an o 
aliquot of the ethyl acetate layer was removed for scintillation 
counting. Blanks.containing boiled microsomes, and [ h ] - 
benzo(a)pyrene-4,5-oxide standards were also prepared. 
Scintillation counting was carried out in a toluene/metapol 
(3:1) scintillant containing 0.02% (w/v) dimethyl POPOP and 
0.5% (w/v) PPO. Samples were counted on an LKB 1216 Rack Beta 
scintillation counter. Standardization was by an external 
standard channels ratio method. Counting efficiencies were 
calculated by computer, using a quench correction curve 
prepared with ^ h J-toluene as standard.
2.7.2. NADPH: cytochrome c reductase (E.C. 1.. 6 .2. 4)
This enzyme is thought to be the same as NADPH: 
cytochrome P-450 reductase. However, direct measurement of
cytochrome P-450 reduction is difficult to carry out routinely, 
so cytochrome c is used as. an alternative electron acceptor.
The reduction of cytochrome c was monitored spectrophoto- 
metrically using the method of Williams and Kamin (1962). 
Reagents
0.1 M Potassium phosphate buffer (pH 7.4) containing 
1 mM KCN 
0.1 mM Cytochrome c
3 mM NADPH in 0.1 M potassium phosphate buffer (pH 7.4)
Method
Microsomal suspension (0.1 mg protein/ml) , cyto-. 
chrome c (33 yM) and 0.1 M potassium phosphate buffer (pH 7.4) 
containing 1 mM KCN were placed in each of two cuvettes to 
give a final volume of 2.9 ml in the sample and 3.0'ml in the 
reference. The cuvettes were preincubated at 25° for 5 min, 
and the reaction was started by addition of NADPH (0.1 mM) to 
the sample cuvette. The reduction of cytochrome c was 
measured by monitoring the absorbance change at 550 nm, and 
an extinction coefficient of 18.5 mM ^.cm \  was used to 
calculate the rate of reduction.
2.7.3. UDP qlucuronyltransferase (E.C. 2.4.1.17)
UDP glucuronyltransferase activity was measured 
using two aglycones as substrate: 1-naphthol and 4-nitro- ■ 
phenol.
For the measurement of the glucuronidation of 1- 
naphthol the method of Bock (1974) was used.
Reagents
2.0 mM 1-naphthol containing 25 mM. MgCl^
0.2 M Tris-HCl buffer (pH 7.6) containing 0.2% (v/v)
Brij 35 
50 mM UDP-glucuronic acid 
0.5 M Glycine-TCA buffer (pH 2.2)
1.0 M Glycine-NaOH buffer (pH 10.6)
Method
UDP-glucuronic acid (5mM), 1-naphthol (0.4 mM) , 
Tris-HCl buffer (pH 7.6, 0.1 M) , M g C ^  (5 mM) and Brij 35
(0.1% v/v) were mixed together to give a final volume of 
0.4 ml. Preincubation was carried out at 37° for 5 min, and 
the reaction was started by the addition of microsomal 
protein (0.1 mg protein/ml) which gave a final incubation 
volume of 0.5 ml. After incubation at 37° for 4 min, the 
reaction was terminated by the addition of ice-cold 0.5 M 
glycine-TCA buffer (pH 2.2, 1.0 ml). Each incubate was 
extracted with chloroform (6 ml) for 10 min on a rotary mixer 
and centrifuged at 2,000 gav for 5 min. An aliquot, of the 
aqueous layer (0.5 ml) was removed and adjusted to a final
volume of 2.0 ml with 1.0 M glycine NaOH buffer (pH 10.6).
The fluorescence was measured using an excitation wavelength 
of 300 nm and an emission wavelength of 344 nm. Appropriate 
blanks and standards containing l-naphthol-£,D-glucuronide 
(40 yM) were run in parallel.
The glucuronidation of 4-nitrophenol was measured 
using a method modified from that reported by H&nninen (1968). 
Reagents
3.5 mM 4-nitrophenol
0.2 M Tris-HCl buffer (pH 7.6) containing 10 mM MgC^ ,
and 0.2% (v/v) Brij 35
70 mM UDP-glucuronic acid 
0.17 M TCA
5.0 M NaOH
Method
UDP-glucuronic acid (3.0 mM), 4-nitrophenol (0.35 
mM),'Tris-HCl buffer (pH 7.6, 0.1 M ) , Brij 35 (0.1%, v/v) and 
MgCl2 (5.0 mM) were mixed together to give a final volume of 
60 yl. Following preincubation at 37° for 5 min, the reaction 
was. started by the addition of microsomal suspension (0.25 mg 
protein/ml) which gave a final volume of 100 yl. After 
incubation for 10 min the reaction was terminated by the 
addition of 0.17 M TCA (0.9 ml). After centrifugation 5 M 
NaOH (0.1 ml) was added to the supernatant and the absorbance 
at 400 nm was measured. Appropriate blanks containing either 
no 4-nitrophenol or no UDPGA were run in parallel.
2.7.4. Glutathione S-transferase (E.C. 4.4.1.7)
Glutathione S-transferase activity was measured 
using l-chloro-2,4-dinitrobenzene as substrate by the method 
of Habig et al. (1974).
Reagents
50 mM l-Chloro-2:, 4-dinitrobenzene in ethanol
0.1 M Potassium phosphate buffer (pH 6.5)
50 mM GSH in 0.1 M potassium phosphate buffer (pH 6.5)
Method
GSH (1 mM), l-chloro-2,4-dinitrobenzene (1.0 mM)
and 0.1 M Potassium: .phosphate buffer (pH 6.5) were mixed in two
cuvettes to give a final volume of 2.5 ml in the reference c
cuvette and 2.4 ml in the sample cuvette. Both cuvettes
were incubated at 25°C for 4 min and the reaction was initiated
by addition of soluble fraction (5-10 y9 protein in 100 yl)
to the sample cuvette. The change in absorbance was monitored
at 340 nm, and the rate of reaction was calculated using an
-1 -1extinction coefficient of 9.6 mM .cm .
2.8. GEL ELECTROPHORESIS OF MICROSOMAL PROTEINS
2.8.1. Sodium dodecyl sulphate polyacrylamide disc gel
electrophoresis
The method of Laemmli (1970) was used routinely for 
analysis of microsomal proteins. The microsomal suspensions 
are initially solubilized with sodium dodecyl sulphate and 
then -separated on polyacrylamide using a discontinuous buffer 
system.
Reagents
Gel Stock: 30% (w/v) acrylamide containing 0.8% (w/v) 
N,Nf-methylenebis-acrylamide 
Buffer 1: 1.5 M Tris-HCl (pH 8.8) containing 0.4% (w/v) 
SDS
Buffer 2: 500 mM Tris-HCl (pH 6.8) containing 0.4%
(w/v) SDS
Buffer 3: 25 mM Tris-HCl (pH 8.3) containing 192 mM 
glycine and 0.1% (w/v) SDS 
Buffer 4: 62.5 mM Tris-HCl (pH 6.8) containing 2.3%.
(w/v) SDS, 15% (v/v) glycerol, 5% (v/v) 
2-mercaptoethanol and 0.001% bromophenol blue
Ammonium persulphate 10% (w/v)
Method
A vertical slab gel apparatus made in the workshop 
of the Biochemistry Department was used. The gel was contained 
in a glass and perspex cuvette, with internal dimensions of 
120 mm x 100 mm x 1.5 mm. Electrophoresis was carried out at 
room temperature.
The glass plates of the gel cuvette were washed 
in detergent; rinsed with tap water:, distilled water, methanol 
and acetone, and allowed to dry. The cuvette was assembled 
and sealed with 1.5% (w/v) molten agar and then clamped in 
a vertical position. The lower (running) gel was prepared 
by mixing Buffer 1 (10 ml), gel stock (13.3 ml), water (16.6 
ml), and polymerization was initiated by addition of N,Nf- 
tetramethylethylenediamine (20 yl) and freshly prepared 
ammonium persulphate solution (240 yl). The solution was 
poured into the glass cuvette to a height of 80 mm. A layer 
of distilled water was introduced above the gel mixture to 
ensure a flat interface between the separating gel and 
stacking gel after polymerization. When polymerization was 
complete the water layer was removed and the upper (stacking) 
gel, consisting of a mixture of Buffer 2 (2.5 ml), gel stock 
(1.0 ml), water (6.5 ml), ammonium persulphate solution 
(10%(w/v), 60yl) and TEMED (20 yl) was added to the cuvette 
above the stacking gel. A perspex comb was introduced into 
the r u-nndng gel before polymerization to form the sample 
wells. The comb was removed when polymerization was complete 
and a small amount of Buffer 3 was introduced into the sample 
wells to keep them separate. The lower spacer was removed 
from the cuvette, and the cuvette was then placed in the 
electrophoresis tank. Buffer 3 was added to the upper and 
lower reservoirs, arid air bubbles trapped underneath the gel 
were removed using a syringe..
Microsomal suspensions were diluted with Buffer .4 
to a final concentration of 1 mg protein/ml. Samples were
placed in a boiling water bath for 3 min. The samples were 
cooled and applied to the stacking gel. The amount of 
protein for electrophoresisiof microsomal protein was gener­
ally 15 y g. A constant current of 20 mA was used until the 
bromophenol blue entered the separating gel, and then this 
was increased to a constant current of 40 mA until the 
bromophenol blue was within 5 mm of the end of the gel. The 
cuvette was removed from.the tank when electrophoresis was 
complete. The glass plates were separated, the stacking gel 
removed and the gel stained a s .described below.
2.8.2. Gradient gel electrophoresis
Gradient gel electrophoresis was carried out using 
a Uniscil gradient gel tank and Gradipore continuous concave 
gradient gels (2.5 - 28% acrylamide and crosslinker gradient 
of 3.5 - 6.2%). A continuous circulating buffer system was 
used.
Reagents
Buffer 1: 90 mM Tris (pH 8.3) containing 2.5 mM EDTA,
81.5 mM boric acid and 0.1% (w/v) SDS 
Buffer 2: 62.5 mM Tris-HCl (pH 8.3) containing 2.3%
(w/v) SDS, 15% (v/v) glycerol, 5% (v/v) 2- 
mercaptoethanol and 0.001% bromophenol blue
Method
The precast gels were loaded into the electrophoresis 
tank and the electrode reservoirs filled with Buffer 1. The 
gels were pre-electrophoresed at 10 mA (50 V) for 40 min before 
application of the sample. Micfosomal suspensions were 
diluted with Buffer 2 to give a protein concentration of 1 mg/ 
ml, and heated in a boiling water bath for 3 min. The samples 
were applied to the gel using a spacer to keep the samples 
separate. This was removed after the samples had migrated 
into the gel. Electrophoresis was carried out for 16 h at 
15 mM (75 V). The gels were then removed from the cassettes 
and stained appropriately, as described below.
Gradient gel electrophoresis was also carried out 
using sodium cholate as detergent.
Reagents
Buffer 1: 25 mM Tris-HCl (pH 8.3) containing 192 mM 
glycine and 0.1% (w/v) sodium cholate 
Buffer 2: 62.5 mM Tris-HCl (pH 7.7) containing 20%
(v/v) glycerol, 2 mM EDTA, 1 mM DTT 
10% (w/v) sodium cholate
Method
The gels were pre-electrophoresed with Buffer 1 for 
40 min at 10 mA.
Microsomal suspensions were diluted with Buffer 2 
to give a protein concentration of 5 mg/ml, and then sonicated 
for 3 x 10 s intervals using a Soniprobe (Dawe Instruments Ltd., 
London). Sodium cholate solution was added to give a ratio 
of 3 mg cholate/mg protein. The samples were applied to the 
gel and electrophoresis was carried out at 4° at a constant . 
voltage of 150 V for 18 h. Following electrophoresis, the 
gels were removed from the cassettes and stained appropriately.
2.8.3. SDS polyacrylamide continuous gel electrophoresis
The continuous buffer system of Fairbanks et uZ.(1971) 
was used with a 5.6% acrylamide gel..
Reagents
Gel Stock: 40% (w/v) acrylamide containing 1.5% (w/v)
N,N*-mefchylenebisacrylamide 
Buffer 1: 0.4 M Tris-Acetate (pH 7.4) containing 0.2 M
sodium acetate and 0.02 M EDTA 
Buffer 2: 40 mM Tris-Acetate (pH 7.4) containing
20 mM sodium acetate, 2 mM EDTA and 0.1%
(w/v) SDS
Buffer 3: 10 mM Tris-HCl (pH 8.0) containing 15% (w/v)
glycerol,.1 mM EDTA, 1% (w/v) SDS and 0.001% 
(w/v) bromophenol blue.
10% (w/v) SDS
Method
The gel cassette was washed and sealed as described 
in 2.8.1. The gel was prepared by mixing gel stock (5.6 ml), 
Buffer 1 (4.0 ml) 10% SDS. (0.4 ml), ammonium persulphate sol­
ution (0.6 ml of 10% (w/v)) and water (29.4 ml). The gel 
mixture was poured into the cassette and the sample comb was 
introduced into the unpolymerized gel. When polymerization 
was complete the comb was removed, and the top of the gel was 
covered with Buffer 2. The electrode reservoirs were filled 
with buffer and the cassette placed in position in the tank.
Microsomal samples were diluted with Buffer 3 to 
give a protein concentration of 3 mg/ml. The samples were 
allowed to stand for 20 min at room temperature, before 
application to the gel at 4°. Electrophoresis was carried 
out at 20 mA until the samples had entered the gel and then 
the current was increased to 40 mA. Following electror- 
phoresis the gel was removed and stained appropriately.
2.8.4. Disc gel electrophoresis using Renex 690 as detergent
This method is an adaptation of that used by Ueda 
et al, (1972).
Reagents
Gel Stock: 30% (w/v) acrylamide containing 0.8% (w/v) 
N,N'-methylenebisacrylamide 
Buffer 1: 1.5 M Tris-HCl (pH 8.8) containing 0.1%
(v/v) Renex 690 
Buffer 2: 500 mM Tris-HCl (pH 6.8) containing 0.1%
(v/v) Renex 690 
Buffer 3: 25 mM Tris-HCl (pH 8,3) containing 192 mM
glycine and 0.1% (w/v) Renex 690 
Buffer 4: 62.5 mM Tris-HCl (pH 6.8) containing 1.4%
(v/v) Renex 690, 15% (v/v) glycerol 'and 
0.001% bromophenol blue 
10% (w/v). Ammonium persulphate
Method
The gel cassette was prepared as described in 2.8.1. 
The separating gel solution was prepared by mixing gel stock 
(10 ml), Buffer 1 (10 ml), water (20 ml), and polymerization 
was initiated by adding ammonium persulphate solution (0.24 
ml) and TEMED (20 ul). The stacking gel was prepared by 
mixing gel stock(0.83 ml), Buffer 2 (2.5 ml), water (6.7 ml) 
ammonium persulphate solution (60yl) and TEMED (20 yl). When 
the gel had polymerized the spacer comb was removed and the 
gel placed in the electrophoresis tank, filled with Buffer 
3.
Microsomal samples were prepared by diluting with 
Buffer 4 to give a concentration of 5 mg protein/ml, and 
stirring on ice for 20 min. The samples were applied to the 
gel and electrophoresed at 4° at 17 mA in the stacking gel and 
40 mA in the running gel.
2.8.5. Detection of proteins on polyacrylamide gels
The principal means used for the detection of
proteins was the Coomassie Blue stain.
Reagents
Propan-2-ol/acetic acid/water (5:2:13 by vol.) containing 
0.05% (w/v) Coomassie Blue G-250 
Propan-2-ol/acetic acid/water (1:1:8 by vol.)
Method
Staining of the proteins was achieved by immersing 
the gel overnight in propan-2-ol/acetic acid/ water (5:2:13 
by vol.). containing O.o5% w/v Coomassie Blue G-250. The gel 
background was destained by immersing in progressive changes 
of propan-2-ol/acetic acid/water (1:1:8 by vol.) over a period 
of 48 h. The gels were stored in 3% (v/v) glycerol at 4° 
once the background was cleared.
2.8.6. Detection of haemoproteins after SDS gel electro­
phoresis
Staining for peroxidase activity has been widely 
used for the detection of haem and haemoproteins following gel
electrophoresis. Treatment of cytochrome P-450 with SDS 
results in conversion to cytochrome P-420 which has considerable 
peroxidase activity (Hrycay and O'Brien 1971 a,b):. Under 
the mild conditions of electrophoresis described below a 
proportion,of the haem remains attached to the apoprotein, thus 
facilitating identification as a haemoprotein. The tetramethyl- 
benzidine-peroxide-Stain described by Thomas et at, (19 76 c) was 
used.
Reagents
Buffer 5: 62.5 mM Tris-HCl (pH 6.8) containing 1.0%
(w/v) SDS, 15% (v/v) glycerol and 0.001% (w/v) 
bromophenol blue
6.3 mM 3,3',5,51-Tetramethylbenzidine (TMBZ) in methanol 
Buffer 6: 250 mM Sodium acetate buffer (pH 5.0)
Buffer 7: 250 mM Sodium acetate buffer (pH 5.0) containing 
30% (v/v) propan-2-ol
Method
The separating and stacking gels were prepared as 
described in 2.8.1. The microsomal samples were diluted to . 
give a protein Concentration of 3 mg/ml with Buffer 5. Samples 
(15 - 60 yg protein) were applied to the stacking gel. Electro­
phoresis was carried out at 4° in the dark using 10 mA in the 
stacking gel and 25 mA in the separating gel. When the 
tracking dye was within 5 mm of the end of the gel, the 
separating gel was removed and placed in a mixture of freshly 
prepared 6.3 mM TMBZ in methanol and Buffer 6 (3:7, v/v) at
room.temperature in the dark.. After 1 h with occasional mixing,
hydrogen peroxide was added to the mixture to give a final 
concentration of 3 mM. Staining was complete after 30 min, 
and the gel was placed in Buffer 7. The stain could be 
removed completely by soaking the gel in several changes of 
70 mM sodium sulphite solution, thus facilitating subsequent 
staining for protein as described in 2*8.5.
2.8.7. Detection of NADPH:cytochrome c reductase following
gel electrophoresis
NADPH:cytochrome c reductase can be detected 
following electrophoresis by!.the reduction of 2-(p-iodo-
phenyl)-3-(p-nitrophenyl)-5-phenyltetrazolium chloride (INT) 
which forms an insoluble pink formazan dye on reduction 
(Ueda et ,al.9 1972).
Reagents
100 yM INT 
NADPH (solid)
Method
Electrophoresis was carried out as described in
2.8.4. Following electrophoresis the separating gel was 
immersed in 100 yM INT for 30 min. NADPH was added to give 
a final concentration of 0.1% (w/v). The gel, still immersed 
in the staining solution, was incubated at 37° for 20 min 
until the pink colour developed.
CHAPTER 3
CHARACTERISATION OF CYTOCHROME P-450 
AND OTHER MICROSOMAL PROTEINS USING 
GEL ELECTROPHORESIS
3. CHARACTERIZATION OF CYTOCHROME P-450 AND OTHER
MICROSOMAL PROTEINS USING GEL ELECTROPHORESIS
3.1. INTRODUCTION
•3 .1 .1 . Electrophoretic techniques
The most important early method for the electrophor­
etic analysis of proteins was that of Tiselius (1937), involving 
moving boundary electrophoresis in a liquid system. The advent 
of zonal electrophoresis on a paper support permitted routine 
examination of multiple samples of proteins, and cellulose 
acetate strips have since displaced paper as the preferred 
support for routine electrophoresis. The resolving powers 
of electrophoresis on paper and cellulose are not very great, 
but have been greatly increased by using starch, agar or poly­
acrylamide as support. Acrylamide readily forms gels over a 
wide range of concentrations from 2% up to greater than 20%,
facilitating separation of proteins with molecular weight as
6high as 1 - 2x; 10 and as low as 2,000.
Two striking differences can be seen when comparing 
the behaviour of proteins during separation by zone electro­
phoresis in gels with their behaviour during paper or moving 
boundary electrophoresis:
i) the measured mobilities are different in magnitude and even 
the order of mobilities can be reversed, due to the sieving 
effect of the gel... This is related to the molecular size of 
the protein relative to pore size (Smithies, 1955);
ii) more fractions are resolved in gels and the zones are 
usually sharper than in paper or free electrophoresis due 
to reduced diffusion spreading.
Acrylamide gels are considered to have an average 
pore size which is inversely related to the acrylamide 
concentration, T. When macromolecules are forced through the 
gel by the applied electric field, the relative mobility of 
the macromolecule in the gel, R^, is less than the relative 
mobility in the solution, Yq .
These relationships define the retardation coefficient, K 
(Ferguson, 1964):
-K = log R- - log Y r ■ f  ^ o (1)
T
.Within certain ranges Kr is a uniform function of the Stokes 
radius.
herent advantages of the polyacrylamide gel matrix are 
enhanced by the use of planned buffer discontinuities which 
lead to the concentration of the sample into a thin starting 
zone prior to the resolving phase of electrophoresis (Ornstein, 
1964; Davis, 1964). The theoretical basis for the concentration 
of proteins bydiscontinuous buffer systems or 'steady-state 
stacking' (Ornstein, 1964) is derived from the Kohlrausch 
regulating function by extension of the treatment for moving 
boundaries of weak electrolytes. If two solutions of ions are 
layered one on top of the other such that a solution with ions 
of a substance y of high mobility is placed below a solution 
with ions of a substance ct of low mobility with the same sign 
and charge, then the boundary between the two ionic species 
would be sharply maintained as they migrated in an applied 
electric field (provided that the lower solution was the 
denser of the two and migration was downward). In gels and 
porous media, given sufficient time, a sharp moving boundary 
will be formed and maintained independent of the densities of 
the starting solution and their initial concentrations, 
provided that the faster ions precede the slower. The following 
equation provides the ratio of the total concentrations of a 
substance (A) to y substance (r) for initiating and maintaining 
a-stable moving boundary:
where x is the fraction of dissociation, c is the concentration, 
m is the mobility and a ,$ and yare the ions (with $ of opposite 
charge to a and y and common to both solutions). To achieve 
steady-state stacking the conditions of pH and gel concentration
In the case of 'disc' gel electrophoresis the in-
(2)
are chosen so that the proteins have intermediate mobilities
between those of the leading ion y and the trailing ion a . As
electrophoresis proceeds, the proteins will concentrate in
order of mobility at the boundary between the leading ion and
trailing ion at a concentration satisfying equation (2) where
a is. now a single protein, 3 is the counter ion and y the
' leading ion. The final concentration of a component in the
stack is independent of the starting concentration of the
sample. When the moving boundary is established, all the
proteins will have concentrated into very thin discs, one
stacked on top of another in order of decreasing mobility, with
the. last followed immediately by the trailing ion. This process
is termed A steady-state stacking* (Ornstein,1964). The ultra-
- 2thin 'stacks' (^ 10 cm thick) result’ in markedly improved 
resolution. If the leading ion and the following stacked 
proteins are allowed to pass into a gel of’smaller pore size 
than the stacking gel such that the mobility of the fastest 
protein falls below that of the trailing:’ion, then the trailing 
ion will overrun the protein discs and run directly behind the
leading ion. The proteins will now be in a uniform linear
voltage gradient, each effectively an extremely thin starting 
zone and migrate as in zone electrophoresis with separation 
based on charge and molecular sieving. Alternatively, if 
the boundary and the following stack of discs are allowed to 
pass into a region of higher or lower pH such that the mobility 
of the trailing ion is higher than the mobility of the proteins,
. the trailing ion will overrun the proteins and run directly 
behind the leading ion. The proteins will now be in a linear 
voltage gradient*, each effectively an extremely thin starting 
zone* and will migrate as in zone electrophoresis with separation 
based on charge. These two features may also be used in 
combination to bring about unstacking.
It has been shown (Hendrick and Smith, 1968) , that 
by use of the Ferguson equation (1) rewritten as:
log Rf = -KrT + log Yq (3)
molecular weights of globular proteins could be calculated if 
relative mobilities are measured at more than one gel
concentration. By plotting log Rf values against T, Hendrick 
and Smith obtained straight lines with slopes of -K • Replotting 
Kr against mol. wt. provides a linear relationship from which 
molecular weights of unknown proteins can be obtained. Using 
this approach the relative mobility in solution, Y , or the 
mobility at zero gel concentration is a function of the protein 
and depends on charge, shape and size.
Polyacrylamide gradient gels have been used to 
separate proteins on the basis of molecular weight, with protein 
molecules of different sizes coming to a 'dead stop' on reaching 
a limiting pore size (Margolis and Kendrick, 1968). However, it 
has since been shown (Rodbard et at.* 1971) that proteins do not 
come to a 'dead stop* and that mobility is a function of time 
and the gel gradient. By using gels with an exponential concen­
tration gradient and sufficiently long electrophoresis times, 
the distance migrated by the protein will approximate to the 
distance of the limiting pore size, and this can be used to 
yield information about the molecular weight (Manwell,1977). The 
major advantage in using gradient gels is that protein mixtures 
.of widely varying molecular weights can be separated relatively 
easily (Rodbard et al.s 1971).
The use of sodium dodecyl sulphate as a detergent in 
electrophoresis systems was pioneered by Shapiro et al. (1967) and 
extended by Weber and Osborn (1969). These workers described a 
linear relationship between log R^ and Kr at any given gel conc­
entration for SDS protein complexes. If the cross-linking and 
shape factors are constant then log R^ is a direct function of 
molecular wt. Molecular weights could then be calculated from 
the mobility of a given set of standards at a single gel concen­
tration. Ferguson plots for different SDS-protein complexes 
intersect the y axis at virtually the same point for a wide 
range of proteins (Neville,1971; Weber and Osborn,1975) indicat­
ing that Yq is nearly a constant, which confirms the findings 
of a linear relationship between Kr and log R^ (Shapiro et al.3 
1967; Weber and Osborn, 1969). The nearly constant value for 
in SDS-gel electrophoresis indicates that protein-SDS complexes 
behave such that their free mobility is independent of charge 
and size. Independence of protein charge demands a high degree 
of SDS binding, and independence of size demands that the ratio 
of effective charge to frictional coefficient must be constant.
These considerations indicate that for protein-
SDS complexes the charge per unit mass is approximately
constant, and the ratio of effective charge to frictional
coefficient is approximately constant and independent of
molecular weight. Experimental work on protein-SDS complexes
supports these assumptions. Above an SDS monomer concentration 
-4o f .8 x 10 M, 1.4g of SDS are bound per gram of protein (Pitt- 
Rivers and Enpiombato 1968; Reynolds and Tanford, 1970 a, b) . 
This indicates that the number of molecules of SDS bound to 
a polypeptide chain is approximately half the number of amino 
acid residues. The high level of binding and constant ratio 
of SDS to protein will 'swamp out' the intrinsic charge of the 
protein, giving essentially a polysulphate with constant 
negative charge per unit mass. The hydrodynamic and optical 
properties of protein-SDS complexes indicate behaviour as 
prolate ellipsoids or rods (Fish et al,3 1970; Reynolds and 
Tanford, 19 70 b). The short axis is constant and of the order 
of 18A, while the long axis varies in proportion to the 
number of amino acids in the polypeptide chain. Subsequent 
investigators concluded that the complexes are flexible 
free-draining prolate ellipsoids (Wright, et aZ-.^  1975).
SDS-polyacrylamide gel electrophoresis has been 
widely used as an analytical tool for the study of membrane 
proteins. Disruption of the membrane and denaturation of the 
proteins within the membrane can be brought about by treatment 
with SDS and a sulphydryl-reducing agent. The application of 
SDS-polyacrylamide gel electrophoresis to membrane proteins 
depends on three assumptions (Maddy, 19 76):
i) The binding of detergent to a polypeptide disrupts all but 
the covalent interactions within chains and between chains, 
and interactions between proteins and lipids are destroyed.
ii) The binding of a detergent per unit length of polypeptide 
is constant and sufficient to abolish charge differences 
between polypeptides.
iii) Conformational differences between polypeptides are 
destroyed. Consequently differences in frictional drag during 
passage through the gel are caused by variation in molecular 
weight alone.
Various anomalies concerning the behaviour of membrane proteins 
on SDS-polyacrylamide gel'electrophoresis have been reported.
Not all membrane proteins are solubilized by SDS under standard 
conditions used in most laboratories (Maddy, 19 76). Although 
the bulk of the membrane lipid moves as a band of high mobility 
in front of the proteins on electrophoresis (Simons and Helenius, 
19 70), some lipid may be dissolved in the SDS associated with 
proteins (Dunn et aZ.,1975). Maddy (1976) has reported that 
the binding isotherms of SDS to different proteins indicate 
variations in the maximal amount of detergent bound between 
1.2 and 1.5 g/g. Grefarth and Reynolds (1974) have reported 
that one of the erythrocyte membrane glycoproteins binds
8-10g SDS/g. Although cytochrome b^ has a typical overall 
binding ratio of 1.3 g/g, the hydrophilic end'of the protein 
binds only 0.7 g/g while the hydrophobic end which is buried 
in the membrane binds 3.0 g/g (Robinson and Tanford, 1975).
3.1.2. Electrophoresis of microsomal cytochrome P-450
SDS-polyacrylamide gel electrophoresis has been 
used to examine the heterogeneity of microsomal cytochrome 
P-450. Using the continuous buffer system of Fairbanks et at. 
(1971), Welton and Aust (1974) resolved three haemoproteins 
with molecular weights of 45,000, 50,000 and 5 3,000 in rat 
liver microsomes. The haemoprotein of 50,000 mol. wt. 
predominated in control microsomes. Pretreatment with pheno- 
barbitone induced the 45,000 mol. wt. band, whereas pretreatment 
with 3-methylcholanthrene induces the band of 5 3,000 mol. wt. 
Alvares and Siekevitz (1973), using the discontinuous buffer 
system of Neville(1971) and a slab separating gel with a
7-15% linear acrylamide gradient, confirmed the above findings 
with phenobarbitone increasing bands of 47,000 and 49,000 mol. 
wt., whereas methylcholanthrene induced one band of mol. wt.
53,000. These authors also described the induction of all 
three bands by polychlorinated biphenyls. Haugen et al» (1976) 
demonstrated the potential of the same approach for analysis of 
the response of mouse liver microsomal membrane polypeptides 
to treatment with various inducing agents, including PCN.
SDS-polyacrylamide gel electrophoresis has been used as a 
method of classification of different types of cytochrome 
P-450 in purified preparations based on electrophoretic 
mobility (Haugen et ai,a 1975). Other inducing agents have 
also been examined using this technique. Cameron et aZ. (1976) 
described the induction of two membrane polypeptides by 
2-acetylaminofluorene and certain other nitrogen containing 
carcinogens. These proteins differed from those induced by 
phenobarbitone or 3-methylcholanthrene. One band was thought 
to be epoxide hydratase and the other a new cytochrome P-450 
band. Ohnishi and Lieber (19 77) have reported that chronic 
ethanol administration results in the induction of one or 
two microsomal polypeptides. Birnbaum et at. (1976) reported 
the' induction of a polypeptide in rat by PCN which was 
electrophoretically distinct from those induced by 3-methyl 
cholanthrene or phenobarbitone. Dickinset aZ. (1978) have 
reported the induction of a novel haemoprotein by isosafrole, 
which has an intermediate molecular weight between the bands 
induced by 3-methylcholanthrene or phenobarbitone. Sharma et 
al, (1979) have recently described twelve different patterns 
of induction following treatment of rats with phenobarbitone, 
methylcholanthrene, PCBs, acetylaminofluorene/ safrole, PCN or 
ethanol, either singly or in various combinations.
3.2 . RESULTS
3.2.1. Comparison of the effect of pretreatment with
phenobarbitone, 3-methylcholanthrene and isosafrole 
on the microsomal haemoproteins
In microsomes from animals pretreated with either 
saline or corn oil there are four major protein bands in the 
region of 47,000 - 55,000 mol. wt. (see Fig. 3.1.). Band 1 
(48,000 mol. wt.) is slightly increased by treatment with 
phenobarbitone or isosafrole. Band 2 (49,000 mol. wt.) remains 
unchanged on pretreatment. Band 3 (50,000 mol. wt.) is induced 
by phenobarbitone. This band may consist of more than one 
protein with similar molecular weights because of its length 
following electrophoresis. Band 4 (mol. wt. 53,000), which is 
barely detectable in control microsomes, is not induced by 
phenobarbitone, as is band 5 (mol. wt. 55,000). Pretreatment 
with 3-methylcholanthrene produces little change in bands 1, 2 
and 3, but produces a small increase in band 4 and a large 
increase in band 5. Isosafrole produces a major increase in 
band 4 and a possible slight increase in band 3, and no change in 
bands 2 and 5.
Measurement of molecular weight was carried out by 
plotting a graph of log mol. wt. against mobility for standard 
proteins, and using this graph calculating the molecular r'- 
weights of unknown proteins by interpolation (see Fig. 3.2.).
3.2..2. Staining of microsomal haemoproteins for peroxidase
activity following SDS-polyacrylamide gel electro­
phoresis
Sample pretreatment with the omission of 2-mercapto- 
ethanol and a heat treatment step as described in 2.8.6. 
facilitates staining of the polyacrylamide gel following 
electrophoresis for the peroxidase activity of haemoproteins.
In Fig. 3.3. the result of peroxidase staining using TMBZ 
and hydrogen peroxide can be seen. There appear to be three 
bands in the 45,000 - 55,000 mol. wt. region. Microsomal ■ 
samples from animals pretreated with phenobarbitone (wells 1 
and 6) and 3-methylcholanthrene (wells 4 and 9) showed the . 
greatest staining intensity. Isosafrole pretreatment seems
FIGURE 3.1.
SDS-Polyacrylamide gel electrophoresis of liver 
microsomal proteins from rats pretreated with 
phenobarbitone, 3-methylcholanthrene or isosafrole
r
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Rat hepatic microsomes were solubilized and 
subjected to SDS disc gel electrophoresis as 
described in 2.8.1. After electrophoresis, 
the gel was stained for protein with Coomassie 
Blue. Samples were microsomes from rats pre­
treated with the following: Well 2, pheno­
barbitone; Well 3, saline; Well 4, corn oil;
Well 5, 3-methylcholanthrene; Well 6, isosafrole. 
The same amount of protein (15 yg) was applied 
to the gel for each sample. Standard proteins 
(1.5 yg) were applied in Wells 1 and 7. The 
arrows on the left denote the protein bands
1,2,3,4,5. The origin is at the top of the gel.
FIGURE 3.2.
SDS-Polyacrylamide gel electrophoresis of 
standard molecular weight proteins
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Standard molecular weight proteins were . 
dissolved in 62.5 mM Tris-Hcl (pH 6.8) 
containing 2.3% (w/v) SDS, 15% (v/v) 
glycerol, 5% (v/v) mercaptoethanol and 
0.001% bromophenol blue. The proteins 
(1.5 yg of each) were applied to the gel 
in parallel with the solubilized micro^- 
somal samples. The proteins used were: 
bovine serum albumin (6 7,000), catalase
(60.000), hen egg albumin (45,000) aldo­
lase (40,000), chymotrypsinogen A
(25.000). Determination of the molecu­
lar weight of microsomal proteins was 
carried out by interpolation from a 
graph of log mol. wt. versus mobility 
of the standard proteins.
to increase a higher molecular weight band as does 3-methyl- 
cholanthrene, whereas phenobarbitone pretreatment increased 
the intensity of two lower mol. wt. bands. Following removal 
of the peroxidase stain and restaining for protein using 
Coomassie Blue it can be seen (Fig. 3.4.) that the resolution 
of the protein bands is greatly reduced compared- to that 
achieved in Fig. 3.1., where more vigorous sample pretreatment 
is employed. The use of a slightly more vigorous sample 
pretreatment was investigated using lower amounts of protein 
than those required for peroxidase staining. Samples were 
placed on ice following mixing with sample buffer, or incubated 
at room temperature for 15 min, or boiled for 1 min. The 
result of these pretreatments can be seen in Fig 3.5. Although 
the resolution is improved by boiling for 1 min, it is still 
not directly comparable to that achieved on boiling with 2- 
mercaptoethanol. Use of the continuous buffer system of 
Fairbanks et at. (1971) did not bring about any improvement 
in the resolution of the protein bands (see Fig. 3.6.), and 
the vast majority of the haem staining material did not migrate 
from the origin. Incorporation of 2.5% (v/v) 2-mercapto- 
ethanol into the sample buffer to improve the resolution of 
the discontinuous buffer system of Laemmli (1970).: produced 
interference with the peroxidase stain (results not shown), 
since no bands with peroxidase activity could be found on the 
gel. This is in contrast to the situation where mercapto- 
ethanol is omitted, when a peroxidase band is located near 
the bottom of the gel following electrophoresis. This band is 
thought to be due to free haem and cytochrome b^. Substitution 
of DTT for mercaptoethanol does not inhibit haem staining, but 
the resolution of protein is not greatly improved, and the 
retention of haem by the proteins is low.
3.2.3. Non-denaturing detergent systems for the resolution
of cytochrome P-450
The use of non-denaturing gel systems for reso­
lution of cytochrome P-450 was studied using several gel
FIGURE 3.3
SDS-Polyacrylamide disc gel electrophoresis 
of microsomal proteins from animals treated 
with various inducing agents: the tetramethyl- 
benzidine stain for haem-containing polypeptides,
Samples were prepared ~ and electrophoresed as 
described in 2.8.6. The gel was immersed in 
a mixture of 6.3 mM TMBZ in methanol and 
250 mM sodium acetate buffer pH.'5.0 (3:7 v/v) 
in the dark. After one hour with occasional 
mixing hydrogen peroxide was added to give a 
final concentration of 3: mM. After 30 min, 
the gel was placed in 250 mM sodium acetate 
buffer (pH 5.0) containing 30% (v/v) propan-
2- ol. Samples were microsomes from rats 
pretreated with the following: Wells 1 and 6, 
phenobarbitone (30 and 45 yg);Wells 2 and 7, 
saline (30 and 45 y .g ) ? Wells 3 and 8, corn oil, 
(30 and 45 yg);Wells 4 and 9, 3-methylcholan- 
threne (30 and 45 yg); Wells 5 and 10, iso­
safrole (30 and 45 yg). Migration was from 
top to bottom. The stained bands are in the
45,000 - 60,000 mol. wt. region.
FIGURE- ••3 . 4 .
SDS-Polyacrylamide disc gel electrophoresis of 
microsomal proteins from animals treated with 
various inducing agents: protein staining 
f ollowing haem .staining. .
Following staining for peroxidase activity (Fig.3. 
the gel was washed in several changes of 70 mM 
sodium sulphite followed by several changes of 
30% propan-2-ol. The gel was then stained for 
protein with Coomassie Blue. 15, 30 and 45 yg 
of protein were applied to the gel in the 
following wells:
phenobarbitone
15 yg 
1
30 yg 
6
45 yg 
11
saline 2 7 12
corn oil 3 8 13
3-methyl-
cholanthrene 4 9 14
isosafrole 5 10 15
FIGURE 3.5.
Effect of heat treatment on the resolution 
of microsomal proteins by SDS-polyacryl­
amide gel electrophoresis
Samples were prepared for electrophoresis as 
described in 2.8.6. for haem staining. Samples 
1-4 were placed on ice following mixing with 
buffer 5. Samples 5-8 were mixed and left at 
room temperature for 15 min. Samples 9-12 were 
boiled for 1 min. Microsomal samples were from 
animals pretreated with the following agents: 
phenobarbitone, Wells 1,5 and 9; saline, Wells 
2,6 and 10; corn oil, Wells 3,7 and 11; 3-methyl 
cholanthrene, Wells 4,8 and 12. Migration is 
from top to bottom.
FIGURE' '3v6 .■
Electrophoresis of microsomal proteins 
using the Fairbanks buffer system
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SDS-polyacrylamide gel electrophoresis was carried 
out using the continuous buffer system of Fairbanks 
et at. (1971) as described in 2.8.3. The microsomal 
samples were diluted with 10 mM Tris-HCl pH 8.0 
containing 15% (v/v) glycerol, 1 mM EDTA, 1% (w/v) 
SDS and 0.001% bromophenol blue and allowed to stand 
at room temperature for 20 min prior to application 
to the gel. Microsomal proteins were applied to the 
gel in the following order:
15 yg 30 yg 45 yg
phenobarbitone 2 8 13
saline 3 9 14
corn oil 4 10 . 15
3 methylcholanthrene 5 11 16
isosafrole 6 12 17
Standard proteins (1. 5 yg) were applied in wells 1,
7 and 18. Migration is from top to bottom.
systems. Renex 690 has been used as a detergent for the 
electrophoresis of microsomal NADPH: cytochrome P-450 reductase 
in an active form (Dignam and Strobel,1977). This enzyme was 
detected by the reduction of INT in the presence of NADPH 
(2.8.7.). The gel was also stained for peroxidase activity 
and.protein. Although the INT reductase activity did resolve 
as discrete bands oh electrophoresis, the peroxidase activity 
and the majority of the protein stayed mainly at the origin.
The indications from this were that either the gel pore size 
excluded the vast majority of the protein, or that Renex 690 
was .not a sufficiently strong detergent to solubilize the 
majority of the microsomal proteins, including the microsomal 
haemoproteins.
Gradient gel electrophoresis of microsomal proteins 
using a Tris-borate buffer system (pH 8.3) incorporating SDS 
on a Gradipore concave gradient gel (2.8.2) produced resolution 
which was much inferior to that obtained with a discontinuous 
system. This is probably due to the fact that the limiting 
pore size region of interest (40,000 - 60,000) is condensed 
into a very small region of several millimetres in length, 
whereas on a linear gel this range can be expanded to cover 
several centimetres. Since the majority of microsomal protein 
does not migrate into a 7% acrylamide gel following solubili­
zation with Renex 690/ the use of a gradient gel as a system 
for the resolution of undenatured cytochrome P-450 was 
explored. Sodium cholate, a detergent which has been 
extensively used for the solubilization of cytochrome P-450, 
was used in the electrophoresis buffer. Solubilization of 
the microsomal components was carried.out by sonication with . 
sodium cholate (2.8.2.). Following electrophoresis, peroxi­
dase staining showed the presence of a single band which had 
migrated into the gel in the variously pretreated microsomes 
(Fig.3.7.). A large amount of haem staining material 
remained at the origin, perhaps due to incomplete solubili­
zation. Subsequent staining.for protein revealed approxi­
mately 20 bands.
FIGURE 3.7.
Gradient gel electrophoresis of microsomal 
proteins using sodium cholate as detergent
1 2 3 4
Microsomal proteins were solubilized in 62.5 mM 
Tris-HCl (pH 7.7) containing 20% (v/v) glycerol,
2 mM EDTA and 1 mM DTT, with sodium cholate .added 
to give 3 mg detergent/mg protein.Samples (2 mg protein) 
were applied to the surface of each gel and electro­
phoresis was carried out at 4° for 18h at 150 V. 
Following electrophoresis, a strip 2 cm wide was 
cut from each gel and stained for peroxidase activity 
Samples were from animals pretreated with the 
following agents: 1, phenobarbitone; 2, 3-methyl- 
cholanthrene; 3, corn oil; 4, isosafrole.
Migration was from top to bottom of the gel. The 
anode is at the bottom of the gel and the cathode, 
at the top.
3.2.4. Induction of microsomal proteins by SKF 525-A,
16g-PCN and . tPans-stilbene oxide.
Pretreatment of rats with SKF 525-A produces a 
metabolite cytochrome P-450 complex and also an induction of 
cytochrome P-450 (Buening and Franklin, 1976). SDS disc gel 
electrophoresis shows that pretreatment with SKF 525-A induces 
a band with similar molecular weight to that induced by pheno­
barbitone (Fig, 3.8.). Band 3 is induced to a greater extent 
by SKF 525-A than by phenobarbitone. Band 1 also appears to 
be slightly increased by SKF 525-A.
Treatment of rats with 16a-PCN causes an induction 
of a protein band with molecular weight similar to that 
induced by phenobarbitone (see Fig. 3.9.).
Pretreatment of rats with trans -stilbene oxide 
causes an increase in the staining intensity of two bands, 
one with molecular weight similar to the major protein induced 
by phenobarbitone (band 3) and a second band of 48,000 mol. 
wt. (band 1) which is thought to be epoxide hydratase (see . 
Fig. 3.10.).
FIGURE 3.8.
SDS-polyacrylamide disc gel electrophoresis 
of hepatic microsomal proteins from rats 
pretreated with SKF 525-A
Electrophoresis was carried out as described in 
the legend to Fig. 3.1. Microsomal samples (15 
yg protein) from animals pretreated with inducing 
agents were applied in the following order:
Wells 1 and 1, phenobarbitone; Well 2, saline?
Well 3, corn oil; Wells 4 and 8,. 3-methyl- 
cholanthrene; Wells 5 and 9, isosafrole; Well 6 , 
SKF 525-A.
FIGURE 3.9.
SDS-polyacrylamide disc gel electrophoresis of 
microsomes from rats pretreated with 16a-PCN
Electrophoresis was carried out as described 
in the legend to Fig. 3.1c Microsomal samples 
(15 yg protein) were applied to the gel in the 
following order: Well 1, phenobarbitone; Well 
2, saline; Well 3, corn oil; Well 4, 3-methyl- 
cholanthrene; Well 5, 16a-PCN; Well 6, isosafrole.
FIGURE 3.10.
SDS-Polyacrylamide gel electrophoresis of 
liver microsomal proteins from rats pre­
treated with trans -stilbene oxide
Sample preparation and electrophoresis were carried 
out as described in the legend to Fig. 3.1. Micro­
somal proteins were applied to the gel in the 
following sequence: Well 2, phenobarbitone; Well 3,
saline; Well 4, corn oil? Well 5, 3-methylcholanthrene 
Wells 8,9 and 10, .trans-stilbene oxide. Wells 1 
and .7 contained 1.5 yg of standard proteins.
3.3. DISCUSSION
The induction of microsomal proteins by methyl- 
cholanthrene and phenobarbitone described here is largely in 
agreement with results published by other workers (Alvares and 
Siekevitz, 1973; Welton and Aust, 1974). The pattern of 
induction by isosafrole described here is similar to that 
reported by Dickins et at, (1978), who found that isosafrole 
pretreatment caused the induction of a protein with a 
molecular weight between those of the major protein bands 
induced by phenobarbitone and 3-methylcholanthrene.
In the rat (Birnbaum et at. ,1976) and the mouse 
(Haugen et at, ,1976), electrophoresis of microsomal proteins 
has indicated that PCN induced a protein with a molecular 
weight between those induced by phenobarbitone or 3-methyl­
cholanthrene. In this study I have found that in the rat, PCN 
induces a protein with a molecular weight similar to the 
phenobarbitone-induced protein. This may be due to differences 
in the resolving capabilities of the gel systems used, or it 
may be due to strain differences in the rats used. However, 
in this strain of rats and in the gel- system described here,
PCN seems to induce a protein which differs from that induced 
by isosafrole.
SKF 525-A forms a metaboiite-cytochrome P-450 
complex which differs from the complexes formed by benzo- 
dioxole compounds in several respects. Although the complex 
is stable in the reduced form, it is dissociated on oxi­
dation, and it has a single absorbance maximum at 455nm. 
However, in common with the benzodioxole metaboiite-cytochrome 
P-450 complexes, those formed by SKF 525-A act as inhibitors 
of monooxygenase reactions and can be isolated from 
pretreated animals. Administration of SKF 525-A causes an 
induction of cytochrome P-450 and an increase in monooxygenase 
reactions (Buening and Franklin, 1976). Electrophoretic 
studies described here indicate that SKF 525-A induces a band 
of similar mobility to that induced by phenobarbitone and 
different from the band induced by isosafrole. This indicates 
that there are probably several forms of cytochrome P-450
capable of being induced by compounds which form cytochrome 
P-450-product complexes.
Various microsomal proteins which are not related 
to cytochrome P-450 have molecular weights in the 45,000 -
60.000 mol. wt. region. Epoxide hydratase has been reported 
to have molecular weights of 49,000 (Bentley and Oesch, 1975) 
using the discontinuous buffer system of Laemmli (1970), or
54.000 (Lu et at.,1975) using the discontinuous buffer system 
of Neville (1971). Lu et at, (1979) have since measured the 
molecular weight using different protein standards and the 
buffer system of Laemmli (1970), and have confirmed the 
molecular weight of 49,000. • Multiple forms of UDP-glucuronyl 
transferase with molecular weights of 48,000, 52,000 and
56.000 (Bock et alf±911) and a single form with a molecular • 
weight of 5 7,000 (Burchell, 19 77) have been reported.
Stearoyl CoA desaturase has been reported to have a molecular 
weight of 53,000 (Strittmatter et al, ,19 74).
Trans -stilbene oxide has been reported to be a 
selective inducer of rat liver epoxide hydratase over a wide 
range of doses, with little or no effect on the level of 
cytochrome P-450 and monooxygenase activities (Schmassmann 
and Oesch, 1978). Other workers have found that in addition 
to epoxide hydratase, trans -stilbene oxide induces aminopyrine 
N-demethylase, benzphetamine N-demethylase, ethylmorphine 
N-demethylase, aryl hydrocarbon hydroxylase, cytochrome P-450 
and.UDP-glucuronyl transferase using 4-nitrophenol as 
aglycone (Mukhtar et aZ.,1978; Elmamlouk and Mukhtar, 1979) . 
Recently Seidegard et aZ.(1979) also reported an induction of 
cytochrome P-450 by trans -stilbene oxide, and suggested that 
the discrepancy between their results and those of Schmassmann 
and Oesch (1978) may be due to differences in the basal level 
of cytochrome P-450 (perhaps due to strain differences or 
partial induction by xenobiotics in the environment of the 
animals). These authors also suggest that the type of
cytochrome P-450 induced is different from that induced by 
methylcholanthrene, and that it may be similar to that induced 
by phenobarbitone. I have found that at the dose level used 
(400 mg/kg for 3 days) trans -stilbene oxide causes an induction 
of several bands on electrophoresis. In addition to inducing 
band 1, which is thought to be epoxide hydratase, trans - 
stilbene oxide induces band 3 to give a pattern similar to 
that seen with phenobarbitone. It is notable that pretreatment 
with phenobarbitone has been reported to cause induction of 
epoxide hydratase in rat liver (Bresnick et al .,1977), and 
the increase in band 1 on pretreatment with phenobarbitone could 
be consistent with it being epoxide hydratase. Isosafrole has 
been reported to induce epoxide hydratase (Vainio and Parkki, 
1976) which could account for the increase in band 1 seen with 
isosafrole.
It is of interest to note that Ferguson plots for 
purified cytochrome P-450 proteins from rat liver (types A, B 
and D from phenobarbitone-pretreated rats and type B from 3- 
methylcholanthrene-pretreated rats) in the SDS system of Laemmli 
(1970) give straight lines with free mobilities approximately 
equal to each other and equal to those of six other proteins. 
(Guengerich, 1978 b).: This indicates that electrophoresis under 
these conditions does give a valid measurement of molecular 
weight for cytochrome P-450.
Various methods have been used to identify the 
polypeptide bands which are derived from cytochrome P-450 
following gel electrophoresis. The comparison of molecular 
weights of purified cytochrome P-450 preparations with the 
molecular weights of protein bands is a possible means of 
identification. To use this method would require the purifi­
cation to homogeneity of all the different types of cytochrome 
P-450, and the power to resolve each polypeptide in the 
microsomal preparations. Identity of molecular weights does 
not necessarily indicate identity of proteins. Purity of 
cytochrome P-450 on SDS gel electrophoresis can not be 
treated as an absolute criterion of homogeneity (Thomas et al.3 
1976 b) , since preparations which are pure on electrophoresis 
may contain several immunologically distinct polypeptides.
An ^increase in the specific activity of cytochrome P-450 
caused by induction has been used to locate the apocytochrome 
on gels (Alvares and Siekevitz, 1973; Welton and Aust, 1974). 
Samples with the same or similar amounts of protein are applied 
to the gel, and bands which are enhanced in samples with in­
creased specific activity are considered as potential 
cytochrome P-450 proteins. The limitation of this method lies 
in the assumption that bands which are induced are cytochrome 
P-450 proteins. This is not necessarily the case, since 
inducers of cytochrome P-450 may also induce other microsomal 
enzymes such as epoxide hydratase.
The selective binding of haem at neutral pH to 
polypeptides in the 50,000 mol. wt. region has been used as 
evidence of their original haemoprotein nature (Siekevitz, 
1973). However, Bell and Hodgson (1977) have reported that 
haem binding is totally nonspecific, with patterns similar 
to protein staining patterns being produced.
Staining for residual haem peroxidase activity has 
been used for the location of haemqproteins on gels (Welton 
and Aust, 1974; Haugen.gt al.^  1975) . This method is based on the 
observation that cytochrome P-450, on conversion to cytochrome 
P-420 by SDS, retains peroxidase activity (Hrycay and O'Brien, 
1971, a,b). Using a benzidine/hydrogen peroxide stain, Welton 
and Aust (19 74) demonstrated that haem was associated with 
particular microsomal proteins in the 45,000 - 60,000 mol. 
wt, range. This staining system has several major disadvant­
ages. Benzidine is a potent bladder carcinogen in man (wendel 
et al. ,1914} Holland et al., 1974), and therefore presents a 
hazard for the operator. The gels become opaque during 
staining and the stained bands diffuse, making photography 
difficult. A more sensitive method using the safer 3,3',5,5'- 
tetramethylbenzidine (TMBZ) has been reported (Thomas et al.
19 76 c).Other advantages with this stain are that there is 
little or no diffusion of stained bands, the stain is stable 
for several months and can be removed easily to permit 
subsequent protein staining. The conditions normally used 
for sample treatment and electrophoresis in an SDS system do
not favour the retention of haeiri. Siekevitz (1973) reported 
virtually complete removal of haem from the cytochrome during 
sample preparation and electrophoresis. The haem moiety is 
removed from cytochrome P-450 by pretreatment with SDS (Levin 
et al. ,1972; Rajamanickam et al»r, 1975) . Mild sample treatment 
which avoids the use of a heat treatment stage is used to 
prepare the samples. Electrophoresis is carried out <at 4° and 
sulphydryl reagents are omitted from sample pretreatment 
because of their reported interference with haem staining . 
(Welton and Aust, 1974). The. amount of protein on the gel is 
also increased to compensate for the low sensitivity of the 
stain. Initial experiments in this study were carried out 
using the TMBZ stain with the discontinuous buffer system of 
Laemmli (19 70) with the omission of 2-mercaptoethanol and 
boiling from the sample pretreatment stage. The resulting loss 
of resolution makes it impossible to compare results for haem 
staining with results for protein staining under optimum 
conditions for resolution. The use of'a heat treatment 
stage in sample preparation produces an increase in resolution, 
but this is still not comparable with optimal conditions.
The omission of sulphydryl reagents has been reported to 
favour haem retention (Welton et al.3 1975; Haugen et al.j 1976). 
In this study the inclusion of 2-mercaptoethanol inhibited-the 
peroxidase stain, whereas DTT increased the retention of haem 
by the protein but did not inhibit the peroxidase stain to 
the same extent. The interference of reducing agents with the 
benzidine peroxidase stairi has been previously described 
(Moore et al.> 1978 b).
The loss of haem is a problem with any method 
where detection of haem is used as a marker for a haemo- 
protein in an SDS-polyacrylamide gel system, when the haem 
moiety is non-covalently bound to the protein. The retention 
of haem and the resolution of the proteins seem to be inversely 
linked. The loss of haem may not be the same for different 
types of cytochrome P-450, and dissociated haem may bind to 
other proteins giving a false positive.
With the discontinuous buffer system used, haem loss seemed to 
be a particular problem. It is of interest to note that 
reports of successful use of haem staining have been made when 
the continuous buffer system of Fairbanks et dl. (19 71) was 
used (Welton and Aust, 1974;Haugen et al.3 1975;Thomas et al.s 
1976c;Sharma et al.^1919) . The reason for this may be more than 
coincidence. The voltage gradient to which proteins are 
subjected during electrophoresis in a stacking gel is much 
higher than that experienced by the proteins in the running 
gel.. In the stacking gel, under steady state conditions, a 
step gradient is set up, which extends over a small distance.
If two ions are loosely associated they will tend to move apart 
to their respective positions designated by the order of their 
mobilities. The dissociation will be proportional to the 
square of the voltage gradient (Ornstein, 1964). It is there­
fore probable that a large proportion of the haem which remains 
bound to the apoprotein following sample pretreatment is removed 
during passage through the stacking gel. In a continuous 
buffer system the voltage gradient is lower, so the complex 
will tend to remain associated. However, the resolution 
obtained using continuous buffer systems does not compare with 
that obtained using discontinuous buffer systems under optimal 
conditions, and especially not under the conditions used for 
haem staining.
It is apparent that the results obtained for 
peroxidase staining cannot be directly compared with results 
from protein staining under optimal conditions. The use of the 
peroxidase stain in SDS systems appears to be valid in several 
instances:
i) where the haem moiety is covalently linked .to 
the protein under investigation
ii) where the polypeptide is. sufficiently isolated 
from other protein material in a mixture that the loss of 
resolution resulting from adjustments in technique to obtain 
retention of haem do not make subsequent location of the 
protein impossible
iii) as an extension of ii), where highly purified 
material is being analysed.
Although we can see from the results presented here that in 
the 45,000 - 60,000 mol. wt. region there are several haem 
staining bands, and that the relative proportions of these 
change on animal pretreatment, it is impossible to equate 
each haem staining band with a single polypeptide band, in 
view of the limitations described above.
The determination of molecular weights under the 
conditions used for haem staining of cytochrome P-450 on SDS- 
polyacrylamide gels is theoretically unsound. For a valid 
measurement of molecular weight of a membrane protein the 
conditions required are complete disruption of all but covalent 
interactions within and between chains and between proteins and 
lipids, a constant ratio of SDS bound to protein sufficient to 
eliminate charge differences, and the elimination of confor­
mational differences (Maddy, 19 76). Under the conditions used for 
haem staining of cytochrome P-450, non-covalently bound haem 
is retained. The condition for disruption of non-covalent 
interactions has not been fulfilled, and it is improbable that 
the remainder of the conditions can be met as a consequence.
It is possible that the proportion of the cytochrome P-450 
protein which retains haem may have a different mobility from 
the completely denatured polypeptide, due to differences in 
conformation or SDS binding. This could lead to erroneous 
identification of a polypeptide as either haem-containing or 
lacking in haem.
It has been shown that administration of allyl- 
isopropylacetamide (AIA) causes significant destruction of 
the haem moiety of cytochrome P-450 (De Matteis,1973), and 
this effect has been used to locate cytochrome P-450 derived 
polypeptides on gels (Siekevitz, 1973). In addition to causing 
haem destruction, AIA was reported to cause the destruction of 
a band of 50,000 mol. wt. in the rat. Baird et al. (1976) 
also reported the selective destruction of a band of 50,000 
mol. wt. by AIA, and used this as a basis for determining the 
type of cytochrome P-450 destroyed by AIA. Bell and Hodgson 
(19 77) reported similar findings using microsomes from mice,
with AIA causing a decrease in a polypeptide band of 48,000 
mol. wt. However, in the absence of a clear understanding of 
the short term effects of AIA on apocytochrome P-450, these 
authors concluded that the loss can not be interpreted as 
evidence that the 48,000 mol. wt. band was derived from 
cytochrome P-450.Ivanetioh and Bradshaw (1977) found that 
treatment of rats with flu roxene or AIA resulted in haem 
destruction, but did not bring about any significant changes in 
electrophoretic profiles. Since sample treatment removes haem 
from the cytochrome, it is logical that unless AIA causes 
degradation of the apoprotein, the electrophoretic profiles 
obtained would not be affected by AIA.
Electrophoresis systems containing SDS for the 
resolution of membrane proteins are of great use when the reso­
lution of the maximum number of polypeptide bands is the main 
object. When the_ separated proteins are to retain and be detected 
by their enzyme activity, SDS is of limited use because it 
produces extensive inactivation of many enzymes. For many 
membrane enzymes, methods which have been described for the 
initial stages of purification can be successfully applied to 
their electrophoretic separation, provided that the proteins 
are maintained in a solubilized state and their enzyme activity 
is retained (Penefsky and TZagoloff, 1971 ;Tzagoloff and 
Penefsky, 1971), Electrophoresis of purified NADPH: 
cytochrome P-450 reductase has been carried out in the presence 
of 0.1% Renex 690 (Dignam and Strobel, 1977) using the gel 
system of Davis (1964) and staining with NADPH and INT. In 
this study, electrophoresis of microsomal proteins solubilized 
with Renex 690 proved useful for the separation of NADPH: 
cytochrome P-450 reductase. However, this system did not 
resolve the haem-containing proteins, which did not migrate 
into the gel. This may have been due to inadequate solubil­
ization of the protein, or limiting pore size of the gel. The 
mobility of proteins in this system will depend on the intrinsic 
charge of the protein since the non-ionic detergent will not 
mask the intrinsic charge of the solubilized protein. The
isoelectric point (pi) of rat liver NADPH: cytochrome P-45D 
reductase has been reported to be in the range 4.7 - 5.4 . 
(Guengerich, 19 77 hj)Y which would mean that this protein would 
have a negative charge both in the stacking and running gels 
of this system, ensuring a relatively high mobility. The pis 
of cytochrome P-450 proteins have been determined in several 
different isoelectric focusing systems. Ingelman-Sundberg • 
and Gustafsson (1977) reported the resolution of four haem 
containing polypeptides from an electrophoretically homogenous 
preparation of rabbit liver cytochrome P-45 OL.M2 , using Triton 
X-100 as solubilizing detergent and Sephadex G-75 as support.
Of these four polypeptides which had pis in the range 7 - 9 ,  
one catalysed the 6 3-hydroxylation of androstenedione . 
supported by sodium periodate. Guengerich (1977b),described 
pis of 8.1 for rabbit liver cytochrome P-450LM2 and 8.3 for 
cytochrome P-450LM^, using Emulgen 913 and polyacrylamide gels 
as support. Isoelectric focusing of partially purified 
cytochrome P-450 preparations has been used to show the 
presence of eight haem staining proteins in the pH range 5-8 
(Warner et aZ.,19 78) in acrylamide gels which did not contain 
detergent. It seems possible that the majority of cytochrome 
P-450 proteins have pis in the basic range, and some may be as 
high as pH 9. If this is the case it could provide an 
explanation for the poor separation of cytochrome P-450 
proteins in polyacrylamide gels with non-ionic detergents.
At the pH of the stacking gel and the running gel, basic proteins 
will have little net charge, and may be positively charged, 
which would rule out migration in an anionic buffer system like 
the one described above. In order to resolve the more basic 
proteins in an anionic buffer system, it would be necessary to 
increase the pH of the stacking and running gels above the pis 
of the proteins. This would almost certainly cause denaturation 
of the cytochrome P-450 proteins. An alternative approach 
which may prove useful for the separation of cytochrome P-450 
proteins would be to use a cationic buffer system, with electro­
phoresis at a pH lower than neutrality, giving the proteins a 
net positive charge. Such a system has been described for the
separation of basic proteins using K + as the leading ion,
3-alanine as the trailing ion and acetate as the buffering 
counter ion at an operating pH of 3.6 (Reisfeld etal,1962) . The 
principles for the selection of the various ions in a discon­
tinuous buffer system have been discussed by Williams and 
Reisfeld (1964) , and by application of these principles a more 
suitable buffer system for the resolution of cytochrome P-450 
may be found. By selection of an appropriate weak base or amino 
acid with a. pKa 'in the correct range and an appropriate buffering 
counter ion, it may be possible to design a system with running 
conditions which will separate cytochrome P-450 proteins on 
the basis of intrinsic charge, and minimise denaturation, 
enabling characterisation of the resolved forms.
Another approach which was examined is the use of 
sodium cholate, an anionic detergent, incorporated in gradient 
polyacrylamide gels. In this system, a proportion of the 
haem staining material is retained at the origin, perhaps due 
to inadequate solubilization or insufficient net charge at the 
operating pH. The haem staining material which migrated into 
the gel produced a single band, with similar mobilities in 
the pretreated microsomes. It is probable that this material 
is derived from cytochrome P-450, since cytochrome b^, the other 
major microsomal haemoprotein, would have migrated beyond the 
end of the gel. The minimum exclusion limit of the gradient 
gels used is approximately 35,000 and the molecular weight of 
cytochrome b^ is 16,700 (Spatz and Strittmatter, 1971). Although 
this sytem does not seem capable of resolving the various 
proteins induced in the microsomal preparations, it may be a 
useful system for electrophoresis in one dimension of a 
two-dimensional system.
CHAPTER 4
INDUCTION OF CYTOCHROME P-450 AND 
FORMATION OF METABOLITE COMPLEXES 
BY BENZODIOXOLE AND RELATED 
COMPOUNDS: 
STRUCTURE/ACTIVITY RELATIONSHIPS.
4. INDUCTION OF CYTOCHROME P-450 AND FORMATION OF
METABOLITE COMPLEXES BY BENZODIOXOLE AND
RELATED COMPOUNDS: STRUCTURE/ACTIVITY RELATIONSHIPS.
4.1. INTRODUCTION
The formation of metabolite-cytochrome P-450 complexes 
in vitro has been reported for a large number of benzodioxole 
compounds in various species (for reviews see Franklin,1977; 
Philpot and Hodgson, 1974). Some of the compounds which form 
complexes in vitro also form stable metabolite complexes in vivo 
which can be isolated in the microsomal fraction of liver 
following administration to animals. These compounds include 
safrole and isosafrole in the rat (Parke and Rahman, 19 71;
Lake and Parke, 1972; Elcombe et al., 1975 a). Piperonyl butoxide 
has also been reported to form a metabolite-cytochrome P-450 
complex in the rat (Franklin, 1976). In mouse liver, piperonyl 
butoxide and propyl isome form metabolite-cytochrome P-450 
complexes in vivo (Philpot and Hodgson, 1971 b). These benzo­
dioxole compounds also act as inducing agents of cytochrome 
P-450 (Wagstaff and Short, 1971; Lake et al .,1973). The fact 
that the induced cytochrome P-450 appears to be a novel haemo- 
protein (Dickins et al. , 1978) and the possible link between 
this induction and the formation of the metabolite complex fa 
vivo prompted an investigation of the capabilities of benzo­
dioxole and related compounds to induce cytochrome P-450, the
53,000 mol. wt. band on electrophoresis and to form metabolite- 
cytochrome P-450 complexes fa vivo• Experiments by Dickins 
(1978) on the time course of the appearance of the 455 nm peak 
and the induction of biphenyl 4-hydroxylase following a single 
injection of isosafrole suggest that the induction process and 
the formation of the 455 nm peak with time may be relatedo 
There appears to be no formation of the 455 nm complex until 
8h after the administration of isosafrole, and this is paralleled 
by an initial decrease in biphenyl 4-hydroxylase, and an 
induction after 8h. A range of compounds with chemical structures 
similar to safrole was studied, which included naturally 
occurring and synthetic benzodioxole compounds (see Table 4.1.).
Benzodioxole and related compounds examined for metabolite
•complex formation and induction of cytochrome P-450,
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4.-2. RESULTS
4.2.1. Safrole/ isosafrole and dihydrosafrole
Safrole (I), isosafrole (II) and dihydrosafrole 
(III) all gave Type I binding spectra and formed metabolite- 
cytochrome P-450 spectra with rat liver microsomes. The 
spectrum shown in Fig.4.1. shows the generation of the double 
Soret peaks in vitro with isosafrole with microsomes from 
phenobarbitone-pretreated rats. Safrole and dihydrosafrole 
also produced similar spectra in vitro.
Pretreatment of rats with isosafrole, safrole or 
dihydrosafrole followed by isolation of liver microsomal 
fractions and measurement of the reduced minus oxidized 
spectra showed the presence of a peak at 455 nm which was 
not present in microsomes from control animals (see Figs.4.2. 
and 4.3.). The 427 nm component of the spectrum is increased 
compared to that of control. Incubation with 2-n-heptyl- 
benzimidazole of microsomal suspensions from rats pretreated 
with safrole, isosafrole or dihydrosafrole caused a decrease 
in the level of the 455 nm peak and an increase in the level 
of cytochrome P-450 (see Fig.4.2. and Table 4.2.). Of these 
compounds, isosafrole causes the largest increase in total 
cytochrome P-450, the largest increase in cytochrome P-450 
.on displacement and production of the largest 455 nm complex 
in vivo. in Fig.4.4., the effect of these three compounds 
on the level of 53,000 mol. wt. band can be seen. Isosafrole 
produces a greater increase in this band than either safrole 
or dihydrosafrole.
FIGURE 4.1.
Generation in vitro of a double Soret 
spectrum with isosafrole in microsomes
360 380 400 420 440 460 480 500
nm
Microsomes obtained from phenobarbitone-pretreated 
rats were diluted with 66 mM Tris-HCl to give a 
protein concentration of 1 mg/ml. The suspension 
was equally divided between two cuvettes, and 
placed in a thermostatted cuvette holder at 37°.
A baseline of equal light absorbance was established. 
Isosafrole (250 ,yM) was added to the sample cuvette 
and the binding spectrum was recorded (-— •— ) .
NADPH (250 yM) was added to both cuvettes and the 
spectrum was rescanned after 30s, 2.5, 5, and 7.5 
min.
FIGURE 4.2.
Reduced minus oxidized spectra of liver microsomes 
from rats pretreated with isosafrole before and 
after incubation with 2-n-heptylbenzimidazole
0-02A
420 500
nm
Microsomes obtained from rats pretreated with isosafrole 
were diluted with 66mM Tris-HCl (pH 7.4) to give a 
protein concentration of 1 mg/ml. The suspension was 
either incubated for 5 min at 37° followed by the addition 
of 2-n-heptylbenzimidazole (250 yM) and further incubation 
for 30 min, or the reduced minus oxidized spectrum was 
measured immediately. The suspensions were divided 
equally between two cuvettes and a baseline of equal light 
absorbance was established. Solid sodium dithionite 
(1-2 mg) was added to the sample cuvette and the spectrum 
recorded. Before (------ ) and after displacement (------ ).
■ FIGURE 4.3.
Reduced minus oxidized spectrum of control 
rat liver microsomes .
0-02 A
400 420 440. 460 480 500
nm
•Microsomes obtained from rats pretreated with corn oil 
were diluted with 66mM Tris-HCl (pH 7.4) to give a 
protein concentration of 1 mg/ml. The suspension was 
equally divided between two cuvettes and a baseline 
of equal light absorbance was established. Solid 
sodium dithionite (1-2 mg) was added to the sample 
cuvette and the spectrum was recorded.
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FIGURE 4.4.
SDS-polyacrylamide disc gel electrophoresis of 
rat liver microsomes obtained from animals 
pretreated with various compounds
1 2 3 4 5 6 7 8 9 1011 12 1314 1516 17 18
Solubilization arid electrophoresis of microsomal 
proteins were carried out as described in 2.8.1. 
After electrophoresis the gel was stained with 
Coomassie Blue G-250. Samples (15 yg protein) 
were applied as follows:
Well 2 phenobarbitone
3 saline
4 corn oil
5 methylcholanthrene
6,8 isosafrole
9 safrole
10,17 dihydrosafrole
11,16 piperonyl butoxide
12,13,14;, 15 benzodioxole
Well 1,7,18 contained molecular weight standards
4.2.2. Compounds which lack the methylene bridge
Eugenol (IV) , methylisoeugenol (V) and estragole 
(VI) are all naturally occurring compounds which are found 
in herbs and spices, and are used as flavouring agents.
Eugenol (4-ally1-2-methoxyphenol) occurs in bay, pimenta, 
calamus, clove, cinnamon leaf, nutmeg and betel leaf (Guenther 
1949; Nigam and Purohit, 1962). Methylisoeugenol (3,4- 
dimethoxypropenylbenzene) is found in mace (Shulgin e± alor 
1967). Estragole (4-allylmethoxybenzene) occurs.in tarragon, 
anise, bay, basil and fennel.(Guenther,1949), and has been 
found to be hepatocarcinogenic (Drinkwater ei a~b9 s 1976) .
It is therefore of importance to determine whether the side 
chain is the. determining factor for induction, or whether 
the methylene bridge is the important molecular constituent.
In addition to these naturally occurring compounds, 2,3- 
benzofuran (VII) was examined as a model compound with a 
single hetero-atom in a 5-membered ring.
Addition of these compounds to microsomes from 
phenobarbitone-pretreated rats produced Type 1 binding spectra 
On addition of NADPH to both the sample and reference cuvettes 
a trough at 425 nm was produced. There was no production of 
a 427 or 455 nm peak associated with the formation of a 
metabolite complex with any of these compounds (see Fig.4.5. 
for spectrum produced with methylisoeugenol).
Administration of these compounds to rats followed 
by isolation of the microsomal fraction did not produce a 
metabolite complex, and there was no induction of the 53,000 
mol. wt. band (see Figs.4.6.,4.7. and 4.8.). There were small 
increases in the levels of cytochrome P-450 compared to 
control levels, and there was a decrease in the level of 
cytochrome P-450 on pretreatment with benzofuran. In 
addition, benzofuran caused a large increase in the.level 
of a protein band of 48,000 mol. wt.
FIGURE 4.5.
Oxidized and reduced spectra of microsomes 
following addition of-methylisoeugenol
0-01A
360 380 A00 £20 ££0 £60 £80 500
nm
Conditions were as described in Fig.4.1., except that 
methylisoeugenol (250 uM) was added to the sample 
cuvette and the spectrum was recorded (— +— ). NADPH 
(250 yM) was added to both cuvettes and the spectrum 
was recorded after 30s, 2.5 min and 5 min.
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FIGURE 4.6.
Electrophoresis of microsomes from rats pretreated 
with estragole or hexenylbenzodioxole
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Sample pretreatment and SDS-polyacrylamide gel 
.electrophoresis was carried out as described in 
2.8. Samples (15 yg.) were applied in the following 
order
Well 2,15 phenobarbitone
3 saline
4,17 corn oil
5,16 methylcholanthrene
6,14 isosafrole
8,9,10 hexenylbenzodioxole
11,12,13 estragole
FIGURE 4.7.
Electrophoresis of microsomal proteins from rats 
pretreated with methylisoeugenol or benzofuran
1 2 3 4  5 6 7 8 9  10 11 12 13 14
8 i  i f * i  8  ?  1 1 1 1 1 8 ?
Sample pretreatment and SDS-polyacrylamide disc gel 
.electrophoresis were carried out as described in 2.8. 
Samples (15 yg protein) were applied as follows:
Well 2 phenobarbitone
3 saline
4 corn oil
5 methylcholanthrene
6 isosafrole
7,8,9,10 methylisoeugenol
11,12,13,14 benzofuran
FIGURE 4.8.
Electrophoresis of microsomal proteins from rats 
pretreated with sesamol, piperonyl alcohol, 
piperonal or eugenol
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
% ^ tw
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Sample pretreatment and SDS-polyacrylamide disc.gel 
electrophoresis were carried out as described in 2.8. 
Microsomal protein samples (15 yg) were applied in 
the.following order:
Well 2,10 isosafrole
3 sesamol
4 piperonyl alcohol
5 piperonal
6 eugenol
111 phenobarbitone
12 methylcholanthrene
13 saline
14 corn oil
Wells 1 and 18 contain standard molecular weight 
proteins.
4.2.3. Effects1 of polar ring substituents on complex
formation and induction
Benzodioxole (VIII) gave a Type I binding spectrum 
and readily formed a metabolite-cytochrome P-450 complex in 
'vitro'- (see Fig. 4.9.) . Administration of 1,3-benzodioxole to 
rats resulted in the formation of a very small 455 nm complex 
(Fig.4.10.). The presence of the 455 nm complex was not
apparent from the values of A455-49o ^uo:^ e^ Table 4.4.
This dicrepancy is due to a consistent increase in absorbance 
towards 500 nm. This happened with some of the compounds 
investigated, making measurements of low levels of the 455 nm 
complex difficult to quantitate, although they may be 
evident from the shape of the spectra. There was a small 
increase in cytochrome P-450 on displacement and the 53,000 
mol. wt. band is induced to a small degree (see Fig.4.4.).
Band 3 appeared to be induced to a small degree and total 
cytochrome P-450 levels were elevated above control values.
The 427 nm peak was increased in size when compared to control 
values, and was larger than that obtained with safrole, iso­
safrole or dihydrosafrole. Whether this increase was due.to 
an increase in cytochrome b^ levels or the formation of a 
metabolite complex with an absorbance maximum at 427 could 
not be resolved at present.
Sesamol. (IX) (5-hydroxy-l,3-benzodioxole) is a 
natural constituent of sesame oil. It formed a weak Type RI 
binding spectrum and did not form a metabolite complex in vitro 
on incubation with NADPH. A trough at 425 nm was formed on 
reduction of both sample and reference cuvettes and after 
several minutes a peak at 450 nm rapidly developed (Fig.4.11.). 
Piperonal (X) (1,3-benzodioxole-5-carboxaldehyde) which is
found in pepper, gave a Type RI binding spectrum and did not 
form a metabolite complex in vitroc Piperonyl alcohol (XI)
(1,3-benzodioxole-5-methanol) gave a Type RI binding spectrum 
and formed a' metabolite-cytochrome P-450 complex in vitro. 
Pretreatment of animals with piperonal, piperonyl alcohol 
or sesamol did not result in the formation of a metabolite 
complex, there was little change in cytochrome P-450 levels, 
and there was no induction of the 53,000 mol. wt. band 
(Table 4.4. and Fig.4.8.).
FIGURE 4.9.
NADPH-mediated formation of absorption maxima at 
427 and 455 nm with benzodioxole in hepatic 
microsomes from phenobarbitone-pretreated rats
0-01A
500450
nm
Conditions were as described in Fig. 4.1. except 
that 1,3-benzodioxole (250 yM) was added to the 
sample cuvette (— A ■ - ) . NADPH (250 yM) was 
added to both cuvettes, and the spectrum was 
recorded after 30s, 2.5,5,7.5 and 10 min.
FIGURE 4.10.
Reduced . minus oxidized spectrum of hepatic 
microsomes from rats pretreated with 1,3- 
benzodioxole
0 02 A
400 420 440 460 480 500
nm
Microsomes obtained from rats pretreated with 
1,3-benzodioxole were treated as described in 
Fig. 4.2. The spectrum was recorded on addition 
of sodium dithionite to the sample cuvette.
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FIGURE 4.11.
Oxidized and reduced spectra of hepatic microsomes 
from phenobarbitone-pretreated rats following 
addition of sesamol
400 450  500
nm
Conditions were as described in Fig.4.1. except that 
sesamol (250 yM) was added to the sample cuvette.
and the spectrum was recorded ( •— ) . NADPH
(500 yM) was added to both the sample and reference 
cuvette and the spectrum was recorded after 30s,
2.5 amd 5 min.
4.2.4. The effect of additional ring substituents on
complex formation and induction
In addition to safrole there are several naturally 
occurring allyl-containing benz'odioxole compounds. Myristicin 
(6-allyl-4-methoxy-l,3-benzodioxole) is found in nutmeg, 
parsley, carrot, mace and dill (Guenther, 1949; Stahl and 
Jork, 1964). Myristicin has certain hallucinogenic properties, 
and has been taken in the form of nutmeg to induce hallucina­
tions in man, mainly in places where other drugs are not 
available, e.g. in prisons. Nutmeg is acutely toxic at the 
levels required to induce hallucinations (probably due to the 
effects of other constituents in addition to myristicin:) and 
the lethal dose of nutmeg is of the order of 2 nutmegs/person. 
Groweacin (5-ally1-4-methoxy-l,3-benzodioxole) is found in the 
oil of Eriostemon Crowei and in plants of the Heterotropa 
genus (Guenther, 1949; Saiki et at. , 1967 a). Apiol (5-allyl- 
4,7-dimethoxy-l,3-benzodioxole) is found in parsley leaves and 
seeds (Guenther, 1949; Stahl and Jork, 1964). Asaricin (5- 
allyl-6-methoxy-l,3-benzodioxole) is found in plants of the 
Asiarum genus (Saiki et al,9 1967 b) . Dillapiol (6-allyl- 
4 ,5-dimethoxy-l,3-benzodioxole) is a constituent of dill 
(Guenther, 1949).
Of the compounds listed above, only two: myristicin 
(XII) and apiol (XIII), were examined. Both of these 
compounds gave Type I binding spectra in phenobarbitone- 
pretreated microsomes, but only myristicin gives a 427/455 nm 
complex on addition of NADPH (Fig.4.12). Pretreatment of 
rats with myristicin resulted in the formation of a 455 nm 
peak and an increase in cytochrome P-450 on displacement 
with 2-n-heptylbenzimidazole (see Fig.4.13. and Table 4.5.). 
Pretreatment of rats with apiol did not give rise to a 455 nm 
complex, nor was there an increase in cytochrome P-450 levels 
on incubation with 2-n-heptylbenzimidazole. Myristicin did 
induce the 53,000 mol. wt. band, but not to the extent seen 
with safrole, whereas apiol did not induce this band (Fig. 
4.14.).
FIGURE 4.12.
NADPH-mediated formation of absorption maxima 
at 427 and 455 nm with myristicin in hepatic 
microsomes from rats pretreated with phenobarbitone
0.01 A
400 450  500
nm
Conditions were.as described in Fig. 4 . 1. except 
that myristicin (250 yM) was added to the sample 
cuvette and the binding spectrum recorded (— +— ). 
NADPH was added to both the sample and reference 
cuvettes and the spectrum was recorded after
2.5,5, and 7.5 min.
.FIGURE 4.13.
Reduced minus oxidized spectra of liver microsomes 
from rats pretreated with myristicin before and 
after incubation with 2-n-heptylbenzimidazole
0-02A
I I I ) I I
400 420 440 460 480 500
nm
Microsomes obtained from rats pretreated with 
myristicin were treated as described in Fig.4.2.,
and spectra were recorded before (------ ) and
after (—   -) incubation with 2-n-heptylbenzi-
midazole.
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FIGURE 4.14.
Electrophoresis of microsomal proteins from 
rats pretreated with safrole, myristicin or 
apiol
Sample pretreatment and SDS-polyacrylamide disc 
gel electrophoresis were carried out as described 
in 2.8. Microsomal samples (15 yg protein) were 
applied in the following order:
Well 2 phenobarbitone
3. saline
4 corn oil
5 methylcholanthrene
6 isosafrole
8,9,10 safrole
11,12,13,14 myristicin
15,16,17 apiol
Wells 1, 7 and 18 contained molecular weight standards.
4.2.5. Effect of side chain length on complex formation
and cytochrome P-450 induction
The synthetic benzodioxole compounds 5-hex-l1- 
enyl-1,3-benzodioxole (XIV) and S-oct-l'-enyl-l,3-benzodi- 
oxole (XV) both gave Type I binding spectra and both formed 
metabolite-cytochrome P-450 complexes in vitro in microsomes 
from rats pretreated with phenobarbitone. Pretreatment of 
rats with hexenylbenzodioxole gave rise to a metabolite 
cytochrome P-4 50 complex (see Fig.4.15. and Table 4.6.). 
However, on incubation with 2-n-heptylbenzimidazole, there 
was incomplete displacement of the complex as can be seen 
from Fig. 4.15. and the ^ 4 5 5 - 4 9 0  va^ues -^n Table 4.6. 
Octenylbenzodioxole also gave a 455 nm complex in vivo r but 
as with hexenylbenzodioxole, there was incomplete displacement 
of the complex (see Fig.4.16.). Both of these compounds 
induced the 53,000 mol. wt. band (Fig.4.17). However, because 
of incomplete displacement it is difficult to relate the 
amount of this band which is induced to the amount of the 
cytochrome P-450 revealed by displacement.
FIGURE 4.15.
Reduced, minus oxidized spectra of hepatic 
microsomes from rats pretreated with hexenyl­
benzodioxole before and after incubation with 
2-n-heptylbenzimidazole
0 0 2 A
500
nm
Microsomes obtained from rats pretreated with 
hexenylbenzodioxole were treated as described 
in Fig.4.2. Reduced . minus oxidized spectra
were recorded before (------ ) and after (---- )
incubation with 2-n-heptylbenzimidazole.
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FIGURE 4.16.
Reduced minus oxidized spectra of hepatic microsomes 
from rats pretreated with octenylbenzodioxole before 
and after incubation with 2-n-heptylbenzimidazole
0-02A
£ 0 0  £ 2 0  £ £ 0  £60  £ 8 0  500
nm
Microsomes obtained from rats pretreated with octenyl­
benzodioxole were treated as described in Fig.4.2.
Spectra were recorded before (----:— ) and after (---- )
incubation with 2-n-heptylbenzimidazole.
• FIGURE :4'.T7.
Electrophoresis of microsomal proteins from rats 
pretreated with 1 '-hydroxysafrole, octenylbenzo- 
dioxole or hexenylbenzodioxole
1 2 3 4 5 6 7 8 9 10 11 12 13 1415 16 17 18
Sample pretreatment and SDS-polyacrylamide disc gel 
electrophoresis were carried out as described in 2.8 
Microsomal samples (15 yg protein) were applied as 
follows:
Well 2 phenobarbitone
3 saline
4 corn oil
5 methylcholanthrene
6 isosafrole
8,9,10,11 1 'hydroxysafrole
12,13,14 octenylbenzodioxole
15,16 hexenylbenzodioxole
Wells 1,7,17,18 contained molecular weight standards
4.2.6'. The effect of polar substituents in the side chain
in combination with side chain length on complex
formation and cytochrome P-450 induction.
The hydroxylated metabolite of safrole, l 1- 
hydroxysafrole (XVI) formed a Type I binding spectrum in micro­
somes and also formed a metabolite complex in vitro (see Fig. 
4.18.). Pretreatment of animals with 1*-hydroxysafrole 
resulted in the formation of small amounts of the 455 nm 
complex (Fig.4.19. and Table 4.7.). There was a small increase 
in the amount of cytochrome P-450 after displacement, and a 
small degree of induction of the 53,000 mol.wt. band (see Fig. 
4.17.).
The synthetic benzodioxole compounds 5-(3 *-oxopent- 
1*-enyl)-1,3-benzodioxole (XVII), 5- (S'-oxohex-l1 enyl)-1,3- 
benzodioxole (XVIII) and 5-(3J-oxooct-l1-enyl)-1,3-benzodioxole 
(XIX) were examined for production of a metabolite complex in 
vivo. There was an increase in the level of complex formed 
with increasing chain length (see Table 4.8.). The levels 
of cytochrome P-450 revealed by displacement did not parallel 
the changes seen in the levels of the 455 nm complex. SDS- 
polyacrylamide gel electrophoresis of microsomes from animals 
pretreated with these compounds showed that there is an increase 
in amount of the 53,000 mol. wt. band induced with increasing 
chain length. Oxopentenyl-benzodioxole induced the band to a 
slight extent, whereas oxohexenyl-and oxooctenyl-induced 
increasing amounts of the band (see Fig.4.20.).
FIGURE 4.18. .
NADPH-mediated formation of absorption peaks 
at 427 and 455 nm with 1 'hydroxysafrole in 
hepatic microsomes from phenobarbitone- 
pretreated rats
002A
400 £20 ££0 £60 £80 500
n m
Conditions were as described in Fig.4.1., 
except that 1 '-hydroxysafrole (250 yM) was 
added to the sample cuvette. The binding 
spectrum was recorded (— •— ) and NADPH (250 
y.M) was added to both cuvettes. The spectrum 
was recorded after 30s, 2, 5, 7, and 10 min.
FIGURE 4 .19. .
Reduced minus oxidized spectra of hepatic microsomes 
from rats pretreated ..with 1 1 -hydroxysafrole before 
and after incubation with 2-n-heptylbenzimidazole
0-02A
400 420 440 460 480 500
nm
Microsomes obtained from rats pretreated with l'hydroxy- 
.safrole were treated as described in Fig. 4.2. Spectra
were recorded before (— :-- ) and after (------) incubation
with 2-n-heptylbenzimidazole.
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FIGURE .4 . 20. .
Electrophoresis of microsomal proteins from rats 
pretreated with oxopentenyl-, oxohexenyl- or 
oxooctenylbenzodioxole, or piperine
1 2  3 4 5 6 7 8 9 10 11 12 13 .14 15 16 17 18
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Sample pretreatment and SDS-polyacrylamide disc gel 
electrophoresis were carried out as described in 2.8. 
•Microsomal samples (15 . yg protein) were applied as
follows:
Well 2 phenobarbitone
3 saline
4 corn oil
5 methylcholanthrene
6 isosafrole
7,8 oxopentenylbenzodioxole
9,10 oxohexenylbenzodioxole
11,12 oxooctenylbenzodioxole
14-17 piperine
4.2.7. Piperonyl butoxide,naphthodioxole and piperine
Piperonyl butoxide (XX) is one of the most widely 
used insecticide synergists. Although it readily formed a 
Type I binding spectrum and a metabolite complex spectrum in 
vitro (Fig.4.21.), there was no 455 nm complex formed in vivo
at the dose level used. The 53,000 mol. wt. band was not
induced by piperonyl butoxide (Fig.4.4.). The levels of 
cytochrome P-450 were elevated (Table 4.8.).
Naphtho-(2,3 d)(1,3)-dioxole (XXI) gave a Type I 
binding spectrum in phenobarbitone-induced microsomes, and on 
incubation with NADPH gave a small peak at 455 nm and after 
a period of approximately 5 min a peak at 450 nm appeared.
This compound did not give a 455 nm peak in vivo , nor did it
induce the 53,000 mol. wt. band.
Piperine (XXII), which is one of the major • 
constituents of pepper, gave a double Soret spectrum in vitro 
(see Fig.4.23.). This compound has a high acute toxicity 
when administered by i.p. injection, and so was administered 
at a much lower dose level (20 mg/kg i.p.for 3 days) than 
normally used in this study. At this low dose level no complex 
was isolated in the microsomal fraction, and there was no 
induction of cytochrome P-450 or the 53,000 mol. wt. band 
(see Table 4.8. and Fig.4o20.).
FIGURE 4.21.
NADPH-mediated generation of absorption maxima 
at 42 7 and 455 nm with piperonyl butoxide in 
hepatic microsomes from rats pretreated with 
phenobarbitone
0.02 A
450 500
n m
Conditions were as described in Fig.4.1., except that 
piperonyl butoxide (250 yM) was added to the sample 
cuvette. The binding spectrum was recorded (— •— ) 
and NADPH (250 yM) was added to both cells. The 
spectrum was recorded after 30s, 2.5 and 5 min.
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FIGURE 4.22.
Oxidized and reduced difference spectra of hepatic 
microsomes from phenobarbitone-pretreated rats on 
addition of naphthodioxole
0.02 A
350 400 450 500
nm
Conditions were as described in Fig.4.2., except that 
glucose-6-phosphate (4.0-mM).^and-glucose-6-phosphate 
dehydrogenase (2 units/ml) were added to both.sample 
and reference cuvettes. Naphthodioxole (25o vM)' was 
added to the sample cuvette and.the spectrum was 
recorded (*— •— ) . NADPH (250 yM) was added to both 
sample.and reference cuvettes and the spectrum was 
recorded after 30s, 2.5, 5, 7.5 and 10 min.
FIGURE 4.23.
NADPH-mediated generation of absorption maxima at
42 7 and 455 nm with piperine in hepatic microsomes
from rats pretreated with phenobarbitone
0-02A
£20 ££0 £60 £80 500
n m
Conditions were as described in Fig.4.1., except that 
piperine (250 yM) was added to the sample cuvette. The 
baseline was recorrected because of the intense absorbance 
Of piperine in the 400 nm region, and NADPH (250 yM) was 
added to both the sample and reference cuvettes. The 
spectrum was recorded after 30s, 2.5, 5, 7.5 and 10 min.
4.2.8. Interaction of isosafrole 'in vivo with cytochrome
P-450 following treatment with phenobarbitone or
3-methylcholanthrene
Treatment of rats with corn oil for three, days 
followed by a single injection of isosafrole (150 mg/kg i.p.) 
resulted in the formation of a 455 nm complex which could be 
displaced to yield cytochrome P-450 (Fig 4.24. and Table 4.9.). 
Pretreatment of rats with phenobarbitone followed by isosafrole 
resulted in levels of 455 nm complex similar to those seen 
after a single injection of isosafrole (Fig. 4.25. and Table 
4.9.) and a corresponding increase in the amount of cytochrome 
P-450 following displacement. A smaller percentage of the 
total cytochrome P-450 was present as complex following pheno- 
barbitone-isosafrole pretreatment than corn oil-isosafrole 
(25.3% compared with 47.8%). Pretreatment with 3-methyl­
cholanthrene followed by treatment with isosafrole resulted in 
the largest induction of the 455 nm complex (Fig. 4.26.) with 
47% of the total cytochrome P-450 represented as complex, 
and the largest induction of total cytochrome P-450 following 
displacement of the complex. On SDS polyacrylamide gel 
electrophoresis it can be seen (Fig 4.27.) that corn oil- 
isosafrole resulted in the induction of the 53,000 mol. wt. 
band, but to a lesser extent than treatment with isosafrole 
for three days. Treatment with phenobarbitone-isosafrole 
resulted in an additive induction, with the 5 3,000 and
50,000 mol. wt. bands being induced. Treatment with methyl- 
cholanthrene-isosafrole produced a very large increase in 
the intensity of the 53,000 mol. wt. band which seemed to be 
greater than one would expect from a purely additive effect. 
These effects do not appear to be due to any direct action of 
isosafrole on the proteins induced by methylcholanthrene or 
phenobarbitone, since incubation of microsomes from 
phenobarbitone- or methylcholanthrene-pretreated rats with 
isosafrole and NADPH did not bring about any change in 
electrophoretic pattern.
FIGURE 4.24.
Reduced minus oxidized spectra of hepatic microsomes
from rats pretreated with corn oil - isosafrole, before
and after incubation with 2-n-heptylbenzimidazole.
0-02A
£00 £20 ££ 0 £60 £60 500
Microsomes were obtained from animals pretreated with 
corn oil for 3 days and isosafrole for 1. day. The 
spectra were obtained as described in Fig.4.2., except 
that incubation with 2-n-heptylbenzimidazole (200 vM)
was carried out for 20 min. Before (— -----) and after
(--   ) displacement.
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FIGURE' .'4.25.
Reduced minus oxidized spectra of hepatic microsomes
from rats pretreated with phenobarbitone-isosafrole,
before and after incubation with 2-n-heptylbenzimidazole
i 1
i i
0 -0 2 A
500420
nm
Microsomes obtained from rats pretreated with 
phenobarbitone for 3 days and isosafrole for 1 
day were treated as described in Fig. 4.2 4.
Spectra were recorded before ( *—  —  ) and after
(— ---) displacement.
FIGURE 4.26. .
Reduced minus oxidized spectra of hepatic microsomes
from rats pretreated with methylcholanthrene-isosafrole
before and after incubation with 2-n-heptylbenzimidazole
0-05A
Z,00 £20 UO £60 £80 500
Microsomes obtained from rats pretreated with methyl- 
cholanthrene for 3 days.and isosafrole for 1 day were 
treated as described in Fig. 4.24. Spectra were 
recorded before (---- -) and after displacement (----).
FIGURE 4.27.
Electrophoresis of hepatic microsomal proteins
from rats pretreated with phenobarbitone, methyl*
cholanthrene or corn oil followed by isosafrole
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
- -'I- ' - - ^  , «
Sample treatment and SDS-polyacrylamide. disc gel 
electrophoresis were carried out as described in 
2.8. Microsomal samples .(15 yg protein) were 
applied as follows:
Well 2 phenobarbitone
3 saline
4 corn oil
5 methylcholanthrene
6 isosafrole
9,10,11 corn oil-isosafrole
12,13,14 phenobarbitone-isosafrole
15,16,17 methylcholanthrene-isosafrole
Wells 1,8 and 18 contained molecular weight standards
4.3. DISCUSSION
From the results presented in this chapter it 
can be seen that for the large number of substituted benzo- 
dioxole compounds studied, there is great variability in the 
extent of complex formation in vivo compared with complex 
formation in vitro. An attempt will be made here to 
rationalise some of these findings.
Safrole, isosafrole and dihydrosafrole all form 
455 nm complexes in vivo which can be displaced to, reveal 
cytochrome P-450, and all three induce the 53,000 mol. wt. 
band. The extent of induction and formation of the 455 nm 
complex seem to be parallel for each compound, and the 
compounds can be ranked .in order of ability to form a 455.nm 
complex and to induce the 53,000 mol. wt. band: isosafrole > 
safrole- - dihydrosafrole. The position of the side chain 
double bond will influence the metabolism of the side • 
chain, and may also influence the stability of the metabolite 
formed which binds to cytochrome P-450 e.g. a carbene.‘ The 
major products of metabolism of the allyl-.group of safrole 
are safrole epoxide, 2 1,3'-dihydroxypropylbenzodioxole and 
1 1-hydroxysafrole (Stillwell et al.9 1974). By analogy, 
metabolism of the propenyl— group of isosafrole would be 
expected to give isosafrole epoxide, 1 1,21-dihydroxypropyl­
benzodioxole and 3’-hydroxyisosafrole. The hydroxylated 
metabolite of safrole, 1'-hydroxysafrole, which is thought 
to be the proximate "carcinogen of safrole (Borchert et al.9 
1973 a) forms low levels of metabolite complex in vivo 
although it readily forms a metabolite complex in vitro•
There is a small degree of induction with this compound.
The ability of 1 ’-hydroxysafrole to form a complex in vitro 
and its poor inducing ability and complex formation in vivo 
suggest that the differences between the situations in vivo and 
in vitro may be due either to the ineffective absorption and 
distribution of 1'-hydroxysafrole, or to its preferential 
metabolism by conjugation enzymes.
Studies on compounds which lack the methylene 
bridge and are therefore incapable of forming a metabolite 
complex (eugenol, methylisoeugenol, estragole and benzo- 
furan) reveal that these compounds are not able to induce 
the 53,000 mol. wt. band. The fact that these compounds 
readily produce binding spectra indicates that they are 
sufficiently lipophilic to interact with cytochrome P-450.
The structural similarity to safrole and isosafrole indicates 
fairly precise structural requirements for induction of the 
novel haemoprotein. This may be due to the formation of a 
stable metabolite-cytochrome P-450 complex or to the presence 
of a highly specific receptor involved in the induction 
process.
Of the compounds with polar ring substituents 
studied (piperonal, piperonyl alcohol and sesamol) only 
piperonyl alcohol forms a metabolite-cytochrome P-450 complex 
in vitro. None of these compounds gives a metabolite complex 
in vivo or induces the 53,000 mol. wt. band. It is . 
improbable that piperonal and piperonyl alcohol are meta­
bolized by cytochrome P-450 in vivo since these compounds 
in the mouse are metabolized to give piperonylic acid, and- .. 
are excreted as the glycine conjugate, piperonyl glycine 
(Kamienski and Casida, 1970). Lake and Parke (1972) 
reported that piperonal, piperonyl alcohol and piperonylic 
acid do not form 455 nm absorption maxima after administration 
to male rats for 4 days (100 mg/kg). Sesamol gives a Type RI 
binding spectrum but does not give a metabolite spectrum on 
addition of NADPH. In the mouse, an inverted cytochrome b^ 
spectrum is formed initially with sesamol on addition of 
NADPH, and on addition of dithionite leads to the formation 
of a carbon monoxide-like peak at 450 nm (Hodgson et al,9 1973). 
With sufficient NADPH, or an NADPH generating system, the 
carbon monoxide-like peak will appear with time. Dahl and 
Hodgson (1979) have proposed that this inverted cytochrome b^ 
spectrum, and the production of carbon monoxide may be brought 
about by the formation of a carbene which breaks down to
form a quinone and carbon monoxide:
HO
Quinones will act as oxidants in microsomal systems, and 
could be responsible for the oxidation of cytochrome b^
in the sample cuvette. On addition of dithionite, the 
cytochrome P-450 carbon monoxide spectrum would be obtained.
It is therefore unlikely that sesamol would form a stable 
metabolite complex in vivo,
1,3-Benzodioxole, which in vitro readily forms 
a metabolite-cytochrome P-450 complex, forms a very small 
455 nm complex in vivo , gives a small increase in cytochrome 
P-450 on displacement of the complex, and a small induction 
of the 5 3,000 mol. wt. band on electrophoresis. Why this 
compound should give a small 455 nm complex can probably 
be explained on the basis of partial lipophilicity, with the lack 
of atlipophilic side chain leading to the formation of an 
unstable 455 nm complex in vivo. Ring hydroxylation may 
also provide a significant route of metabolism ■ in vivo • 
is of interest to note that benzodioxole gives a large 4 27 nm 
peak. How much of this can be ascribed to a 427 nm component 
of the complex, and how much to cytochrome bj- remains a point 
for debate.
substituted analogue of safrole, forms a metabolite complex 
in vitro in rat liver microsomes. This compound also forms 
a complex in microsomes from mouse liver (Hodgson et al, r 197 3) . 
Apiol, the dimethoxy-analogue of safrole, does not give a 
metabolite complex in vitro or in vivo. The successive 
introduction of methoxy-groups into the ring causes a decrease 
in the ability to form a stable complex in vivo and to act 
as an inducing agent, with apiol having no inducing ability.
The introduction of methoxy- groups in the ring will decrease
Myristicin, the naturally occurring methoxy-
the calculated log P (log partition coefficient for an 
octanol water “system), and will provide alternative routes 
for metabolism, with O-demethylation being the most probable 
route. The presence of two methoxy-groups adjacent to the 
d'ioxole ring may sterically or chemically influence the 
formation of a stable complex. Potent directing groups
may all have these effects.
Measurement of initial displacement rates of 
the isosafrole metabolite-cytochrome P-450 complex generated 
in vivo using a series of 2-alkylbenzimidazoles, n-alkyl- 
carbamates and fatty acids as displacers indicated that . 
there is an optimum side chain length of 7 carbon atoms for 
the 2-alkylbenzimidazoles, and 10 carbon atoms for the 
fatty acids and the n-alkyl-carbamates (Dickins et aZ.,1979; 
Dickins, 1978). This suggested that the 455 nm complex may 
be stabilized by a lipophilic interaction with the substrate 
binding site, and if displacement is brought about by 
competition between the displacing agent and the benzodioxole 
metabolite, then there might be an optimum side chain length 
for an alkenyl-substituted benzodioxole for the formation 
of a stable complex, and the induction of the 53,000 mol. 
wt. band. It seems that of the compounds investigated, 
isosafrole gives the largest degree of induction, and that 
increasing the side chain length of the inducing agent 
decreases the total amount of cytochrome P-450 present.
The.interpretation of the data for hexenyl- and octenyl- 
benzodioxole is complicated by incomplete displacement of 
the complex and by irregularities in the redox spectrum 
in the 490 nm region. The Induction of the 53,000 mol. wt. 
band on electrophoresis appears to be similar for octenyl- 
and hexenyl-benzodioxole. Prediction of the inducing 
ability is complicated by the stability of the complex and 
alternative sites of metabolism.
The introduction of a 3 f-oxo- group into the 
side chain significantly reduces the ability of the shorter 
chain compound (3f-oxopentenylbenzodioxole) to form a 
metabolite complex in vivo and to act as an inducing agent.
Extension of the side chain seems to overcome the effect 
of the 3 1-oxo-substituent and results in increased induction 
and increased complex formation. The introduction of the 
3'-oxo- group will decrease the lipophilicity of the 
compound and hence its distribution, and will also provide 
an alternative site for metabolism. Increasing the side 
chain length will increase the lipophilicity of the compound, 
making it more likely to be metabolized by cytochrome P-450 
in vivo,.
The insecticide synergist piperonyl butoxide 
will form a metabolite-cytochrome P-450 complex in vitro in 
rat liver microsomes. Pretreatment of rats with piperonyl 
butoxide at the dose levels routinely used in this study 
does not result in the formation of a 455 nm complex, nor 
is there induction of the 53,000 mol. wt. band on electro­
phoresis. The formation of a metabolite-cytochrome P-450 
complex in vivo in the rat with piperonyl butoxide is a 
matter of some debate with reports that it does form a 
complex (Franklin, 19 76) and others that it does not 
(Lake and Parke, 1972), and reports of induction of mono­
oxygenase activity (Franklin, 1976 ; Lake et al.JL973) . The 
levels of 455 nm complex reported by Franklin (1976) were 
determined in the presence of NADPH, so it is possible that 
the complex is obtained by metabolism in vitro of residual 
piperonyl butoxide isolated in the microsomal fraction, ' 
rather than from the isolation of a stable complex generated 
in vivo. The reported induction of cytochrome P-450 mediated 
activities in the rat has been brought about by much higher 
dose levels than those used in this study , with admini­
stration at 500 mg/kg by i.p. injection (Franklin, 1976) 
or 0.25% (w/w) in the diet for 7 days (Lake et al,9 1973). 
There have been no conclusive reports of complex formation 
and induction occurring simultaneously with piperonyl 
butoxide in the rat.
Naphthodioxole forms a Type I binding spectrum
in vitrOj and on incubation with NADPH gives a very small 
peak at 455 nm, and on prolonged incubation with an NADPH 
generating system a peak at 450' nm appears. This peak is 
probably due to the production of carbon monoxide. Although 
NADPH-dependent lipid peroxidation can result in the formation 
of carbon monoxide (Wolff and Bidlack, 1976), the breakdown 
of a metabolite of naphthodioxole may also result in the 
formation of carbon monoxide, by a mechanism similar to that 
proposed by Dahl and Hodgson (19 79) for sesamol. If naphtho­
dioxole were hydroxylated in either the 1- or 6- positions, 
subsequent formation of a carbene could lead to the formation 
of carbon monoxide and a naphthoquinone:
Naphthodioxole does not form a stable complex in vivo3 nor
naphthodioxole is rapidly metabolized in vivo to give 2,3- 
dihydroxy naphthalene,. its conjugates; and carbon dioxide 
(Sacher et al,3 1969). A significant proportion of 1-hydroxy- 
naphthodioxole was also found (approx. 10% of the administered 
dose). That the major metabolite was 2,3-dihydroxynaphthalene 
does not support the above hypothesis for the production of 
an unstable metabolite and carbon monoxide in vitro. However, 
the identification of 2,3-dihydroxynaphthalene by these 
authors was made by a comparison of the chromatographic 
behaviour of metabolites and authentic 2 /3-dihydroxynaphthalene 
alone., and is not unequivocal.
does it induce the 53,000 mol. wt. band. In the mouse,
Piperine, one of the constituents of pepper was found to be 
acutely toxic in the rat, so only low doses of this compound 
have been studied. Although this, compound forms a 455 nm 
complex in vitro3 it does not form a metabolite complex in 
vivo at the dose level used, nor does it induce the 53,000 
mol. wt. band. It is probable that piperine will undergo 
hydrolysis in vivo to give piperic acid which could easily 
undergo further metabolism and excretion. Whether piperine 
itself or its metabolites are responsible for the observed 
toxicity remains to be seen.
Benzofuran, which contains a single oxygen atom 
in a 5-membered ring, does not form a metabolite complex 
in vivo or in vitro. This is to be expected, since there is 
only one hetero-atom in the ring, and carbene formation 
is thought to require the presence of two hetero-atoms.to 
stabilize the structure (Werringloer and Estabrook, 1978).
It does not induce the 5 3,000 mol. wt. band, but causes a 
reduction in the level of cytochrome P-450 without the 
production of cytochrome P-420. It does cause a large 
increase in Band I, which has been tentatively identified 
as epoxide hydratase (see Chapter 3). The induction of this 
and other proteins will be discussed in Chapter 7.
To summarise the results presented, the requirements 
for induction of the 53,000 mol. wt. band appear to be:
i). the presence of a dioxole ring
ii). metabolism of the methylene group of the dioxole
ring to form a stable adduct with cytochrome P-450
iii). the presence of a lipophilic side chain which enhances
inducing ability 
iv). the absence of alternative sites of metabolism which 
undergo preferential metabolism.
The formation of a stable 455 nm complex in vivo seems to be 
.associated with the induction of the 53,000 mol. wt. band. 
There could be a relationship between the formation of a 
stable metabolite-cytochrome P-450 complex in vitro and 
induction of the 53,000 mol. wt. band. This possibility
will be discussed in Chapter 6.
There are several compounds which were not 
investigated, but which could prove to be important: the 
naturally occurring methoxy-substituted compounds asaricin, 
croweacin and dillapiol; the psychoactive compounds methysticin, 
(5-hydroxy-3-methoxy-7-(3,4-methylenedioxypheny1)-2,6- 
heptadienoic acid <5 - lactone) and dihydromethysticin which 
are obtained from the root of pepper. The benzodioxole 
structure has been incorporated into several drugs amongst 
which are methylenedioxyamphetamine, an. hallucinogen which has 
enjoyed popularity with members': of the drug subculture 
(Ratcliffe, 1974). Another class of compounds which form 
metabolite-cytochrome P-450 complexes with a single absorbance 
maximum at 427 nm in vitro are the diolaxanes and methylene- 
dioxycyclohexane (Dahl and Hodgson, 1979;Hodgson et ol,31913) ,
The administration to rats of phenobarbitone 
followed by isosafrole results in induction of the 53,000 
mol. wt. band and formation of a 455 nm complex with levels 
similar to treatment with corn oil-isosafrole. Methylchol­
anthrene followed by isosafrole produces a large increase 
in the 53,000 mol. wt. band, an increase in the 455 nm complex
and an increase in total cytochrome P-450 levels. The
magnitude of increase in total cytochrome P-450 with methyl­
cholanthrene-isosafrole compared to methylcholanthrene or 
isosafrole alone suggests that isosafrole may have an induction 
mechanism with features common to that of methylcholanthrene. 
These may include interaction at a common receptor, transcrip­
tion or translation of-similar mRNA.species, or post- 
.transcriptional modification of a protein induced by methyl­
cholanthrene . It seems improbable that interaction at a 
common receptor is the reason for synergism, since less than
additive induction would be expected for the inducer
combination. The most probable mechanisms are: translation 
of a similar mRNA species in which isosafrole may stimulate 
protein synthesis; complex formation with one of the induced 
cytochromes initiating induction of a common cytochrome 
species; post-translational modification induced by isosafrole 
of a protein synthesised in response to methylcholanthrene..
Treatment with methylcholanthrene induces a minor protein 
with molecular weight similar to that induced by isosafrole.
At present it is not known if these proteins are identical, 
but complex formation with this protein could result in a 
large increase in its rate of synthesis, if vastly increased 
levels of mRNA coding for this protein had already been 
produced. Activation of translation could then account for 
the rapid increase in the 5 3,000 mol. wt. band and the 
increase in complex formation.
Similar experiments have been carried out following 
the administration of SKF-525A to phenobarbitone- and 
methylcholanthrene-pretreated rats (Buening and Franklin,
1976). Animals which received phenobarbitone and SKF-525A 
showed an increase in total cytochrome P-450 and had 41% 
of the total cytochrome P-450 present as metabolite complex, 
compared to SKF-525A alone, which produced 33% of the total 
hamoprotein as complex. Methylcholanthrene followed by 
SKF-525A produced only 3% of the total cytochrome P-450 as 
metabolite complex. However, these measurements were made 
three and six hours after administration of SKF-525A, which 
will result in a limited induction response. The level 
of complex after the various pretreatments will therefore 
be a measure of the ability of existing cytochrome P-450 
to form a metabolite complex rather than a measure of newly 
synthesised cytochrome P-450. These results, together with 
the electrophoretic data presented in Chapter 3, suggest 
that SKF-525A and isosafrole interact with different species 
of cytochrome P-450 in vivo to bring about formation of 
metabolite complexes.
CHAPTER 5
INDUCTION OF CYTOCHROME P-450 BY 
ISOSAFROLE IN MICE
5. INDUCTION OF CYTOCHROME P-450 BY
‘ ISOSAFROLE IN MICE
5.1. INTRODUCTION •
In the mouse, substituted benzodioxole compounds 
have been found to form metabolite-cytochrome P-450 
complexes both in vitro and in vivoc The original observation 
of the metabolite-cytochrome P-450 complex was made using 
an in vitro • system of mouse microsomes with NADPH and 
piperonyl butoxide (Philpot and Hodgson, 1971a). A wide 
range of benzodioxole compounds have since been shown to 
form metabolite-cytochrome P-450 complexes in vitro in 
mouse microsomal preparations (Hodgson et at. ,1973).
The formation of metabolite-cytochrome P-450 complexes in 
the mouse in vivo with piperonyl butoxide and propyl 
isome has been reported (Philpot and Hodgson, 1971b).
Induction of cytochrome P-450 dependent activities by 
piperonyl butoxide in the mouse has been described. The 
hydroxylation of biphenyl (Jaffe et at., 1969), the 
hydroxylation of aniline and hexobarbital, the O-demethylation 
of 4-nitroanisole and the N-demethylation of dimethyl-4- 
nitrophbnylcarbamate are induced by piperonyl butoxide 
(Skrinjaric-Spoljar et at. ,19 71; Matthews et at. ,19 70) .
From our own work in the rat there seems to be a close 
correlation between the formation of a 455 nm complex 
in vivo and induction by benzodioxole compounds. Piperonyl 
butoxide fails to produce a 455 nm complex in vivo in 
the rat, and appears not to be an inducing agent, whereas 
in the.mouse it does produce a 455 nm complex and does act 
as an inducer (Philpot and Hodgson, 1971b). On the basis 
of our present understanding, piperonyl butoxide in mice 
should induce form(s) of haemoprotein identical to those 
induced by isosafrole.
In mice the capacity for induction of 1 cytochrome 
P-4481 and certain monooxygenase activities by polycyclic 
aromatic hydrocarbons is referred to as aromatic hydrocarbon 
responsiveness. This genetic trait is inherited as a
single autosomal dominant gene in certain inbred strains 
of mice (Nebert et ale , 1975). Using SDS disc gel 
electrophoresis, Haugen et dl. (1976) showed that in the 
responsive C57BL/6N strain,3-naphthoflavone and 2,3,7,8- 
tetrachlorodibenzo-P-dioxin (TCDD) induced a polypeptide 
band of mol. wt. 55,000. In both the nonresponsive DBA/2N 
strain and the responsive C57BL/6N strain, phenobarbitone 
induced two bands of mol. wt. 51,000 and 55,000 with a 
small increase in a band of mol. wt. 49,000. Pregnenolone 
16 a-carbonitrile (PCN) caused an increase in a band of
54,000 mol. wt. in both strains. In the nonresponsive 
DBA/2N strain, 3-naphthoflavone does not induce a band of 
mol. wt. 55,000, whereas TCDD does. The protein induced by 
polycyclic aromatic hydrocarbons has since been resolved into 
two separate bands on electrophoresis (Boobis et ale , 1977).
In the rat, the pattern of induction with safrole 
and isosafrole has been found to show similarities with the 
induction produced by methylcholanthrene. Lotiikar and 
Wasserman (1972) indicated that safrole and isosafrole 
induced the 3- and 5- hydroxylation of 2-acetamidofluorene 
to a greater extent than the N-hydroxylation reaction, which 
is similar to the pattern of induction with methylcholanthrene 
Elcombe et at. (1975a) observed a shift in the absorbance 
maximum of the reduced carbon monoxide spectrum from 450 
to 488 nm following treatment of rats with isosafrole.
However, safrole and isosafrole induce both the 2- and 4- . 
hydroxylation of biphenyl (Parke and Rahman, 1970), and 
similar induction of cytochrome P-450 and cytochrome P-448 
mediated activities by isosafrole has been reported 
(Wagstaff and Short, 1971? Lake et at. 1973; Vainio and 
Parkki, 1976). From our present work, treatment with either 
phenobarbitone or methycholanthrene followed by isosafrole 
in the rat produces a more than additive induction with 
methycholanthrene indicating a possible link in the inducing 
mechanisms of isosafrole and methylcholanthrene (see Ch.4 ).
A study of the inducing capabilities of isosafrole and 
piperonyl butoxide in responsive and nonresponsive mice was 
undertaken in an attempt to produce a clearer understanding 
of the relationship between induction by benzodioxole 
compounds and methylcholanthrene.
5.2. RESULTS
Measurement of cytochrome P-450 levels (see 
Table 5.1.) indicates that phenobarbitone caused an induction 
in both the C57BL/10 and DBA/2 strains, whereas methyl­
cholanthrene only induced cytochrome P-450 in the responsive 
C57BL/10 strain. PCN caused an increase in cytochrome P-4 50 
in both strains. Piperonyl butoxide and isosafrole produced 
increases in cytochrome P-450 in both strains of mice, 
although these increases were not as large as those seen with 
other inducing agents. However, these values represent the 
levels of cytochrome P-450 in the free uncomplexed form, and 
not total cytochrome P-450 levels.
The reduced minus oxidized spectrum of microsomes 
from C57BL/10 mice pretreated with isosafrole shows the 
presence of the 455 nm complex (Fig. 5.1.). Incubation with 
safrole brings about a reduction in the amount of the 455 nm 
complex. Displacement of the complex can also be measured 
in the oxidized state, with a time dependent increase in the 
magnitude of the binding spectrum of safrole, and a shift in 
the absorbance maximum towards 438 nm (see Fig. 5.2„)o 
Microsomes obtained fromIBA/2 mice treated with isosafrole 
also exhibit the 455 nm peak associated with the metabolite 
complex which is diminished on incubation with safrole.
Pretreatment of mice of both strains with piperonyl 
butoxide leads to the formation of a 455 nm absorption peak 
in the reduced minus oxidized spectrum (see Figs. 5.4. and 
5.5.). However, the.magnitude of the 455 nm peaks is not 
as great as that seen on pretreatment with isosafrole. The 
possibility exists that the complex may be formed with 
piperonyl butoxide to an extent similar to that formed with
TABLE 5.1.
Effect.of pretreatment with various inducing agents
on the microsomal levels of cytochrome P-450 in
mouse liver
Treatment Cytochrc 
(nmol/mg mic
m e  P-450 
:rosomal protein)
C57BL/10 DBA/2
Saline 0.78 + 0.09 0.84 + 0.19
Phenobarbitone 1.76 + 0.28 1.46 ’+ 0.54
Sunflower oil 0.64 + 0.29 0.72 + 0.24
Piperonyl butoxide 1.49 + 0.24 1.00 + 0.16
Isosafrole 1.18 + 0.22 1.07 + 0.27
PCN 1.36 + 0.37 1.24 + 0.29
Methylcholanthrene 1.54 +0.46 0.71 + 0.08
Values represent mean t standard deviations of three 
separate experiments on the pooled microsomal fractions 
obtained from four animals. The values for piperonyl 
butoxide and isosafrole represent the cytochrome P-450 
levels before displacement of the metabolite complex.
FIGURE 5.1.
Redox difference spectrum of microsomes from
C57BL/10 mice pretreated with isosafrole
0-02 A
450 470390 430 490410
Microsomes from C57BL/10 mice pretreated with 
isosafrole were suspended in 66 mM Tris-HCl 
(pH 7.4) to give a protein concentration of 
0.5 mg/ml and divided equally. One half 
was used to record the reduced minus
oxidized spectrum before displacement (---- ).
The other half was incubated with 250 yM 
safrole for 30 min at 37 before recording 
the reduced minus oxidized spectrum (----- ) .
FIGURE 5.2.
Displacement of the isosafrole metabolite 
cytochrome P-450 complex in microsomes 
from C57'BL/LO mice
0-01 A
380 400 420 440 460nm
Microsomes fromC57BL/10 mice pretreated with 
isosafrole were suspended in 66 mM Tris-HCl 
(pH 7.4) to give a protein concentration of 
0.7 mg/ml, divided equally between two 
cuvettes and incubated at 37 for 5 min.
A baseline of equal light absorbance was 
established and 250 yM safrole was added 
to the sample cuvette. Spectra were 
recorded every 2.5,min. The arrows indicate 
the direction of change with time.
FIGURE 5.3.
Redox difference spectrum of microsomes from
DBA/2 mice pretreated with isosafrole
001 A
430 450390 410 470nm
Conditions were as described in Fig. 5.2. except 
that microsomes were obtained fromEBA/2. mice 
treated with isosafrole. Spectra were recorded 
before (—---- ) and after (— -— ) displacement.
FIGURE '5.4.
Redox difference spectrum of microsomes from
C57BL/10 mice pretreated with piperonyl butoxide
0-02 A
390 430 450 470 490nm
Microsomes prepared from the livers of C57BL/10 
mice pretreated with piperonyl butoxide were 
suspended in 66 mM Tris-HCl (pH 7.4) to give a 
protein concentration of 0.9 mg/ml. Subsequent 
measurements were made as described in Fig.5.1.
Spectra were obtained before (-— ) and after
(----- ) displacement.
FIGURE 5.5.
Redox difference spectrum of microsomes from
DBA/2 mice pretreated with piperonyl butoxide
0 02 A
490450430410 470nm
i
Microsomes from DBA/2 mice pretreated with 
piperonyl butoxide were suspended in 66 mM 
Tris-HCl (pH 7.4) to give a protein 
concentration of 1.0 mg/ml. Subsequent 
measurements were made as described in Fig.
5.1. Spectra were recorded before (— ----)
and after (----- ) displacement.
isosafrole, but that the piperonyl butoxide metabolite 
complex undergoes displacement during isolation of the 
microsomal fractions.
Measurement of monooxygenase activities was 
carried out both before and after displacement. The 
substrate for the reaction'was used as the displacing 
agent. For measurements before displacement the 
microsomal suspensions were preincubated in the presence 
of reduced cofactor, and the reaction initiated by the 
addition of substrate. For measurements of activity after 
displacement the microsomal suspensions were preincubated 
in the presence of substrate at 37° for 30 min and the 
reaction initiated by the addition of reduced cofactor.
Biphenyl 4-hydroxylase is increased in both 
strains by pretreatment with phenobarbitone, and to a 
lesser extent by pretreatment with isosafrole and piperonyl 
butoxide. There is little change on treatment with PCN 
or methylcholanthrene in either strain. Preincubation with 
substrate causes little change with isosafrole- and 
piperonyl butoxide-pretreated mice of both strains.
Biphenyl 2-hydroxylase is increased in the 
C57BL/Q.O strain by pretreatment with methylcholanthrene 
but not in the DBA/2 strain (see Table 5.3.). Piperonyl 
butoxide causes an increase in both strains before 
displacement, whereas with isosafrole the levels in both 
strains are not significantly different from control 
levels. Preincubation with biphenyl causes an increase 
in biphenyl 2 -hydroxylase in microsomes from piperonyl 
butoxide-pretreated mice of both strains. Preincubation 
of microsomes from isosafrole-pretreated mice of both 
strains with biphenyl results in an increase of biphenyl 
2 -hydroxylase, and the final activities are comparable 
with those obtained with piperonyl butoxide.
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Ethylmorphine N-demethylase activities are increased 
in.both strains by pretreatment with phenobarbitone and PCN, 
but are little changed by methylcholanthrene pretreatment. 
Piperonyl butoxide and isosafrole pretreatment causes an 
increase in both strains. There is, however, little change 
•in activity .on preincubation with substrate.
Ethoxyresorufin O-deethylase activity is 
increased markedly in the C57BL/LO strain by pre treatment with 
methylcholanthrene. There is no corresponding increase in 
the DBA/2 strain on ;pretreatment- with methylcholanthrene. The 
control levels of ethoxyresorufin O-deethylase are also much 
lower in the DBA/2 strain. Phenobarbitone pretreatment causes 
little change on C57BL/10 mice, but causes an increase in 
activity on DBA/2 mice. Isosafrole and piperonyl butoxide cause 
increases in both strains. The increase with piperonyl 
butoxide is greater in both strains than with isosafrole, and 
the levels induced by both these compounds in theIBA/2 mice 
are less than those induced in the C57BL/10 mice. There is a 
decrease in activity on preincubation of microsomes from 
animals treated with piperonyl butoxide and isosafrole, and 
also with all the other pretreatments.
SDS polyacrylamide disc gel electrophoresis shows 
that in both strains of mouse, phenobarbitone induces two 
polypeptide bands of molc wt„ 49,000 and 54,000 (Fig. 5.6.).
PCN induces in both strains a polypeptide of mol. wt. 54,000. 
Methylcholanthrene induces two polypeptide bands of mol. wt.
54,000 and 55,000 in C57BL/10 mice, whereas in the DBA/2 mice 
methylcholanthrene causes no changes. There is a decrease in 
the staining intensity of several polypeptide bands in the 
region of 44,000 - 46,000 molc wt. on treatment with 
inducing agents, with the exception of methylcholanthrene 
pretreatment of DBA/2 mice. Isosafrole induces a band of 54,000 
mol. wt. in both strains of mice. Piperonyl butoxide also 
induces this band in both strains, and to a lesser extent a 
band of 49,000 mol. wt. Isosafrole induces a band of low 
molecular weight (approximately 25,000) which is not present 
in any of the control or other pretreated microsomal 
preparations.
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FIGURE 5.6.
SDS polyacrylamide disc gel electrophoretogram 
of hepatic microsomes from C57BL/10 and DBA/2 
mice treated with various inducing agents
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Electrophoresis was carried out as described in
2.8.1. A mixture of molecular weight standards 
wereelectrophoresed in positions 1,9,17 and 18. 
The microsomal samples are numbered as follows:
C5 7BL/10 DBA/2
phenobarbitone 2 1 0
saline 3 11
oil 4 12
methylcholanthrene 5 13
isosafrole 6 14
piperonyl butoxide 7 15
PCN 8 16
The gel was stained for protein with Coomassie 
Blue G as described in 2.8o5. The origin is at 
the top of the gel.
5.3. DISCUSSION
Isosafrole and piperonyl butoxide both form 
metabolite-cytochrome P-450 complexes in vivo. This 
differs from the situation in rats where piperonyl 
butoxide does not form a metabolite complex in similar 
experiments. The complexes generated in vivo in the mouse 
will undergo displacement to reveal catalytically active 
cytochrome P-450. These results are similar to those 
found in the rat on treatment with isosafrole (Elcombe 
et at. 1975,1977; Dickins et atD ,1979). Displacement of the 
complex is therefore required for the full extent of 
induction to be revealed. Since good displacing agents 
act as inhibitors of cytochrome P-450, and are, because of 
their liphophilic nature, difficult to remove to enable a 
valid measurement of monooxygenase activity to be made, 
preincubation of microsomes with the substrate under 
investigation was used to carry out displacement of the 
metabolite complex. The substrates under investigation do 
not necessarily act as good displacing agents, and it does 
not follow that the best displacing agents make the best 
substrates for the induced cytochrome. Preincubation of 
microsomes with NADPH, and the initiation of reactions 
by addition of substrates enabled the measurement of 
reaction rates before displacement, since the displacement 
process does not occur under reducing conditions.
The changes in cytochrome P-450 dependent 
activities found with 3-methylcholanthrene, phenobarbitone 
and PCN in the C57BL/10 and DBA/2 mice are similar to those 
described by Haugen et ali±916). Cytochrome P-450 was 
induced in the responsive C57BL/10 strain by treatment with 
methylcholanthrene, and there were increases in biphenyl
2-hydroxylase and ethoxyresorufin O-deethylase. This was 
accompanied by an induction of two proteins of mol. wt.
55,000 and 54,000. These changes were not observed in the
nonresponsive EBA/2 mice on treatment with methylcholanthrene. 
Treatment with phenobarbitone in both strains produced an 
increase in cytochrome P-4 50, biphenyl 4-hydroxylase and 
ethylmorphine N-demethylase, and an induction of two 
proteins of mol. wt. 49,000 and 54,000. Pretreatment 
with PCN caused an induction of cytochrome P-450, an 
increase in ethylmorphine N-demethylase and induction of 
a single.protein of mol. wt. 54,000.
Isosafrole pretreatment caused a small increase 
in the levels of cytochrome P-450 before displacement in 
both strains. There is an increase in biphenyl 4- 
hydroxylase before and after displacement in both strains, 
which is not as large as that seen with phenobarbitone. 
Pretreatment with isosafrole causes little change in 
biphenyl 2 -hydroxylase before displacement, but there is a 
large increase in this activity in both strains of mice 
after displacement of the metabolite complex. Ethyl­
morphine N-demethylase and ethoxyresorufin 0-deethylase 
activity are induced by isosafrole in both strains, but 
give little change on preincubation with substrate. This 
may be due to poor displacing ability of the two substrates, 
since in the rat they act as poor displacing agents 
(Dickins et aZ.f>.1979). A polypeptide band of mol. wt.
54.000 is induced by isosafrole in both the responsive and 
nonresponsive strains.
Piperonyl butoxide in both strains of mice 
produces an induction profile similar to that of isosafrole, 
although it yields smaller increases in enzyme activities 
on displacement and lower levels of metabolite complex 
than those seen with isosafrole. This may be due to 
displacement of the piperonyl butoxide metabolite complex 
from cytochrome P-450 during the microsomal isolation 
procedureoThe additional polypeptide band of mol. wt.
49.000 induced by piperonyl butoxide may be related to
cytochrome P-450 although this is not necessarily so, 
since there do not appear to be significant differences 
in the patterns of metabolism induced by piperonyl 
butoxide and isosafrole, which one would expect if another 
species of cytochrome was being induced. The induction of 
cytochrome P-450 by piperonyl butoxide in the mouse 
contrasts with the situation in the rat where at comparable 
dose levels no metabolite conplex is seen-and no induction of 
cytochrome P-450 is apparent. Only at higher dose levels 
(500 and 1,000 mg/kg) has piperonyl butoxide been reported 
to form a metabolite complex in vivo (Franklin,1976) and 
act as an inducing agent (Lake et at. ,1973) (0.25% w/w
in the diet for seven days).
The pattern of induction with isosafrole seems 
to have superficial similarities to the induction patterns 
of phenobarbitone, methylcholanthrene and PCN. However, 
the changes in metabolic activities on pretreatment with 
isosafrole do not correspond to those seen with any single 
inducing agent. The increase in biphenyl 2-hydroxylase 
suggests that the cytochrome(s) induced by isosafrole may 
be similar to those induced by methylcholanthrene, but 
there is a much smaller increase, in ethoxyresorufin 0 - 
deethylase than that seen with methylcholanthrene. This 
may be due to poor displacing ability of ethoxyresorufin. 
Isosafrole also increases biphenyl 4-hydroxylase and 
ethylmorphine N-demethylase activities, suggesting 
similarities with phenobarbitone or PCN induction.
Gel electrophoresis is of limited help in 
resolving the identity or non-identity of the haemoproteins 
involved, because phenobarbitone, PCN and methylcholanthrene 
all induce-a band of mol. wt. 54,000 similar to that 
induced by isosafrole, although phenobarbitone and 
methylcholanthrene induce additional bands not induced by . 
isosafrole. Similarity of molecular weights on electro-
phoresis does not necessarily indicate identity, and the 
differences in substrate specificity following induction 
by these various agents suggest that the protein bands 
may in fact be different and, indeed, may consist of 
more than one protein.
Major differences in inducing capabilities 
have been shown in the response of DBA/2 mice to methyl­
cholanthrene, compared with isosafrole pretreatment.
Poland et at. (1976) have postulated that the genetic trait 
of aromatic hydrocarbon responsiveness is due to a 
mutation which results in the synthesis of an induction 
receptor with a diminished affinity for the inducing . 
compound. For compounds with low affinity for this 
receptor, such as methylcholanthrene, the result is a 
lack of induction in the nonresponsive strains. However, 
treatment of nonresponsive mice with TCDD, a compound with 
a high affinity for the receptor, results in induction of 
cytochrome P-450 similar to that seen in the responsive 
strains. This indicates that the nonresponsive strains 
are still capable of synthesising the protein(s) induced 
by methylcholanthrene in the responsive strains (Poland 
et al* ,1974). Treatment with isosafrole produced similar 
induction profiles in both strains. This indicates that 
either the cytochrome(s) induced by isosafrole are 
different from those induced by methylcholanthrene, or that 
the mechanism of induction is different. The results 
presented above seem to indicate that either this receptor 
protein is not involved in the induction mechanism of 
isosafrole, or that if it is involved, the mutation in the 
DBA/2 strain does not affect its affinity for isosafrole. 
Alternatively, the receptor may be cytochrome P-450 itself, 
with the formation of a metabolite-cytochrome P-450 complex 
being the. initiating event for induction.
CHAPTER 6
ON THE NATURE OF BENZODIOXOLE METABOLITE-
CYTOCHROME P-450 COMPLEXES
6. ON THE NATURE OF BENZODIOXOLE METABOLITE-
CYTOCHROME P-450 COMPLEXES
6.1. INTRODUCTION
The metabolite complex formed by benzodioxole 
compounds with cytochrome P-450 in vitvo is spectrally 
manifested in the reduced state by two Soret peaks at 42 7 
and 455 nm (Philpot and Hodgson, 1971 a; Franklin, 1971).
The two peaks are in a pH-dependent equilibrium,(Philpot and 
Hodgson, 1971 a) and their ratio is dependent on ionic 
strength and the concentration of the benzodioxole compound 
(Elcombe, 19 76). In the oxidized state the double Soret 
peaks disappear and are replaced by a single peak at 4 38 nm 
(Philpot and Hodgson, 1971 b; Elcombe et al.^1975 b).
The complex generated in vivo also has absorbance 
maxima at 427 nm and 455 nm (Parke and Rahman 1971; Philpot 
and Hodgson, 1971 b), although the contribution of cytochrome 
bg to the 427 nm peak is indeterminate. In the oxidized state 
the complex generated in vivo displays a single absorbance 
maximum at 438 nm, and can be dissociated by incubation 
with various Type I and Type RI ligands, resulting in an 
increase in catalytically active cytochrome P-450 (Elcombe- 
et aZ.^1975 a; Dickins et aZ.,1979). The amount of cytochrome 
P-450 revealed is related to the amount of the metabolite 
displaced from the complex by a 1:1 ratio (Elcombe et al,3 1976). 
The formation of the 455 nm peak in vivo seems to be associated 
with the induction of the new haemoprotein (see Chapter 4.).
One important feature of the displacement of the isosafrole- 
metabolite complex is the dependence of the initial rate of 
displacement on the lipophilicity and molecular size of the 
displacing agent used (Dickins et aZ.,, 1979). The contribution 
of the lipophilicity of the benzodioxole compound to stabiliza­
tion of the metabolite complex is one of the aspects which 
will be discussed in this chapter.
The origin of the two Soret peaks both in vivo and 
in vitro is a matter of some controversy, with a large number 
of possible explanations supported by very little direct 
evidence. Possible explanations include:
(i) Different metabolite products being bound to cytochrome 
P-450. The most probable metabolite capable of forming a 
metabolite complex is a carbene(see Introduction). However, 
the possibilty of other metabolites contributing to the Soret 
peaks can not be disregarded.
(ii)Different protonation states. The relative proportions
of the two peaks formed by benzodioxole compounds is influenced 
by pH (Philpot and Hodgson, 1971 a), with the 42 7 nm peak 
predominating at low pH and the 455 nm peak at high pH.
(iii) Binding at different sites on the same cytochrome P-450.
It is generally accepted that the metabolite forms a ligand 
complex directly with the haemiron. The sixth ligand position 
is readily accessible to react with oxygen, carbon monoxide 
and various other ligands (Chevion et a t 1977) . The .fifth 
ligand position is thought to be occupied by a mercaptide 
group, which forms a strong ligand but can be displaced under 
various circumstances to form cytochrome P -420 (Stern and 
Peisach, 19 74). The probable spatial orientation of the haem 
moiety with respect to the Type I site may preclude binding
of a reactive metabolite to the fifth ligand position.
(iv) Binding of a metabolite to a partially denatured cytochrome 
P-450. This may involve binding of a metabolite to cytochrome 
P-420 or a partially denatured cytochrome P-450. The major 
evidence for this is that on conversion of cytochrome P-450
to cytochrome P-420 the double Soret spectrum of ethyliso- 
cyanide in the reduced state is replaced by a single peak at 
433 nm (Omura and Sato, 19 64 a) .
(v) Binding to different types of protein. This could involve 
binding of a metabolite to two different types of cytochrome 
P-450, each one forming a different absorbance peak. It is 
difficult to see how pH could'influence the proportion of each 
enzyme forming a complex, since the data on the interconversion 
of 427 and 455 nm peaks (Philpot and Hodgson, 19 71 a; Franklin, 
1971) could hot be explained solely on the basis of differing 
pH optima for two enzymes.
6.2. RESULTS
6.2.1. The metabolite-cytochrome P-450 spectrum generated 
in vivo with isosafrole: displacement and 
regeneration.
The spectrum shown in Fig. 6.1. is the oxidized 
spectrum obtained with microsomes from animals pretreated 
with isosafrole following the addition of isosafrole to the 
sample cuvette. There is a time dependent increase in the 
magnitude of the binding spectrum and a shift in ,the wave­
length of the trough towards 438 nm. This is associated 
with the displacement of the metabolite bound to cytochrome 
P-450, which is accompanied by an increase in the amount of 
cytochrome P-450 available, and hence an increase in the Type 
I spectrum. On addition of NADPH to both cuvettes a double 
Soret peak appears with time. On exhaustion of NADPH, a 
binding spectrum appears and increases with time, indicating 
displacement of the metabolite bound to cytochrome P-450.
6.2.2. The metabolite-cytochrome P-450 complex generated
in vitro in microsomes from phenobarbitone- 
pretreated rats.
In Fig. 6.2. the binding spectrum produced by 
isosafrole in phenobarbitone-pretreated microsomes is shown. 
On addition of NADPH to both cuvettes a double Soret spectrum 
is produced with time. Removal of NADPH results in the 
formation of a peak at 438 nm which disappears rapidly with 
time. The addition of sodium dithionite to the sample 
cuvette results in the appearance of a peak at 427 nm and a 
peak at 450 nm. Reduction of the reference cuvette results 
in the disappearance of the 427 nm peak, indicating that it 
was due to reduced cytochrome b^, but the peak at 450 nm 
•remains, indicating the production of carbon monoxide.
FIGURE 6.1.
Dissociation of the isosafrole metabolite-cytochrome P-450 
complex generated in vivo and subsequent regeneration
0.02 A
350 450 500
nm
Microsomes (lmg protein/ml) from isosafrole-pretreated rats 
were suspended in 6 6  mM Tris-HCl (pH 7.4), divided equally 
between two cuvettes and allowed to equilibrate at 37 for 
5 min. A baseline of equal light absorbance was recorded
(AO--- -o) and isosafrole (250yM) was added to the sample
cuvette. Spectra were recorded after 30s (1),2,4,6,8 and 
12 min (6 ). The spectrum in B was recorded after 12 min
(•---- • ). NADPH (250yM) was added to both cuvettes and
spectra were recorded after 30s (1),2,4,6 , 8  and 10 min (6 ). 
Glutamate dehydrogenase (20 units/ml), NH^Cl (5.0 mM) and 
sodium-2-oxoglutarate (2.5 mM) were added to both the sample 
and the reference cuvette (C), and spectra: were recorded 
after 30s (A A ) ,2(2),4,6 , 8  and 10 min.
FIGURE 6.2,
Formation and degradation of the isosafrole metabolite 
cytochrome P-450 complexes in microsomes from phenobarbitone 
pretreated rats
0.01 A
A
0.02 A
B
400 450 500
nm
Microsomes (lmg protein/ml) from phenobarbitone-pretreated 
rats were suspended in 6 6 mM Tris-HCl (pH 7.4) containing 
ImM-EDTA, divided equally between two cuvettes and incubated 
at 37° for 5 min. A baseline of equal light absorbance was 
recorded in .A (o— — o) , isosafrole (250yM) was added to the 
sample cuvette and the binding spectrum was recorded (.#— •). 
NADPH (250yM) was added to both cuvettes and the spectrum 
was recorded after 30 s (1) and 10 min (10). Glutamate 
dehydrogenase (20 units/ml), 2-oxoglutarate (2.5mM) and NH^Cl 
(5.0mM) were added to both cuvettes and the spectrum was
recorded after 30s (■— — ■) and 20 min (□----□) . Sodium
dithi'onite was added to both cuvettes and the reduced •minus reduced 
spectrum was recorded (B) .
6.2.3. Generation of a metabolite-cytochrome P-450 complex
with isosafrole in a suspension of isolated rat 
hepatocytes.
Isolated hepatocytes were prepared from rats 
pretreated with phenobarbitone as described in 2.4.2. The 
addition of isosafrole to a suspension of hepatocytes in 
2.5% (w/v) gelatin at 37° results in the formation of a Type 
I binding spectrum (Fig.6.3.). This is followed by the 
appearance with time of two peaks, one at 427 nm and the 
other at 458 nm.
6.2.4. Displacement of the metabolite-complex generated
in vivo with isosafrole, hexenylbenzodioxole and 
octenyIbenzodioxole.
Using an homologous series of 2-alkylbenzimidazoles, 
the optimum chain length of displacing agent was determined 
for complexes generated in vivo with three benzodioxole 
compounds with differing side chain lengths: isosafrole, 
hexenylbenzodioxole and octenyIbenzodioxole. The rate of 
displacement was monitored by measuring the change in 
absorbance at 438 relative to that at 490 nm. It can be seen 
in Fig.6 .4. that for isosafrole there is a distinct variation 
in the rate of displacement with change in the alkyl 
substituent of the displacing agent. There appears to be 
an optimum chain length of the displacing agent of 7 for the 
isosafrole metabolite complex. With hexenylbenzodioxole, 
the initial rate of displacement is much lower than that seen 
with isosafrole, but there still appears to be an optimum side 
chain length of 7 for the displacing agent. OctenyIbenzo­
dioxole gave the lowest rate of displacement of the three 
compounds investigated, and the rate of displacement is still 
increasing at nonylbenzimidazole.
FIGURE 6.3.
Spectral changes produced on addition of isosafrole 
to a suspension of isolated hepatocytes
0.005 A
400 450 500
nm
6
Isolated hepatocytes (approx.2x10 cells/ml) prepared from 
phenobarbitone-pretreated rats were suspended in phosphate 
buffered saline containing 2.5% (w/v) gelatine and lg/1 
glucoge, divided equally between two cuvettes and incubated 
at 37 for 5 min. A baseline of equal light absorbance was 
established, (o— ;— o) and isosafrole (250yM) was added to
the sample cuvette (•----•). The spectrum was recorded
after 5, 10, 15 and 25 min.
FIGURE 6.4.
Dissociation of the cytochrome P-450-metabolite complexes 
of isosafrole, hexenyl- and octenyIbenzodioxole using a 
series of n-alkylbenzimidazoles
1^ 2^ C3 Cu C5 C6 C7 Cb Cg
I  \-- 1— — l 1 I----- 1 ' 1 " 1
26 r
P
Microsomes (lmg protein/ml) from rats pretreated with isosafrole, 
hexenyl- or octenyIbenzodioxole were suspended in 6 6  mM Tris-HCl 
(pH 7.4), placed in a cuvette and allowed to equilibrate at 37 
for 5 min. The substituted benzimidazole (250yM) was added to 
the cuvette and the initial rate of dissociation of the meta­
bolite complex of cytochrome P-450 was measured(expressed as 
AA438-49o//m^ n^m^ Protein ) • These values were plotted against 
logP Tlog octanol/water partition coefficient) values. The 
measurements were made in the dual wavelength mode (Ai=4 38 nm, 
A2 = 4 9 0 ). Points represent the mean of two determinations. C 3 ,
C^, etc., represent the number of carbon atoms in the alkyl 
substituent of benzimidazole. Isosafrole (•----•),-hexenyl­
benzodioxole (o— — o ), octeny Ibenzodioxole (▼----▼).
6.3. DISCUSSION
It can be seen that there is a major difference in 
the stability in the oxidized state of the metabolite 
complexes generated in vitro and in vivo with isosafrole.
The stability in the oxidized state of the complex generated 
in vivo is evident from its ability to undergo the.micro­
somal isolation procedure and its resistance to dialysis 
(Elcombe et. aZ..1975 a; Dickins et al.^1919) Dickins, 1978).
In the reduced state the complexes generated in vivo and 
in vitro are remarkably stable (Elcombe, 1976; Dickins, 1978). 
Incubation with isosafrole of microsomes from rats pretreated 
with isosafrole resulted in the appearance of a Type I binding 
spectrum and a time dependent decrease in the trough with a 
shift in the trough wavelength towards 438 nm. Subsequent 
addition of NADPH resulted in the generation of a double Soret 
spectrum. On removal of NADPH, a time dependent increase in 
the magnitude of the binding spectrum was seen. This indicates 
that the metabolite complex can be displaced, regenerated and 
redisplaced in microsomes from rats pretreated with isosafrole. 
The initial displacement process is similar to that described 
by Elcombe et al. (1975 a) and Dickins et al. (1979). The
metabolite-complex of isosafrole generated in phenobarbitone- 
pretreated rat microsomes was found to be unstable in the 
oxidized state in agreement with the findings of other 
workers (Elcombe et altJ1915 a; Dickins, 1978). This 
observation was originally attributed to displacement of the 
metabolite complex generated in vitro by substrate remaining 
after exhaustion of NADPH. Elcombe et al. (19 75 a) reported
that following the generation of a metabolite complex with 
safrole and NADPH in phenobarbitone microsomes and removal 
of NADPH, measurement of the reduced spectrum 20 min after 
the initial oxidation showed that the peaks at 427 and 455 nm 
had disappeared and had been .replaced by a single peak at 
450 nm. During this experiment, the reappearance of cata- 
lytically active cytochrome P-450 or of a binding spectrum in 
the oxidized state was not described. These criteria have 
been used as indicators of the displacement process (Elcombe
et al.^1915 a, 1977; Dickins et al.^1919). Dickins (1978) 
described an investigation of the displacement of the complex 
generated in vitro using microsomes from rats pretreated with 
phenobarbitone, isosafrole or methylcholanthrene. The complex 
was generated with isosafrole and NADPH, and the microsomes 
were chromatographed on Amberlite XAD-2 and dialysed for 12 h. 
Following this treatment, the metabolite complex was demon­
strated directly by reduction in the microsomes from isosafrole 
pretreated rats, and displacement was shown to occur with
2-n-heptylbenzimidazole. However, in phenobarbitone- and
3-methylcholanthrene-pretreated microsomes, the metabolite 
complex was not demonstrated directly, and the lack of a 
displacement spectrum was interpreted as inability of the 
complex generated in vitro to be displaced. The utilization 
of and removal of NADPH suggests that the microsomes would 
be in the oxidized state, where the metabolite complex- in 
the phenobarbitone and 3-methylcholanthrene-pretreated micro­
somes would be unstable and would break down. Therefore, the 
reason for the lack of displacement may have been the absence 
of the complex.
The production of carbon monoxide described in Fig.
6 .2 . following oxidation of the complex generated in vitro has 
been reported elsewhere (Elcombe et al.^1915 a) and was 
considered to be a result of the breakdown of the bound 
metabolite, or the breakdown of haem. The production of 
carbon monoxide during the NADPH-dependent peroxidation of 
microsomal lipid was first reported by Nishibayashi et al.
(1968) and subsequently it has been reported that microsomal 
preparations undergoing lipid peroxidation show a loss of 
haem from cytochrome P-450 (Levin et al. ^ 1973,a fk;Schachter et 
al.^1912, 197 3; De Matteis and Sparks, 1973). The possibility 
that the carbon monoxide could be produced by peroxidative 
cleavage of one of the methene bridges of the haem of cyto­
chrome P-4 50 was considered by the above authors. However, 
carbon monoxide can be generated during the peroxidation of 
isolated phospholipids (Wolff and Bidlack, 1976) and haem
degradation as a result of lipid peroxidation does not cause 
the release of a methene carbon atom from haem as carbon 
monoxide (De Matteis et aZ.,, 1977). Therefore, since the 
production of carbon monoxide is not inhibited by EDTA, 
which normally inhibits lipid peroxidation ( Levin et aZ.,,1973 
a,b ; De Matteis and Sparks, 1973; Jacobson, et at.., 1973) the 
carbon monoxide may be produced by degradation of the meta­
bolite.
An interesting feature of the administration of 
some benzodioxole compounds to animals in the initial decrease 
in spectrally measurable cytochrome P-450 and inhibition of 
drug metabolism (Dickins, 1978; Matthews et al.3 1970; Perry 
and Bucknbr, 19 70; Philpot and Hodgson, 19 71 b, 19 72; Franklin, 
19 76) up to 24 h after administration. This initial period 
of inhibition is followed by induction of cytochrome P-450 
and the formation of a 455 nm peak. Although the metabolite- 
cytochrome P-450 complex is formed rapidly in vitro, the 455 
nm complex has not been conclusively observed in vivo at 
time periods of less than 4-8 h (Dickins, 1978). Franklin 
(1976) reported the appearance of a 455 nm complex as early 
as 2 h after the administration of piperonyl butoxide to 
rats. However, the A A ^ ^  _ values (about 0.005 - 0.007 A)
(Franklin, 1976) are extremely small compared to control 
values, and NADPH was used as a reducing agent. It is there­
fore possible that any residual piperonyl butoxide remaining 
in the microsomal fraction at short time intervals after 
administration; could have been metabolized in vitro in the 
presence of NADPH to produce a 455 nm peak. This apparent 
lack of an initial metabolite-cytochrome P-450 complex in 
vivo complicates the elucidation of the induction mechanism, 
since one would expect initial inhibition of cytochrome P-450 
resulting from complex formation to trigger the induction 
mechanism. The reason for the apparent absence of the 455 nm
peak at early time points'following administration of isosafrole 
has been suggested to be the method used for visualization of 
the complex, i.e. by means of a dithionite reduced minus 
oxidized difference spectrum. If the metabolite complex were 
stabilized in the reduced state, it would not be detectable 
under these consitions (Dickins, 1978). An alternative 
hypothesis may be formulated, in view of the stability in the 
oxidized state of the metabolite complex generated in vitro.
If the metabolite complex generated at early time points is 
stabilized in the reduced state in vivo, but on removal of 
reducing conditions by homogenisation and centrifugation it 
becomes unstable and breaks down, this could account for the 
lack of the 455 nm peak at early time periods. Induction of 
cytochrome P-450 by isosafrole and the formation of a 
metabolite-complex with this particular cytochrome which is 
stable in the oxidized state could then explain the simul­
taneous increases in the 455 nm complex, cytochrome P-450 
and cytochrome P-450 dependent activities (Dickins, 1978;
Elcombe et aZ.^1977). Although this hypothesis could explain 
the lack of the 455 nm peak, it could not explain the initial 
reduction in spectrally determined cytochrome P-450. It has 
yet to be established whether the degradation of the metabolite 
cytochrome P-450 complex generated in vitro results in the 
degradation of either cytochrome P-450 or of haem. Dickins 
(1978) investigated the effect of formation of the meta­
bolite complex with safrole or isosafrole in post-mito­
chondrial supernatant from phenobarbitone-pretreated rats
r 14 1which had received 5- amino — [4- CJ— laevulinate, and found 
negligible degradation of haem with either safrole or isosafrole. 
However, this study examined only haem degradation by complex 
formation in the reduced state, and did not look at the effect 
of subsequent oxidization. The use of post-mitochondrial 
supernatant instead of a microsomal preparation may also have
imposed a certain degree Of insensitivity on the determination 
of haem degradation, since cytochrome P-450, while containing 
a large percentage of the total haem present in a microsomal 
system, will represent a much smaller percentage in post- 
mitochondrial supernatant. The formation of the metabolite- 
complex in vitro probably only occurs with a small percentage 
of the total cytochrome P-450 (approxiamtely 20-30%). There­
fore, to detect degradation of this amount of haem will 
require high sensitivity. The breakdown of the metabolite 
complex may result in the generation of a denatured form of 
cytochrome which still retains intact haem, and therefore a 
low level of haem degradation does not preclude degradation 
of cytochrome P-450.
Suspensions of isolated hepatocytes have been used 
extensively to study the metabolism of foreign compounds, and 
provide a system which is an intermediate stage between the 
in vivo situation and isolated subcellular fractions (Bridges 
and Fry, 1976). Cytochrome P-450 can be measured in isolated 
hepatocytes (Moldeus et al.3 1973), and the addition of 
suitable compounds to the medium results in a Type I spectral 
change (Moldeus et al.3 1973;. von Bahr et al,3 1974). The 
formation of a metabolite-cytochrome P-450 complex in a • 
suspension of isolated hepatocytes has been reported for 
norbenzphetamine (Hirata et al.3 1977). Addition of isosafrole 
to a suspension of isolated hepatocytes from phenobarbitone— 
pretreated rats resulted in the formation of a Type I binding 
spectrum which was replaced with time by two peaks at 427 nm 
and 45 8 nm. These peaks are thought to represent an isosafrole 
metabolite-cytochrome P-450 complex. The development of similar 
spectra and also the inhibition of carbon monoxide binding 
have been reported in isolated hepatocytes from control rats 
(Sweatman, 19 79). How accurately the redox potential inside 
the hepatocyte in the isolated cell suspension is a reflection 
of that in vivo is not known, but it is reasonable to suggest 
that the metabolite-cytochrome P-450 complex is formed in the
hepatocyte, and may be stabilized in the reduced state.
The relationship of the 4 38 nm peak in the 
oxidized state to the two peaks at 427 and 455 nm in the reduced 
state has not been conclusively investigated or defined, and 
is complicated by different stabilities of the oxidized 
metabolite complexes generated in vitro and in vivo. Elcombe 
et al. (19 75 a) described an inverse relationship between
the increase in the binding spectrum following addition of a 
displacing agent to microsomes from rats pretreated with 
safrole, and the decrease in the 455 nm peak following reduction. 
Dickins (19 78) confirmed this finding and also reported a 
correlation between the decrease in the absorbance at 438 
nm and the enhancement of the metabolism of 4-nitroanisole 
(Dickins, 1978; Elcombe et al.3 1977). In my experiments 
(Chapter 4), I have found that the disappearance of a 455 nm 
peak in vivo seems to be related to the amount of cytochrome 
P-450 revealed on displacement. From studies on the displacing 
abilities of homologous series of n-alkylbenzimidazoles, 
n-alkylcarbamates and fatty acids (Dickins et al.3 1979;
Dickins, 19 78) it was found that conferring an increased degree 
of lipophilic character to a displacing compound by extension 
of the side chain resulted in an increase in displacing ability, 
and that beyond a certain chain length displacing ability 
decreased, perhaps due to steric factors. From the results 
described in this chapter, it seems that the length of the 
side' chain of the benzodioxole compound forming the metabolite 
complex is also a determinant in the displacement process.
For the isosafrole and hexenylbenzodioxole metabolite complexes 
the lipophilic and steric properties of the displacing agents 
seem to play similar roles, although the rates of displacement 
for hexenylbenzodioxole are lower than those for isosafrole, 
indicating increased stabilization of the hexenylbenzodioxole 
metabolite. For octenyIbenzodioxole the overall rates of
displacement are much lower than for hexenylbenzodioxole 
or isosafrole, and it seems that the lipophilicity of the 
displacing agent is the determining factor for rate of 
displacement, with steric factors at least for the benzimi- 
dazoles playing a lesser part, resulting in an increase in 
displacing ability from octyl- to nonylbenzimidazole. It 
therefore seems that the 455 nm component of the complex is 
stabilized by a lipophilic interaction and will undergo 
displacement, whereas the 427. nm peak does not seem to change 
significantly during the displacement process (Chapter 4, and 
Dickins, 1978).
An interesting group of compounds which may provide 
an insight into the nature of the double Soret peaks is the 
dioxolane series and the related methylenedioxycyclohexane. 
These compounds form metabolite-cytochrome P-450 complexes 
which appear to give a single absorbance maximum of 427 nm 
(Hodgson et ai., 1973; Dahl and Hodgson, 1979). In the 
oxidized state, these compounds give metabolite complexes with 
a.single absorbance maximum at 438 nm (Dahl and Hodgson, 1979; 
Dickins, 1978). The evidence which relates the 427 nm peak 
with cytochrome P-420 is derived from studies on ethyl 
isocyanide, which gives a single absorbance maximum at 
4 33 nm with cytochrome P-420 in the reduced state (Omura and 
Sato, 1964a). However, in the oxidized state cytochrome P-450 
yields a single absorbance maximum at 4 33 nm, whereas 
cytochrome P-420 does not (Dahl and Hodgson, 1978 a). It is 
possible to form cytochrome P-420 complexes with piperonyl 
butoxide or 4-n-butyldioxolane in the presence of cumene 
hydroperoxide (Dahl and Hodgson, 1979), but these complexes 
are readily dissociated by carbon monoxide, in contrast to . 
those of cytochrome P-450.
Dahl and Hodgson (1978 a, b, 1979) have proposed 
a hypothesis which identifies ligands giving double Soret 
spectra as both lipophilic and strong ir-acceptors. From 
their studies on ethyl isocyanide binding to cytochrome P-450 
they suggested the following:
that the 455 nm peak is a species in which cytochrome- 
ligand interaction is mainly through a coordinate bond with the 
haem iron but may be stabilized by a weak or non-disruptive 
lipophilic interaction with the protein,
that the 4 30 nm peak is a 5 or 6 coordinate species where 
the axial mercaptide ligand to metal bond trans to ethyl iso­
cyanide has been lengthened or ruptured by the trans influence 
of ethyl isocyanide, and the mercaptide is displaced by 
torsional strain in the protein brought about by strong lipo­
philic interaction with the ethyl group of ethyl isocyanide. 
(Thiis bond lengthening and displacement results in the 
effective elimination of the mercaptide to porphyrin charge 
transfer which apparently is responsible for the anomalous 
red shifted Soret bands found when strong 7r-acceptor ligands 
combine with cytochrome P-450).
Their explanation of the causerof .the double Soret spectrum 
correctly predicts that :CXY (X,Y = halide), the carbene 
proposed by Wolf et al. (1977) having no lipophilic group, 
should give a single Soret peak around 455 nm as is the 
case for other non-lipophilic 7r-acceptor ligands (CO, SnX2 * 
GeX2 ) (Dahl and Hodgson, 1977). The proposed carbene formed 
by benzodioxole, being a strong n-acceptor and lipophilic, 
ought to and does give a double Soret spectrum. This model 
would also predict that if the dioxolanes give carbenes 
analogous to those of the benzodioxoles, then the dioxolanes 
should also give double Soret spectra (Dahl and Hodgson, 1979). 
However, the chemistry of the dioxolanes differs from the 
benzodioxoles in that the carbene of dioxolane decomposes to 
give ethylene and carbon dioxide. Analogous carbenes of 
substituted dioxolanes should also give carbon dioxode and the 
respective olefins. Binding to the haem moiety of cytochrome 
P-450 in the reduced state would stabilize the carbene of 
dioxolanes by a o-bond with ir-backbonding. However, unless 
the carbene is stabilized by additional lipophilic interaction,
the carbene will decompose to give carbon dioxide and an 
alkene (Dahl and Hodgson, 1979). Therefore, a 455 nm peak, 
if formed, will be transitory. The carbenes from benzodioxoles 
do not decompose in the same way, since high energy benzynes 
would result instead of alkenes. Therefore, the carbenes of 
benzodioxole compounds would have a much longer t, in the free 
state than those of dioxolanes, and would therefore give double 
Soret spectra.
In the light of this hypothesis, it is worth . 
considering several aspects of metabolite complexes generated 
in vivo and in vitro with benzodioxoles. The 455 nm component 
of the complex formed in vivo, is removed by displacement and 
is dependent on the lipophilicity of both the benzodioxole 
and the displacing compound. The 427 nm component generated 
in vivo does not appear to be removed by displacement in the 
oxidized state and seems to be a much stronger interaction 
than the 455 nm peak. In the oxidized state,; the metabolite 
complex is manifested by a single absorbance peak at 438 nm.
It is possible to relate both the 427 nm peak (from studies 
on dioxolanes) and the 455 nm peak (from displacement studies) 
to this 438 maximum. If in the oxidized state the carbene 
interacts with haem by a single a-bond, and a second lipophilic 
interaction occurs at the Type I site to form a bidentate 
ligand, as proposed by Dickins et at. (1979), then it would be 
possible to postulate two different types of lipophilic 
interaction between the Type I site .and the bound metabolite 
of, for example, isosafrole. One type of interaction would be 
weak and would probably involve the propenyl side chain, 
wherease the other type would be a strong lipophilic interaction 
involving both the benzene nucleus and the propenyl side chain. 
In the oxidized state, these two types of interaction could be 
relatively strain free, whereas on reduction, with 7r-back- 
bonding of the carbene to . iron, and possible changes in protein 
conformation, the fifth ligand could be put under strain or 
broken by the stronger lipophilic interaction, resulting in 
a 427 nm peak. The weaker lipophilic interaction would not 
strain the fifth ligand and would result in a 455 nm peak.
The lack of strain with the weaker lipophilic action may be 
due to the extra dimension of the benzene ring bridging the 
haem iron-Type I site gap. The ring system of benzodioxole 
compounds produces an essentially planar molecule, whereas the. 
dioloxanes have a non-planar molecular structure. It is 
probable that, because of the lack of the extra dimension of a 
benzene ring and planarity, the carbenes of dioxoles can only 
be stabilized by lipophilic interaction if the haem moiety is 
sufficiently close to the Type I site. Presumably to provide 
this, proximity, the fifth ligand bond must be distorted, 
resulting in a 427 nm peak alone.
The generation of metabolite-complexes with benzo­
dioxole compounds in known to be pH-dependent, with the 42 7 nm 
peak predominating at lower pH and the 455 nm peak at higher 
pH (Philpot and Hodgson, 1971 a). There is some doubt 
whether the pH-dependence represents a true equilibrium 
process, with conversion of the 455 nm peak to the 427 nm peak 
and vice versa once the complex has been formed either in vitro 
or in vivo• Franklin (1971) suggested that this is not an 
equilibrium process, since on formation of a metabolite complex 
with piperonyl butoxide at pH 7.4, the 455 nm peak was decreased 
and the 42 7 nm peak increased by lowering the pH to 5.9. 
Subsequent raising of the pH resulted in the decrease of the 
427 nm peak, but no increase in the 455 nm peak was found.
This may have been due to complete denaturation of the protein 
at pH 5.9. There is little data available on the effect of pH 
changes in the oxidized state on the complex generated in vivo. 
Although the pH dependence of the double Soret maxima requires 
investigation, one could postulate that ionisation of (a) 
particular group(s) induces changes in the haem-Type I site 
distance, and so influences the formation of one or other 
species.
The concentration dependence of the 427/455 ratio 
seen with benzodioxole compounds (Elcombe, 1976) could be 
explained on the basis of the affinity of the various
lipophilic interactions. The strong lipophilic interaction 
would have a lower Kg and would be expected to predominate at 
lower concentrations. Determination of Kg values for ethyl 
isocyanide (Dahl and Hodgson, 19 78 a) and phosphorous-containing 
ligands (Dahl and Hodgson, 1978 b) has shown that the lower 
wavelength peak has the lower Kg .
If one postulates that different types of 
cytochrome P-450 have different distances between the Type I 
binding site and the haem iron, it becomes possible to explain 
different 427/455 ratios with different animal pretreatments, 
and also differences in stability between complexes generated 
in vitro and in vivo. The complex formed in microsomes from 
phenobarbitone-pretreated rats gives both 427 and 455 nm 
peaks in the reduced state, and breaks down slowly in the 
oxidized state.. When ir-backbonding is removed by oxidation, 
the lipophilic interaction is insufficient to stabilize the 
complex. Microsomes from rats pretreated with methylcholan- 
threne give a metabolite spectrum with isosafrole in which 
the 455 nm peak predominates, and on oxidation, this complex ; 
is highly unstable< (Dickins, 1978). One difficulty of this 
model is that one cannot distinguish between a 455 nm complex 
which is stabilized by lipophilic interaction and one which is 
not, without using indirect methods, such as measurement of 
displacement. The instability of the complex in methyl- 
cholanthrene-pretreated microsomes may be due to lack of 
lipophilic stabilization. The distance between the haem iron 
and the Type I binding site is probably greater than that of 
the phenobarbitone-induced cytochrome P-450, resulting in 
much less stabilization. Therefore on oxidation, the removal 
of -rr-backbonding would result in the rapid disappearance of the 
complex. For the cytochrome induced by isosafrole the model 
becomes more difficult to interpret, because it is not 
conclusively known if both peaks in the double Soret spectrum 
are due to the metabolite complex, or if the 42 7 nm peak is 
due to cytochrome b^ and the metabolite complex produces a 
single absorbance maximum at 455 nm. The selective removal of
cytochrome from microsomes using protease, leaving 
cytochrome P-450 in the microsomal membrane has been reported 
by Ito and Sato (1969). Sweatman (19 79), using a similar 
technique, described the selective removal of the 427 nm peak 
oh digestion, leaving almost 100% of the 455 nm complex in 
the microsomal fraction. However, the results are incon­
clusive, and in addition to selective removal of cytochrome 
bj-, the data could be interpreted on the basis of different 
membrane distribution of two cytochrome P-450 species.
However, the complex in the oxidized state is highly stable, 
but can be removed by displacement to reveal active cytochrome 
P-450. This can be explained by a significant, yet non- 
disruptive lipophilic interaction at the Type I site stabilizing 
the complex, and on addition of a displacing agent, competition 
for the Type I site results in removal of the stabilization 
and breakdown of the complex.
The formation of the two Soret peaks may be due to 
the presence of two pools of cytochrome P-450, one essentially 
at the membrane surface, and one buried in the membrane, with 
each one forming a separate absorbance peak. There is little 
direct evidence to support this hypothesis, apart from the 
digestion experiments of Sweatman (19 79). The hydrophilic 
portion of NADPH: cytochrome P-450 reductase can be released 
from the membrane by protease treatment (Ito and Sato, 1969; 
Orrenius et al.s 1969;De Pierre andDallner, 19 75), and antibody 
against NADPH: cytochrome P-450 reductase inhibits microsomal 
NADPH-mediated electron: transport. This enzyme is similar to 
cytochrome b^ and NADH: cytochrome b^ reductase, which are 
amphipathic, with hydrophobic tails embedded in the membrane, 
whereas the bulk of the proteins, containing the active sites 
of the enzymes are exposed to the cytosol. The localization 
of cytochrome P-450 is less well defined. Treatment of 
microsomes with protease does not result in the solubilization 
of significant amounts of cytochrome P-450 (Ito and Sato, 1969).
Treatment of microsomes with sufficient deoxycholate to 
increase the membrane permeability, but not to solubilize the 
membrane results in an increase in the amount of cytochrome 
P-450 released by tryptic digestion.(Nilsson and Dallner,
19 77), and it has been suggested on the basis of this evidence 
that cytochrome P-450 occurs both on the luminal and on the 
cytosolic face of the endoplasmic reticulum (De Pierre and 
Ernster, 1977; Craft et at.9 1979). Welton et at. (1975), 
using an antibody to partially purified protease-treated 
cytochrome P-450, were unable to inhibit the microsomal meta-- 
bolism of benzphetamine. Investigations by Thomas et at. (1977) 
using antibodies to purified cytochrome P-450 and cytochrome 
P-448, showed that the extent of antibody inhibition was 
dependent not only upon the source of the antibody and micro­
somes, but also on the specific substrate and reactions, 
catalysed. Their results indicated that cytochrome P-450 
is at least partially exposed to the hydrophilic environment 
on the exterior of the microsomal membrane. However, the 
interpretation of antibody inhibition studies is complicated, 
since negative results do not necessarily indicate that 
cytochrome P-450 is buried in the membrane, and only the 
cytoplasmic surface of the membrane will be exposed to the 
antibody. Changes in the lipid environment of cytochrome 
P-450 may influence the binding o f .substrates, ligands and 
inhibitors, so that multiple forms of cytochrome P-450 
differentiated by spectral criteria might in reality 
represent a single form in varying lipid environments (Stier, 
1976).
Elements of each of the hypotheses considered in
6.1. to account for double Soret spectra may be incorporated 
into an overall hypothesis to explain the nature of double 
Soret peaks, their pH- and concentration-dependence, and 
also the stability and displacement of metabolite-cytochrome 
P-450 complexes. Validation of this overall hypothesis will 
require investigation of different aspects. The pH-dependence 
of the formation of the 427 and 455 nm peaks has been 
extensively reported. However, an investigation of the effect
of change in pH following complex generation in vitro could 
clarify the nature of the equilibrium process. Similar 
investigations of the complex generated in vivo may establish 
'the nature of the 427 nm peak. Solubilization of the 
microsomal proteins may result in alteration of peak ratios 
and may give information about the lipid environment of the 
haemoprotein(s) involved. The stability of the metabolite- 
complex generated in vitro requires further investigation.
An understanding of the fate of cytochrome P-450 following 
breakdown of the complex produced in vitro Is required not 
only to understand the nature of the stabilization of the 
complex, but also to understand the initiating events of the 
induction process. An investigation of the stability in the 
oxidized state of metabolite-cytochrome P-450 complexes 
generated in vitro, using substituted benzodioxoles with 
increasing side chain lengths and lipophilicity could provide 
information about complex stabilization. If distance between 
the Type I site and haem is the key to stabilization of the 
metabolite-cytochrome P-450 complex in microsomes from 
phenobarbitone- and methylcholanthrene-pretreated rats, careful 
selection of the benxodioxole compound on the basis of side 
chain length could yield stable complexes in the oxidized 
state. Investigation of the origin of the carbon monoxide
produced during complex breakdown could be made using
ri4 -r 14
2- . |_ CJ -isosafrole and examining for production of CO.
Possible cytochrome P-450 degradation or haem degradation could
also be investigated. Purified cytochrome P-450 preparations
could be used to investigate complex formation and stability
without complications from membrane effects and multiplicity
of cytochrome P-450.
CHAPTER 7
THE EFFECT OF 2,3-BENZOFURAN ON THE LEVELS
OF HEPATIC DRUG METABOLIZING ENZYMES
7. THE EFFECT OF 2,3-BEN ZOFURAN ON THE LEVELS
OF HEPATIC DRUG METABOLIZING ENZYMES
7.1. INTRODUCTION
As already discussed in Chapter 3, one of the 
microsomal protein bands separated on SDS-polyacrylamide gel 
electrophoresis (Band 1) was thought to be epoxide hydratase 
because of its minimum molecular weight (approx. 48,000), and 
changes on induction with phenobarbitone, methylcholanthrene, 
isosafrole and tvans-stilbene oxide. Induction of epoxide 
hydratase by stilbene oxide was thought to be relatively 
specific with.little change in the levels of cytochrome P-450 
and related enzymes (Schmassmann and Oesch, 1978). However, 
a wide range of enzyme activities including those of cytochrome 
P-450, glutathione transferases and UDP-glucuronyl transferase 
were known to be induced by trans-stilbene oxide (Elmamlouk and 
Mukhtar, 1979; Mukhtar et aZ.,, 1979; Seidegard et al, 9197.9).
During a study of a variety of chemicals for ability to induce 
the protein increased by isosafrole, using SDS-disc gel 
electrophoresis, 2,3-benzofuran was found to produce a large . 
increase in the staining intensity of Band 1 (Chapter 4.).
In addition, benzofuran was found to produce a decrease in levels 
of cytochrome P-450. The effect-of benzofuran pretreatment ; 
was investigated further to determine the identity of Band 1 
and also to examine the effect of benzofuran on other hepatic 
drug metabolizing enzymes, in particular cytochrome P-450.
7.2. RESULTS
Administration of -trans-stilbene oxide for 3 days at 
a dose level of 400 mg/kg increased the activity of epoxide 
hydratase by approximately 75%, as measured by the hydration 
of benzo(a)pyrene-4,5-oxide (Table 7.1.). Pretreatment with 
benzofuran (150 mg/kg for 3 days) caused an increase in the 
activity of epoxide hydratase of approximately 150%. The levels 
of cytochrome P-450 were increased by stilbene oxide, but 
decreased with benzofuran by approximately 30% (Table 7.2). 
Stilbene oxide caused little change in the levels of NADPH: 
cytochrome c reductase, but slightly reduced cytochrome b^ levels. 
Benzofuran caused little change in cytochrome b^, and NADPH: 
cytochrome c reductase was slightly increased. Pretreatment with 
stilbene oxide caused an increase in the activity of aminopyrine 
N-demethylase, but little change in ethoxyresorufin 0-deethylase. 
With benzofuran, ethoxyresorufin O-deethylase activity was 
increased slightly, but the level of aminopyrine N-demethylase 
was reduced to the limits of detection.
The effects of stilbene oxide and benzofuran on several 
conjugation enzymes are shown in Table 7.4. Benzofuran caused 
increases in the activity of 4-nitrophenol- and 1-naphthol- 
glucuronidation, whereas stilbene oxide caused little change in 
either activity. Glutathione transferase activity as measured 
by the conjugation of l-chloro-2,4-dinitrobenzene was increased 
by both stilbene oxide and benzofuran.
In Fig. 7.1. the induction of Bands 1 and 3 by stilbene 
oxide- can be seen following electrophoresis. Benzofuran induced 
Band 1, but did not increase any of the other..bands.
On addition of benzofuran to microsomes from pheno- 
barbitone pretreated rats, a Type I binding spectrum was 
produced (Fig. 7.2.). Addition of NADPH produced a trough at 
424 nm which became less pronounced with time.
Table 7.1. Effect of trans-stilbene oxide and benzofuran 
on the activity of epoxide hydratase in rat 
liver microsomes
Pretreatment Epoxide Hydratase Activity 
(nmol/min/mg protein)
Control 7.9 + 2.3
Stilbene Oxide 14.0 + 2.2
Benzofuran 21.0 + 4. lf
<A\W*piro
Activity measured as nmoles of 4,5-jdihydroxybenzopyrene 
formed min/mg protein
Values represent mean + standard deviations of three 
separate experiments
f P< 0.05
Animals received corn oil (2.5 ml/kg), trans-stilbene 
oxide (400mg/kg in corn oil) or benzofuran (150 mg/kg 
in corn oil) by injection i.p. for 3 days.
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Figure 7.1.
SDS-polyacrylamide gel electrophoresis of hepatic
microsomes from rats pretreated with stilbene
oxide and benzofuran
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Sample pretreatment and electrophoresis were carried out as 
described in 2.8. Microsomal samples (15yg) protein were 
applied to the gel as follows:
• Phenobarbitone Well 2
Saline 3
Corn oil 4
Methylcholanthrene 5
Isosafrole 6
Corn oil 8,9,10
Benzofuran 11,12,13
Stilbene oxide 14,15,16
Standard proteins were applied to the gel in Wells 1,7,17 
and 18. Migration was from top to bottom.
Figure 7.2.
Spectral changes produced by 2,3-benzofuran in 
microsomes in both the oxidized-and reduced states
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Microsomes (1 mg protein/ml)•were suspended in 66 mM Tris- 
HC1 (pH 7,4) and dividgd equally between two cuvettes. 
After incubation at 37 for 5 min, a baseline of equal 
light absorbance was established and benzofuran (250 yM)
was added to the sample cuvette ( ---- ). NADPH was then
added to both cuvettes and the spectrum was recorded after 
30 s, 2, 5 and 8 mins.
7.3. DISCUSSION
The specific induction of epoxide hydratase by trans- 
stilbene oxide with little change in cytochrome P-450, aminopyrine 
N-demethylase and benzo(a)pyrene hydroxylase was reported by 
Schmassmann and Oesch (1978). In this study it was found that, 
in addition to inducing epoxide hydratase, stilbene oxide 
induced cytochrome P-450, aminopyrine N-demethylase, glutathione 
S-transferase and several bands;on electrophoresis. The results 
are essentially in agreement with those of Schmassmann and 
Oesch (1978) for the induction of epoxide hydratase, and 
Seidegard et at, (1979) for the increases in cytochrome P-450 
and glutathione S-transferase. Recently Bucker et al. (1979)
reported that although cytochrome P-450 levels were not affected 
by stilbene oxide treatment, ethoxycoumarin O-deethylase increased 
markedly. From inhibition studies using a-naphthoflavone, 
tetrahydrofuran and metyrapone, it was concluded that the 
induced cytochrdme P-450 resembled that induced by phenobarbitone 
(Bucker et at, 1979). Induction of a type of cytochrome P-450 
similar to that induced by phenobarbitone would be consistent with 
the results obtained using electrophoresis in this study. The 
'lack of induction of UDP-glucuronyl transferase following stilbene 
oxide pretreatment in this study is in contrast to the results 
reported by Elmamlouk and Mukhtar (1979) who described an 
increase in the glucuronidation of 4-nitrophenol with stilbene 
oxide. These differences may be due to differences in the 
dose cf stilbene oxide administered, or to differences in the 
response.of the strains of rats used.
Benzofuran caused increases in epoxide hydratase 
activity, UDP-glucuronyl transferase activity and glutathione 
S-transferase activity. However, cytochrome P-450 was 
decreased by benzofuran, and aminopyrine N-demethylase dropped 
to undetectable■levels. The increase in epoxide hydratase 
activity is consistent with the initial hypothesis that Band 1, 
which is increased by benzofuran, is epoxide hydratase. There 
do not appear to be significant changes in the levels of the
microsomal proteins in the 49,000-55,000 region which are 
associated with cytochrome P-450. Benzofuran will interact 
with microsomal cytochrome P-450.in vitro to produce a Type I 
binding spectrum. On addition of NADPH to both cuvettes there 
is'no formation of peaks at 427 and 455 nm similar to those 
seen with benzodioxole compounds, suggesting that the formation 
of a metabolite-cytochrome P-450 complex is not responsible 
for the decrease in cytochrome P-450 levels. The spectrum does 
show a decrease in absorbance at 424 nm which gradually increases
rcdnxcJbioK £»Wouje& tavj
with time. This is probably due to initialxoxidation' of 
cytochrome b,. in the sample cuvette. Incorporation of an 
NADPH-generating system results in the production of a peak at 
450 nm after approximately 6 min, which is probably due to the 
production of carbon monoxide. This may be derived from 
benzofuran itself, or from NADPH-dependent lipid peroxidation.
The induction of epoxide hydratase and the decrease 
in cytochrome P-450 levels following treatment with benzofuran 
prompt the question which characteristics of the benzofuran 
molecule are responsible for these effects. It may be 
be possible that benzofuran acts as an inhibitor of epoxide 
hydratase-which could cause induction. The oxygen atom of 
the furan ring adjacent to the ^-bonded system of the benzene 
ring and the unsaturated bond in the furan ring may be a 
sufficiently close structural analogue of an aromatic epoxide 
to bind strongly to epoxide hydratase, yet presumably benzofuran 
would not be metabolized by this enzyme. An alternative 
explanation is that benzofuran undergoes metabolism e.g. in the 
furan ring, to produce a metabolite which then causes the 
induction of epoxide hydratase and other phase II enzymes. The 
decrease in cytochrome P-450 caused by benzofuran may be brought 
about by the selective destruction of a particular type of 
cytochrome P-450, or may be due to a dramatic increase in 
turnover of a particular type of cytochrome. Proliferation of
the endoplasmic reticulum with little increase in cytochrome 
P-450 synthesis could explain the decrease in spectrally 
determined cytochrome P-450, but could not alone explain the 
decrease in aminopyrine N-demethylase. Benzofuran may act 
as a specific inhibitor of this activity in vitro, Tetra- 
hydrofuran has been reported to be a specific inhibitor of 
cytochrome P-450 induced by ethanol (Ullrich et al,^ 1975b).
The decrease in cytochrome P-450 could be brought about by 
it*s destruction in various ways. Allylisopropylacetamide 
causes a decrease in cytochrome P-450 concentration (Wada 
et al.j 1968; Waterfield et a i, 9 1969), which is accompanied 
by a loss of microsomal haem. (De Matteis, 1970). The 
prosthetic haem is transformed during metabolism both in vitro 
and in vivo into isolatable "green pigments" (De Matteis,
1971; Unseld and De Matteis, 1976). Sulphur-containing 
chemicals such as phosphorothionates and carbon disulphide 
cause a loss of cytochrome P-450 which is not accompanied by 
a loss of microsomal haem, and the apoprotein is probably the 
site of action of these types of compounds (for review see 
De Matteis, 1978). Lipid peroxidation can also cause 
destruction of cytochrome P-450, and this process has been 
implicated in the decrease in cytochrome P-450 seen following 
administration of carbon tetrachloride (for review see De 
Matteis, 1978). The possible roles of these mechanisms in the 
decrease in cytochrome P-450 seen with benzofuran require 
investigation.
Further investigations are required to clarify the 
nature of the interaction of benzofuran with cytochrome P-450 
and with epoxide hydratase. These experiments should 
include investigation of inhibition of epoxide hydratase and 
cytochrome P-450 by benzofuran, the examination of a variety 
of cytochrome P-450 substrates for induction or inhibition 
and the use of different dosage regimes for induction experi­
ments. It is of interest to note that Schmassmann and Oesch 
(1978) described a decrease in cytochrome P-450 levels and
a decrease in aminopyrine N-demethylase at acutely toxic 
doses of trans-stilbene oxide. These dose levels (800 mg/kg 
for 3 days) also produced a decrease in activity from the 
maximally induced levels of epoxide hydratase. The decrease 
in cytochrome P-450 levels was attributed to the possible 
repression of cytochrome P-450 synthesis, and the decrease 
in aminopyrine N-demethylase to high levels of stilbene 
oxide remaining in the microsomal fraction and causing 
inhibition.
Furan compounds are known to be selectively toxic 
and the tissue which shows the toxic lesions depends on the 
compound administered. Ipomeanol (1- Ji-furylJ-4-hydroxypent- 
anone) produces lung necrosis which is thought to be caused 
by the production of a highly reactive metabolite by cytochrome 
P-450 in the Clara cells (Boyd, 1977). The naturally occurring
3-methylfuran also produces pulmonary bronchiolar necrosis, 
probably by a mechanism involving generation of an alkylating
met a 
(N-
Dolite by cytoc 
21-furylmethyl
irome P-450 (Boyd et 1978). Furosemide
-4-chloro-5-sulphamoylanthranilic acid) 
produces hepatic necrosis in mice as a result of metabolic 
activation of the furan ring to produce a metabolite which 
binds extensively to protein (Mitchell et aZ.^1974). Investi­
gation of the toxic effects of various simple furan compounds 
showed that the primary site of lesion depended on the 
compound investigated (Mitchell et and that for
2-ethylfuran, 2-furoic acid and 2,3-benzofuran in mice the 
primary site was the kidney. Phenobarbitone pretreatment 
decreased the renal necrosis seen with benzofuran, as did 
pretreatment with cobaltous chloride and piperonyl butoxide, 
suggesting that cytochrome P-450 may be involved in the 
production of metabolites which are responsible for the toxic 
lesions (McMurty and Mitchell, 1977). At high ;dose levels 
of benzofuran which produced extensive kidney necrosis, there 
was also liver necrosis (McMurty and Mitchell, 1977).
A possible link between the production of toxic 
metabolites, the apparent decrease in cytochrome P-450 and 
the induction of phase II metabolism is a subject which 
requires investigation. It would be interesting to determine
if benzofuran produces toxic lesions in rat liver in addition 
to causing changes in enzyme activity, and also to examine 
the effect of benzofuran on the kidney to see if enzyme 
levels are altered in addition‘to the production of toxic 
lesions. In view of the marked specificity for the primary 
site of necrosis with different furan compounds, it would 
be of interest to examine the structural requirements for the 
induction.of epoxide hydratase and the effects on other 
enzymes.
CHAPTER 8 
FINAL DISCUSSION
8. FINAL DISCUSSION
The use of polyacrylamide gel electrophoresis for 
the resolution of cytochrome P-450 polypeptides has been 
investigated (Chapter 3). The most useful system was found 
to be SDS discontinuous PAGE using the discontinuous buffer 
system of Laemmli (19 70), in agreement with many of the 
workers using this technique for the resolution of microsmal 
proteins. The absolute identification of the polypeptide 
bands is not possible, but the technique is extremely useful 
in cases where determination of monooxygenase activities 
provides equivocal results about the nature of induction, and 
where extensive inhibition makes measurement of enzyme 
activities difficult. The routine measurement of induction 
by benzodioxole compounds represented such a case. SDS-gel 
electrophoresis is also a valuable technique for simultaneously 
monitoring changes in a large number of proteins, although 
identification of separated polypeptides may prove to be 
difficult.
The induction of a microsomal protein band in rat 
liver by isosafrole confirms the report by Dickins et at,
(19 78) of the induction of a novel protein. The induction of 
this band appears to be directly related to induction of 
cytochrome P-450 by benzodioxole compounds, and the appearance 
of a 455 nm complex in vivo (Chapter 4). The structural 
requirements for the generation of a metabolite complex in vivo 
and the induction of the 53,000 mol. wt. band appear to be the 
presence of a benzodioxole ring system, the ability to form a 
stable adduct with cytochrome P-450 in vitvo> the absence of 
alternative sites for metabolism and the presence of a 
lipophilic side chain. In addition to safrole, isosafrole and 
dihydrosafrole, benzodioxole compounds with ring substituents 
such as myristicin, and lipophilic side chains were found 
to induce cytochrome P-450. The inability of eugenol and 
methylisoeugenol to act as inducing agents suggests a well 
defined structural specificity for induction.
The induction of hepatic microsomal monooxygenase 
activity by isosafrole and pipero.nyl butoxide in both 
"responsive" C5 7 BL/10 and "nonresponsive" DBA/2 mice has 
been described (Chapter 5). Isosafrole produces in both 
strains of mice a 455 nm complex which can be removed by 
incubation with displacing agents. Isosafrole also induces 
a protein band of mol. wt. 54,000. The induction of cytochrome 
P-450 in both responsive and nonresponsive strains by 
isosafrole indicates a fundamental difference in inducing 
mechanism between isosafrole and methylcholanthrene. Although 
the possible involvement of the cytosolic receptor postulated 
by Poland and Kende (19 76) in isosafrole induction is 
extremely unlikely, it cannot be ruled out at this stage. The 
involvement of another receptor protein which is not lacking 
in nonresponsive mice is more probable. Whether this receptor 
protein is a cytos\olic receptor protein or is a form of 
cytochrome P-450 itself remains to be seen.
It has been reported that there is no formation of 
a metabolite complex until 6 - 8 h after administration of 
isosafro.le to rats in vivo (Dickins, 1978) and this provides 
a major argument against the hypothesis that complex 
formation is the initiating event for induction. However, 
evidence has been presented here (Chapter. 6) which suggests 
that a complex formed with existing cytochrome P-450 in vivo 
may be unstable in oxidized conditions, and breaks down either 
in vivo or during the microsomal isolation procedure. Whether 
this disappearance of complex results in destruction of 
cytochrome P-450 or of haem has yet to be determined. Studies 
with isosafrole in isolated hepatocytes indicate that the 
metabolite complex is formed in the cell, and that the active 
metabolite is not removed by a competing metabolic route such 
as conjugation. A mechanism which involves the inhibition of 
cytochrome P-450 by formation of a benzodioxole metabolite 
complex as the initiating event for induction can be formulated. 
Initially the benzodioxole compound binds to cytochrome P-450
to produce a Type I spectrum which changes on metabolism to 
produce a metabolite-cytochrome P-450 complex. This complex 
does not seem to undergo displacement in isolated hepatocyte 
suspensions (Sweatman, 19 79) or in vivo. Formation of the 
complex, or breakdown of the cytochrome P-450 present as 
complex, will lead to inhibition of cytochrome P-450 mediated 
metabolism of certain endogenous substrates. The accumulation 
of endogenous substrates may mediate the induction of cytochrome 
P-450. Such compounds could include lipid peroxides, fatty 
acids, steroids or prostaglandins. Induction may be brought 
about by a receptor complex with one of these endogenous 
compounds, causing an increase in the transcription of mRNA 
for a particular protein or proteins which would result in 
the de novo synthesis of haemoproteins.
An ideal technique for the study of the induction 
mechanism of isosafrole would be the use of liver cells in 
culture. Such an approach has been used to evaluate mechanisms 
of induction of aryl hydrocarbon hydroxylase by polycyclic 
aromatic hydrocarbons (see Gelboin and Whitlock, 1978), and 
the use of primary maintenance cultures of hepatocytes rather 
than cell lines is thought to represent a situation closer 
to that in vivo, with phenobarbitone as well as the polycyclic 
aromatic hydrocarbons inducing cytochrome P-450 (Bridges and 
Fry, 1978; Fry et al.3 1978). Initial studies on the 
induction of cytochrome P-450 by isosafrole in primary 
maintenance cultures of hepatocytes have not been successful 
(Sweatman, 1979). However, various methodological problems 
may account for this failure, such as high avidity of safrole 
for plastic culture flasks. It is hoped to overcome these 
problems to obtain a system capable of being used as a model, 
and by the use of appropriate inhibitors of transcription 
and translation to characterize the induction mechanism.
It has already been suggested (Chapter 4) that 
preferential metabolism of benzodioxole compounds by enzymes
other than•cytochrome P-450 may be responsible for the absence 
of complex formation and induction in vivo with compounds 
which form metabolite complexes in vitro. The relative 
importance of these alternative routes of metabolism could 
also be studied using isolated hepatocyte suspensions; a system 
which is closer to the situation in vivo with a full complement 
of enzymes, but without complicating distribution factors.
Evidence has been presented in Chapter 6 which 
relates the 438 peak in the oxidized state to the 455 nm 
component of the metabolite complex in the reduced state.
Data from other workers (Dahl and Hodgson, 1979) have related 
the 438 nm peak with the 427 nm peak of dioxolanes, and the 
42 7 nm complex is thought to be stabilized by a lipophilic 
interaction at the Type I site, which leads to distortion of 
the fifth ligand of cytochrome P-450, resulting in a peak at 
42 7 nm in the reduced state. From studies on the displacement 
of metabolite complexes formed in vivo with isosafrole, 
hexenylbenzodioxole and octenylbenzodioxole, the 455 nm peak 
also appears to be stabilized by a lipophilic interaction. 
Differences in the stability of the complex in the oxidized 
state and differences in the 42 7/455 ratio on pretreatment of 
animals may be explained by differences in the molecular 
dimensions of different forms of cytochrome P-450 at the 
active site. This may also provide an explanation for such 
phenomena as substrate specificities and versatility.
Several other aspects of enzyme induction by 
isosafrole require further investigation. The purification 
of the species of cytochrome P-450 induced by isosafrole 
should facilitate comparison with the types of cytochrome P-450 
induced by other agents. A preliminary report by Ryan et at,
(19 79 b) suggests that isosafrole induces a haemoprotein which 
differs from that induced by phenobarbitone. Comparison 
of the cytochromes induced by isosafrole and by methyl- 
.cholan.threne, and studies on the synergistic induction of 
cytochrome P-450 by methylcholanthrene and isosafrole using 
inhibitors of protein synthesis both in vivo and in primary
hepatocyte culture, should answer the questions posed in 
Chapter 4 about the nature of the interaction between 
isosafrole and methylcholanthrene, and possible common features 
in their induction mechanisms. The determination of substrate 
specificity of the purified haemoprotein, and in particular 
the ability of this cytochrome to metabolize isosafrole and 
safrole to active metabolites may yield information about the 
relevance of its induction to the hepatotoxicity and carcino­
genicity of these compounds.
Examination of the nature of the metabolite- 
cytochrome P-450 complex would be facilitated by the use of 
purified cytochrome preparations. Isolation and 
characterization of the displaced metabolite could be carried 
out using such techniques as radio-gas chromatography in 
conjunction with mass spectrometry. Determination of the 
structure of the displaced metabolite may clarify the nature 
of the metabolite involved in the ligand interaction.
The broader implications of enzyme induction by 
benzodioxole compounds are at the moment a matter for 
speculation. The induction of cytochrome P-450 in general 
can lead to: the loss of efficacy of drugs, increases or 
decreases in toxicity and carcinogenicity, and deficiency 
of endogenous substrates. Whether induction of cytochrome 
P-450 by benzodioxole compounds leads to their increased 
metabolism either to toxic or non-toxic products, or to the 
restoration of the metabolism of endogenous substrates 
remains to be seen. The presence of safrole, myristicin and 
other potential benzodioxole inducers in spices and other 
foodstuffs makes them potentially relevant to man. The 
ingestion of these compounds by individuals with large amounts 
of spices in their diets may lead to both inhibition and 
induction of cytochrome P-450, either caused by the 
benzodioxole compounds directly, or by their interaction with 
other inducing chemicals. In this regard it is interesting
to note that benzodioxole compounds induce cytochrome P-450 
in the kidney (Lake et aZ.^1973) and are capable of forming 
metabolite-cytochrome P-450 complexes in both the kidney 
(Lake et at,, 1973) and the gut (Elcombe, 1976).
Benzodioxole compounds and benzofuran appear to 
have different effects on some of the enzymes of the hepatic 
endoplasmic reticulum. The induction of epoxide hydratase 
by benzofuran has been described in Chapter 7. A decrease 
in tytochrome P-450 levels was also found, together with 
a decrease in aminopyrine N-demethylase, but ethoxyresorufin 
O-deethylase activity was increased. Increases in the 
activity of glutathione S-transferases were also noted.
Although there are similarities between the induction of 
monooxygenase, activities and the induction of epoxide 
hydratase, the enzymes do not appear to be under common control 
(Bentley and Oesch, 1979). The induction of epoxide 
hydratase by benzofuran may be mediated by inhibition or by 
mimicry of an endogenous compound which may cause induction 
of epoxide hydratase. In view of the widespread occurrence 
of furans and their toxic properties, an investigation of the 
effects of furan compounds on microsomal enzymes may be 
fruitful. Benzofuran itself is found in light tar fractions, 
and is used in the construction industry in coumarone-indene 
glues.
It is hoped to investigate the effects of benzo­
furan in vitro on epoxide hydratase activity and on cytochrome 
P-450 activities. The mechanism by which benzofuran brings 
about a decrease in cytochrome P-450. obviously requires further 
investigation, and although speculation about the nature of 
this process may be premature, it is interesting to note that 
AIA may cause destruction of cytochrome P-450 haem by 
formation of a hydroxylactone, rather than a reactive epoxide 
(Ortiz de Montellano &t al.^ 1979). A compound of this nature 
would have a structure similar to a furanone. The possible 
involvement of a furanone (a- or 3-angelicalactone) as a
toxic metabolite of 2-methylfuran has been suggested 
(Franklin and Boyd, 1978). Hydroxylation of the 2,3 double 
bond of benzofuran would lead to the formation of 2(3H)- 
benzofuranone, a metabolite which-may mediate the toxicity 
of benzofuran. and possibly cause destruction of cytochrome 
P-450 haem.
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